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9 i • prologue
A 27 year old Asian woman presented at the outpatient clinic of 
the department of rheumatology with a sudden onset of butterfly 
exanthema, alopecia, fever, and swollen joints of the hands and 
wrists. Laboratory tests revealed a rapid rise in serum creatinine, 
leuco- and thrombocytopenia, low levels of complement c3 and  
c4, positive antinuclear antibodies (ana) and anti–double-stran- 
ded dna (anti-dsdna) antibodies. Urinalysis showed an active 
sediment suggestive of glomerulonephritis. She was diagnosed  
with systemic lupus erythematosus (sle). To determine the stage  
of renal involvement, a renal biopsy was performed, which showed a 
membranous glomerulopathy and a full house immunofluor escen ce 
pattern, compatible with lupus nephritis class v. Prednisone therapy 
was initiated, after which her renal function stabilized, as did the 
other clinical symptoms. 
Two years later, a second renal biopsy was taken because of declin-
ing renal function and pronounced proteinuria. A rise in anti-dsdna 
and low levels of c3 and c4 were detected. The renal biopsy confir- 
med a renal flare, showing a diffuse proliferative glomerulonephritis 
com patible with lupus nephritis class iv. An abdominal ultrasound 
obtained for nausea and stomach ache, unexpectedly revealed a renal 
vein thrombosis in the right kidney. In addition to prednisone, pulse 
cyclophosphamide was administered, and treatment with vitamin 
K antagonists as anticoagulant therapy was initiated. The patient’s 
condition and renal function stabilized after 13 cyclophosphamide 
pulses. The renal vein thrombosis led her clinicians to evaluate anti - 
phospholipid antibody titers. Both anticardiolipin IgG and IgM  
elisas and the lupus anticoagulant test were negative. Therefore,  
it was decided to terminate the anticoagulant therapy after two years.
 
During this time, she was referred to a gynecologist for pre con-
cep tional counseling, and to assess whether there were signs of 
premature ovarian failure induced by cyclophosphamide therapy. 
She had no wish to become pregnant at that moment, but was 
considering pregnancy in a few years. The gynecologist discussed 
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with renal disease and sle. The effect of pregnancy on lupus was set 
out against the effect of lupus on pregnancy and the fetus. Pregnancy 
in an sle patient entails a high risk of lupus-flare, a high risk of 
renal-flare, a higher risk of hypertensive pregnancy disorders such as 
preeclampsia and hellp syndrome and a higher risk of thrombosis. 
Inversely, sle affects pregnancy and the fetus by inducing a higher 
risk of miscarriage, intrauterine growth restriction, (iatrogenic) 
preterm birth and even fetal death. Especially the presence of anti- 
phospholipid antibodies reduces the chance of an uncomplicated 
pregnancy. Finally, the gynecologist talked about genetics and the 
teratogenic effect of certain medications.
It appeared that she was using an oral contraceptive pill for heavy 
menstrual periods, but not for contraception per sé. Due to the renal 
vein thrombosis, it was advised to stop oral contraception to reduce 
the risk of further thrombotic complications, even though antiphos-
pholipid antibodies were still undetectable. Furthermore, it was 
decided that aspirin and a daily prophylactic dose of low molecular 
weight heparin during pregnancy were indicated in case she would 
become pregnant.
Unfortunately, within a year after the visit to the outpatient 
clinic of the department of gynecology she developed menopausal 
symptoms of flushing and an irregular menstrual cycle. Subsequent 
analysis showed premature ovarian failure, most likely induced by 
cyclophophamide pulse therapy. 
 
Despite pulse cyclophosphamide and prednisone therapy,  
the patient’s renal function gradually continued to decline during 
the following years; her blood pressure slowly increased to a mean  
of 180/100, and proteinuria rose to a nephrotic range. A third renal  
biopsy specimen was obtained when she was 36. This time, in 
addition to lupus nephritis class iv, histological evidence of a 
thrombotic microangiopathy was found. Anticoagulant treat- 
ment was resumed. A thorough diagnostic work-up for under- 
lying causes of thrombotic microangiopathy was performed, in  
which antiphospholipid antibodies were still negative, but sero-
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logical complement levels c3 and c4 appeared to be extremely low. 
Further analysis revealed no evidence for hus, ttp, or other condi- 
tions related to thrombotic microangiopathy apart from active sle.
Shortly thereafter, she presented with upper body ataxia and 
progressive aphasia, indicators of cerebral involvement of sle which 
is known as neuropsychiatric sle. She was treated with a high dose of 
immunosuppression, 10 plasmapheresis sessions and hemodialysis, 
but despite this treatment, her gfr had now declined to 15 micro-
moles/liter. Prolonged hemodialysis was started at the age of 39.  
Her condition stabilized, though permanent neurological injury  
had developed for which she was admitted to a rehabilitation center. 
Two years later, she suffered acute neurologic deterioration and 
respiratory distress. She was admitted to the intensive care unit,  
where hemolytic anaemia, deep thrombocytopenia, multiple pur- 
pura and an oliguric state pointed at a recurrence of the thrombotic 
microangiopathy. Despite additional plasmapheresis sessions and 
high doses of immunsuppression she died, most likely due to diffuse 
alveolar hemorrhage and bleeding in and around multiple organs 
caused by severe thrombocytopenia, active lupus nephritis and wide- 
spread microthrombotic injury. 
At autopsy, the kidneys showed signs of extensive chronic damage, 
classified as lupus nephritis class ivc. Furthermore, multiple fibrin 
microthrombi were present in glomeruli. In the brain, diffuse chronic 
and global ischemia was found, accompanied by several vessels in the 
white matter with intraluminal thrombi. For research-purposes, her 
kidney biopsy specimens and available tissue samples from the cere-
bral cortex were stained for complement factor c4d, which revealed 
diffuse and intense complement depositions in all affected organs. 
This patient appeared as a subject in two out of four research articles 
described in this thesis (Chapter 4 and 5). The striking observation of 
widespread thrombo-ischemic injury in combination with extensive 
complement deposition served as a basis for many ideas and research 
questions that will be addressed in the following chapters. Most im-
portantly, this case history underlines that all patients tell a story and 
that all medical science begins and ends with stories like these. 
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Introduction
 
sle: a single disease with many manifestations. what 
is the common denominator? The case presented in the 
prologue illustrates the potential severity and heterogeneity of 
symptoms, the difficult treatment choices clinicians are faced with 
and above all, the unpredictability of the course of the disease of 
patients with sle. This puzzling patient history served as a basis  
for several research questions that have been addressed in this thesis.
sle is a systemic autoimmune disease occurring mainly in young 
women of childbearing age.1 With a prevalence of up to 1-2 cases per 
1000 in high risk groups such as Asian, Hispanic and Afro-American 
women, it is not an uncommon disease.2 Virtually all organ systems 
can get involved, but the skin, the kidney and the brain are amongst 
the most vulnerable.3 However, not two patients with sle present 
alike and the description of the case above thus has limited value 
as one of a ‘typical’ sle patient. This case merely points out that 
investigating common mechanistic pathways which explain the vast 
majority of manifestations is valuable, both for diagnostic purposes 
and the development of guided therapy. The complement system is 
one of the major contributors to the development of tissue damage 
in sle. This thesis will therefore focus on the role of the complement 
system and on its potential as a diagnostic tool and future therapeutic 
target.
antibodies and complement sle is caused by an aberrant 
immune response, and the hallmark of the disease is the presence  
of autoantibodies.4 An impressive variety of autoantibodies have been 
described in sle and interestingly, the antibodies already present 
years before actual onset of the disease.5 Antibodies against nuclear 
components such as anti-dsdna antibodies, antinuclear antibodies, 
anti-ssa, and ssb antibodies are most commonly detected.1 
Antiphospholipid antibodies form a separate group of antibodies  
that can be detected in about 40% of sle patients.6 These antibodies 
are closely correlated to thrombotic and obstetric complications. 
ii 
general introduction  
Complement in auto- and alloimmunity 
and the introduction of C4d
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potent mechanism that has the ability to crudely injure microbes  
and pathogens just as much as self-tissues. Furthermore, the biology 
and clinical significance of the biomarker c4d will be outlined.
As a biomarker c4d was originally described in solid organ 
transplantation. Transplantation and the semi-allogeneic fetus  
in pregnancy provide useful analogous situations for studying the 
effects of antibody mediated complement activation. In the second 
part of the introduction, the potential contribution of complement 
activation to different clinical situations studied in this thesis will  
be outlined. It will be shown that the kidney, the placenta, and the 
brain are target organs for classical pathway activation, both in sle 
and antiphospholipid syndrome (Part 2: Clinical settings). The third 
section of this chapter will focus on the research-questions that form 
the basis of the experiments and the studies performed in this thesis 
(Part 3: This thesis). Finally, an outline of the chapters will be given.
Part 1 – The human complement system
 
powerful immune surveillance The complement sys- 
tem is an ancient element of the human immune system.14;15 
Complement components emerge in the blood during fetal develop- 
ment, long before circulating antibodies appear.16 This probably 
reflects complement’s evolutionary history: Phagocytic cells and 
complement were major defense mechanisms in vertebrates before 
they developed the capacity for an adaptive immune response and 
antibody production.10 
As a part of the first line of defense, complement can be inter- 
preted as a complex immune surveillance system. Like the coagu- 
lation cascade, the complement system needs to be ready for action 
at all times. More than 30 soluble- and membrane-bound proteins 
circulate in a ‘controlled active state’. Specific triggers, such as for 
instance an invading pathogen, can set of a cascade of enzymatic  
reactions and positive feedback loops (known as complement  
activation pathways, see figure 1), that can lead to the destruction  
of the potentially dangerous target within seconds.10 
sle related autoantibodies typically form immune-complexes, which 
deposit in tissues such as the skin, the kidneys, the brain, and the 
lungs. Antiphospholipid antibodies on the other hand, can directly 
bind to endothelial cells and trophoblast cells.7;8 In both situations 
complement activation subsequently initiates a damaging sequence 
of inflammatory events in the tissue where the immune complexes  
or antibodies are deposited.9-11 
Herein lies the clue to why this thesis is focused towards comple-
ment. When an antibody binds or an immune complex deposits,  
this will virtually always lead to activation of the complement  
system. Studying the complement system as a general pathway  
of injury allows overlooking the variety of different antibodies in 
order to see the actual effect of this on tissue level. Complement  
deposition provides an excellent read-out, or tissue-biomarker  
of previous presence of immune complexes or antibodies, despite 
their origin or the kinetics of the binding or deposition process. 
Furthermore, it seems that the occurrence of immune-complexes 
or antibodies per se is not by itself sufficient to induce injury.9 
The blockade of antibodies in sle, for instance with intravenous 
immunoglobulins or with plasmapheresis, has proven unsuccess- 
ful to control disease. The results of the first randomized placebo 
controlled trials with the anti-b-Cell agent Rituximab, a drug that 
aims to stop b-cells from producing antibodies, have also failed to 
show a significant beneficial effect.12;13 Although some uncontrolled 
observational studies showed promising results, these were only 
achieved when Rituximab was used in combination with other 
immunosuppressants such as prednisone or cyclophosphamide. 
 
a focus on classical complement activation This thesis 
focuses on the complement system as the common denominator, or 
common mechanism of injury in several manifestations of sle and 
antiphospholipid syndrome. In the first part of this introductory 
chapter, the background and biology of the complement system  
will be further explained (Part 1: The human complement system) . 
It will become clear that complement activation is an extremely 
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the activated complement cascade will generate specific membrane 
bound fractions and split products that coat the surface of target  
cells or pathogens, thereby further guiding phagocytosis. Thirdly,  
the final stage of the complement cascade leads to the formation  
of the membrane attack complex (mac). The mac is an ingeniously 
formed complex of enzymes that work together to create a pore-like 
structure.18;19 This pore inserts itself into cell membranes, thereby 
causing cell lysis and, subsequently, cell death.
what specific triggers set of the cascade?  The three 
pathways by which the complement system can become activated  
are the classical, lectin, and alternative pathway (figure 1). All of them 
converge at the level of c3, and they all have the same final common 
pathway that leads to the formation of the membrane attack complex 
(mac) on complement activating surfaces.14
The classical pathway of complement is initiated via binding of  
its recognition molecule c1q to immune complex deposits, antibody-
antigen binding, charged molecules, and apoptotic and necrotic cell 
debris. This pathway connects innate immunity to adaptive b-cell 
mediated immunity when an antibody response has developed. 
However, in the setting of autoimmune disease or transplantation, 
classical complement is activated due to the deposition of auto anti-
bodies or allo-antibodies and may lead to severe organ damage or 
graft rejection.9 
The lectin pathway is activated when mannose-binding-lectin or 
ficolins of various carbohydrate ligands are recognized. These can be 
found on the surface of many different pathogens. The lectin path- 
way does not function via c1, as mbl functions as the recognition 
molecule instead.10 Further downstream, this pathway follows the 
same steps as classical activation: c2, c4, and the final common path- 
way. Therefore, it can be difficult to distinguish between classical 
from and mbl pathway activation. 
The third and last pathway is known as the alternative pathway. 
The alternative pathway’s main function is to amplify the inflam-
matory reaction initiated by classical or mbl induced complement 
Apart from directly protecting the host from invading pathogens, 
the proteins of the complement system participate in a variety of 
other physiological activities, such as the augmentation of adaptive 
immune responses (by activating upon the binding of antibodies 
and immune complexes), involvement in tissue regeneration, and 
participation in apoptotic cell clearance.10;17
 
how does the complement cascade cause injury to 
its target?  The complement system operates in a way that can 
be summarized as ‘Call for help while starting to attack’.14;17 Firstly, 
activation of the cascade automatically leads to the generation of the 
potent anaphylatoxins c3a and c5a, which attract neutrophils and 
monocytes to the site of inflammation. Furthermore, c3a and c5a 
cause vasodilatation, smooth muscle contraction, histamine release 
from mast cells, and oxidative burst from neutrophils. Secondly, 
fig 1 schematic overview of the complement system and the  
 different activation pathways
classical pathway lectin pathway alternative pathway
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complement induced tissue injury: excessive acti-
vation or inadequate regulation? When complement 
activation is able to injure host tissue, there must either have 
been so much activation that regulatory mechanisms were over-
whelmed, or regulation must have been inadequate. Too much 
activation is probably the case for most manifestations of sle and 
antiphospholipid syndrome. Constant exposure of host tissue to 
autoantibodies overwhelms the membrane-bound regulatory 
mechanisms, allowing direct complement mediated injury. 
The consequences of inadequate regulation can be observed 
in patients with genetic mutations and deficiencies in regulatory 
molecules, such as mcp, factor i, and factor h. These mutations have 
recently been identified in atypical Hemolytic Uremic Syndrome 
(ahus).22;23 This severe form of thrombotic microangiopathy is a 
consequence of uncontrolled complement activation, which causes 
widespread endothelial injury and thrombosis. Recently, the same 
mutations as those found in ahus have been detected in patients 
with severe preeclampsia and hellp syndrome, providing striking 
and novel insights into these diseases.24 It is not unthinkable that 
many more diseases in which excessive complement deposition  
is observed have a defect in complement regulation as a basis.
how can the activity of the complement system 
be monitored? There are several different ways to monitor 
complement activation.25 In the case report, one method was 
mentioned, namely, measurement of complement components in 
serum. Low levels of c3 and c4 indicate that complement is being 
consumed and deposited in tissues. Although very useful in clinical 
practice, this method gives little mechanistic insight, because it 
cannot be determined where the activation takes place and what  
cells and structures are injured by complement activation. 
To gain this insight, another option is to look at the tissue 
itself. Renal biopsies are diagnostically stained for complement 
components in daily clinical practice. This is done by investigating 
presence of complement components on frozen tissue with immuno-
activation.20 The alternative pathway is, therefore, constantly being 
activated by the hydrolysis of c3, but at the same time it is tightly 
regulated to prevent uncontrolled activation. This situation can  
be compared to a snowball balanced on the top of a hill, on the verge 
of rolling down. Whenever c3 is activated by the classical or mbl 
pathway, this immediately leads to instant binding of factor b and  
d. This complex is subsequently stabilized by properdin forming  
an enzyme that leads to more c3 activation. The alternative path way 
thereby creates a positive feedback loop and amplifies the inflam-
matory reaction initiated by classical or lectin pathway activation. 
maintaining the balance of the cascade: complement 
regulation A mechanism with such potent pro-inflammatory 
and cell-destructing capabilities without any sophisticated strate- 
gies to distinguish self- from non-self-tissue needs tight regulation. 
Nearly half of all complement components have a regulatory func-
tion.21 Their goal is to prevent damage to host tissue by inhibiting 
the cascade on three vital points: Activation, amplification, and the 
formation of the membrane attack complex. Complement-regulating 
proteins can either be membrane-bound or soluble. Membrane-
bound proteins [Decay Accelerating Factor (daf) and Membrane 
Cofactor Protein (mcp) and cd59] are abundantly present on host-
tissues, and they prevent complement from inducing auto-injury. 
For instance, cd59 binds to components of the membrane-attack 
complex, preventing it from inserting itself into the cell membrane. 
daf works by preventing the formation of an enzyme derived from 
of c4, which normally leads to c3 activation and the formation of 
anaphylactoxins c5a and c3a. To prevent ‘harmless bystander injury’, 
most self-tissues that are in direct contact with blood, such as for 
instance endothelium and placental tissues express many different 
complement regulators. 
Powerful soluble regulators are factor i, factor h, and the c4-
binding protein. These soluble regulators mainly affect enzymes 
involved in the alternative route, thereby controlling amplification  
of the cascade and blocking positive feedback loops. 
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antibody formation in the recipient’s serum and histological evidence 
for tissue injury a diagnosis can be made. This makes it complicated 
to give reliable sensitivity and specificity data for c4d alone. In a 
study by Bohmig et al, c4d was shown to have a high specificity (93%) 
but low sensitivity (31%) for the presence of anti-donor antibodies 
(determined by Flow Cytometric crossmatch testing of anti-hla 
panel reactivity), but not for humoral rejection per se. In 58 transplant 
recipients, 5 immunological graft losses occurred, of which 4 out of 
5 had c4d positivity in peritubular capillaries and detectable anti-
donor antibodies, and 1 only had detectable antidonor antibodies 
without c4d. Furthermore c4d positivity was observed to have an 
independent predictive value for inferior graft function one year  
after transplantation (P=0,02).29
Throughout this thesis, c4d plays a central role as a tissue-
biomarker of complement activation. We have studied the clinical 
significance of c4d in new settings such as auto-immunity and 
adverse pregnancy outcome. In these studies c4d helps to elucidate  
so far unknown pathogenic mechanisms. In neuropsychiatric 
sle and in lupus nephritis c4d seems to form the link between 
complement mediated inflammation and the formation of thrombo-
ischemic and microthrombotic injury.30 During pregnancy, placental 
c4d reveals that complement mediated inflammation at the fetal-
maternal interface may contribute to intrauterine fetal death, 
recurrent miscarriage, and even preeclampsia.31 The last part of  
the thesis is dedicated to this marker alone, discussing the pros  
and cons for c4d as a biomarker in different clinical settings.
Part 2 – Clinical settings
are all organs equally vulnerable to complement 
activation? The complement system may act in all organs and 
tissues. However, it is well known that some organs are more prone 
to suffer from complement activation than others. The kidney, 
the brain, and the placenta are predominant localizations for 
manifestations of sle and microthrombotic disease.11 While, at first 
fluorescence techniques. Both immunoglobulins and complement 
components can easily be made visible and deposition patterns can  
be interpreted and used for diagnostic purposes. The kidney of an  
sle patient is known for the deposition pattern of IgG, IgM, IgA,  
c3, and c1q, which is also known as a ‘full-house’ pattern.26 
A disadvantage of the use of immunofluorescence techniques  
on snap-frozen tissue is that the morphology of the tissue cannot  
be made visible. The interaction of the fluorescent components  
with specific cells and structures in the tissue is therefore difficult  
to interpret. In formalin fixed paraffin embedded tissue this problem 
is solved. Furthermore, using paraffin embedded tissue allows retro - 
spective investigation of stored tissue samples, which is a huge 
advantage for research into relatively rare diseases such as sle. 
a special marker: c4d As this thesis mainly addresses antibody- 
mediated diseases, a special focus is placed on classical complement 
activation. To visualize classical complement activation, a frequently 
used marker is c4d.27 After antigen-antibody complex fixes comple-
ment, c4d is generated upon activation of c4. c4d itself has no known 
biological function. A unique feature of c4d is that it binds covalently 
to cell-surfaces or collagen basement membranes, thereby avoiding 
removal and raising the possibility to serve as an immunological 
footprint of antibody-mediated complement activation. The nick-
name ‘footprint’ emphasizes c4d’s ability to remain bound at sites  
of complement activation much better than antibodies, which  
bind to the tissue by hydrostatic, van der Waals type of interactions.  
These interactions allow antibodies to dissociate over time, while  
c4d remains anchored tightly to the tissue.28 
Presence of c4d first of all tells something about the pathophysio-
logical process going on in tissue where it is detected. However, as 
a diagnostic tool in daily clinical practice c4d has is mainly used in 
renal transplantation, where its presence in peritubular capillaries of 
renal allografts is felt to represent humoral – or antibody-mediated- 
allograft rejection. Humoral rejection is not diagnosed solely upon 
c4d positivity in a graft: Only in combination with positivity of allo-
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a vessel.40 On top of this, the glomerular basement membrane  
lacks endogenous membrane-bound complement regulators;  
if complement activation occurs there are a limited number of  
options for preventing damage. Finally, when compared to other  
organs, the kidney is exposed to extraordinary high levels of shear  
stress when glomerular endothelium is injured, promoting acti-
vation of the alternative pathway on exposed and damaged tissue.41  
This also contributes to the activation of the coagulation cascade, 
which explains the kidney’s vulnerability to microthrombotic 
injury.23;42 
The case report in the prologue shows that high levels of glo-
merular complement, in this particular situation caused by sle,  
give rise to severe forms of glomerulonephritis, and subsequent 
thombotic microangiopathy. In conclusion, the kidney’s anatomy 
provides an exceptional setting for inappropriate complement activa-
tion, leading to endothelial injury and, under certain conditions, 
activation of the coagulation cascade. 
 
complement and pregnancy 
 
immunological tolerance In 1953 Peter Medawar intro- 
duced the concept of ‘the fetal allograft’.43 His work served as a basis  
for many theories on immunologic maladaption as a cause of preg- 
nancy complications such as recurrent fetal loss, preeclampsia, and 
hellp syndrome. 
For a successful pregnancy, a fetus should be tolerated by  
the maternal immune system, even though it is half-allogeneic. 
The placenta forms the physical barrier between mother and fetus, 
and it plays a vital role in creating an immune privileged site at the 
fetal–maternal interface. Trophoblast cells form the outer layer of 
the placenta, and they are in direct contact with maternal blood 
and maternal endometrial cells.44 Specific transport mechanisms 
on trophoblasts regulate the uptake of nutrients from the maternal 
blood into the fetal circulation, and they also play a role in the 
immunological protection of the fetus. Trophoblast cells do not 
sight, it may seem there are few common functional features in these 
organs that explain this, there may be clues that can be found at the 
microscopic level. The glomerular filtration barrier, the blood brain 
barrier, and the fetal-maternal interface all serve as a ‘barrier’ or have 
an ‘exchange’ function that is vital for the health of the organ – and 
in case of the placenta – foetus. The research in this thesis is directed 
mainly towards complement activation in these tissues.
complement and the kidney
 
vulnerability of the glomerular filtration barrier
The kidney is extremely vulnerable to complement-mediated injury, 
which is shown by the many renal diseases in which complement 
deposits can be found.32 The vulnerability of the kidney to antibody-
mediated injury and complement becomes clear in diseases with a 
systemic nature, where the kidney is more often affected than other 
organs. In sle, more than 40% of patients develop renal involvement 
in which excessive complement deposits can be identified in the 
glomerulus.2;26 Furthermore, acquired or inherited deficiencies 
of complement regulation could theoretically cause systemic 
symptoms, as the complement system is systemically overactive. 
Clinically, however, this typically leads to kidney-disease in the 
form of atypical hus.22 Finally, in solid organ transplantation, the 
transplanted kidney is most susceptible to antibody-mediated forms 
of rejection, where complement is found in peritubular capillaries 
and is associated with high rates of graft loss.27;33-35 Liver, pancreas, 
and cardiac grafts are less often harmed by this form of rejection.35-39 
Theories about the particular vulnerability of the kidney to 
complement activation have focused on the anatomic composition 
of the renal endothelium. The glomerular basement membrane 
is a unique structure composed of collagen and heparan sulphate 
molecules in between a layer of fenestrated endothelial cells on the 
luminal side and an epithelial layer of podocytes on the other side. 
This fenestrated structure which serves as a filter allows immun- 
ecomplexes to deposit more easily than in the normal lining of  
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The most elegant work in this field comes from experiments with 
complement deficient animal models. In mouse models of anti- 
body-mediated pregnancy loss in which pregnant mice are injec- 
ted with antiphospholipid antibodies, this leads to extensive fetal 
loss. Complement can be detected at the fetal maternal interface. 
When the same procedure is carried out in mice with a deficiency of 
complement components c3 or c5, fetal loss can be prevented.53-55  
These studies underline the vital importance of adequate com ple-
ment regulation in murine pregnancy. 
When focusing on complement activation as a cause for adverse 
outcome in human pregnancy, sle and antiphospholipid syndrome 
are rational diseases to start with given the high prevalence of preg- 
nancy morbidity in these women and the role of complement in  
other manifestations of those diseases. As was shown in the case-
report, pregnancy and sle can be a problematic combination.56  
When accompanied by antiphospholipid antibodies, pregnancies are 
complicated by preeclampsia, fetal death, or recurrent miscarriage  
20 times more often than in the normal population.6 It has been 
shown in vitro that antiphospholipid antibodies can bind to 
and affect trophoblast cells, leading to an impaired production 
of progesterone and placental growth factor.57 Furthermore, an 
association between antiphospholipid antibodies and placental 
complement deposits was reported, showing that these antibodies 
can indeed activate the complement system at the fetal maternal 
interface.58 Whether this leads to an adverse maternal and fetal 
outcome will be studied further in this thesis. 
Another question that arises is whether the complement system 
could also play a role in recurrent miscarriage in women without 
underlying autoimmune diseases. In recurrent miscarriage, anti- 
 bodies against hla have recently been associated with a worse 
outcome in subsequent pregnancies.59 Furthermore, low comple- 
ment levels in mothers with recurrent miscarriages also predict  
a worse outcome. In preeclampsia, placental complement com- 
ponents have been identified and were reported to be present in 
abundance when compared to placentas of uneventful pregnancies. 
express the classical hla-a, hla-b, hla-dr, hla-dq, and hla-
dp molecules that are the main targets for alloreactive t-cells in 
transplantation. However, they do express hla-c, hla-e, and  
hla-g molecules by which they can avoid cell-mediated cytotoxi- 
city. For instance, hla-g-expressing cells have been shown to induce 
regulatory t-cell activity and avoid nk-mediated cytotoxicity.45;46 
Although cellular immune mechanisms have been thoroughly 
studied, much less is known about humoral immunity and the 
interplay with the complement system in pregnancy. It is evident 
that trafficking of maternal immunoglobulins through the pla-
centa is a physiological phenomenon, which is necessary for the 
protection of the neonate against pathogens. However, as lined 
out above, trophoblast itself expresses certain fetal antigens to 
which maternal lymphocytes are exposed, and to which targeted 
antibodies can be formed by maternal b-cells. The formation of 
anti-hla or anti-paternal antibodies does indeed occur in about 
30% of pregnant women, but is normally not associated with overt 
pregnancy morbidity.47;48 One possible explanation for this puzzling 
phenomenon is that placental trophoblast is extremely well prepared 
for maternal anti-fetal antibody mediated attacks. All trophoblast 
cells that are in contact with maternal blood produce high levels 
of membrane bound complement regulatory proteins such as 
Membrane Cofactor Protein, Decay Accelerating Factor, and cd59.49 
By doing this, the placenta can prevent inappropriate activation  
of the classical complement cascade at the fetal-maternal interface. 
what happens in abnormal pregnancies and what 
role does complement play? Experimental models  
pro duced evidence that excessive complement activation at the  
fetal-maternal interface plays a crucial role in inducing pregnancy 
morbidity. Studies in murine models of immunologically-media- 
ted pregnancy loss and preeclampsia indicate that complement 
activation targeting the placenta drives placental inflammation 
and leads to recurrent miscarriage, hypertension, proteinuria, and 
glomerular endotheliosis.50-52 
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and out of the brain. Moreover, the blood-brain barrier allows  
for a reduced immune surveillance from cellular immune mecha- 
nisms. Consequently, under normal circumstances, there is little 
t-cell trafficking to the central nervous system and a negligible 
production of antibodies by b-cells within the brain.61 The current 
understanding is that this attenuated cellular immune response 
limits ‘harmless bystander injury’ of neurological tissue that would 
occur during regular immune responses. 
Complement deposition may occur in cerebral tissue. As comple-
ment components circulate in the blood, activation of the cascade 
in the brain is equal to activation elsewhere in the body. This is 
reflected by the relatively large amount of complement regulatory 
mechanisms expressed on cerebral endothelial cells.63 Theoretically, 
the direct binding of autoantibodies or deposition of c1q-binding 
immunecomplexes may trigger classical complement activation at 
the blood brain barrier. There are many potential pathways through 
which complement may induce damage. For instance, c5a can 
induce heparan-sulphate release from endothelial cell membranes, 
promoting endothelial proliferation and the upregulation of 
e-selectin and vcam.64 Also, the membrane attack complex might 
cause lysis and it can mediate von Willebrand secretion and Tissue 
Factor expression in response to endothelial injury, contributing  
to a procoagulant state.8;55;65 In experimental lupus models, Alexander 
et al showed that the inhibition of complement attenuates disease 
symptoms in the brain. This group further demonstrated that 
c5a production can alter the integrity of the blood-brain barrier.66 
Furthermore, the complement system seems to be able to amplify 
thrombo-ischemic damage. In an elegant study performed in 
neonatal mice, it was shown that the infarcted area that developed 
after clipping of a cerebral artery was more than 3 times smaller in 
c1q deficient animals compared to wild type mice.67
Taken together, experimental models show that complement 
activation at the blood-brain barrier can cause endothelial damage 
and mediate thrombo-ischemic injury, and that it also has the ability 
to induce a breach in the blood-brain barrier. 
Interestingly, a recent cohort study revealed that many patients with 
severe preeclampsia have mutations in genes coding for complement 
regulatory mechanisms, similar to those found in atypical hus.24 
All in all, excessive complement deposition at the fetal maternal 
interface seems to be a pathological finding, which is associated with 
adverse pregnancy outcome.24;50;52;53;60 The placenta is normally very 
well prepared for complement mediated injury. Whenever comple - 
ment deposits manage to injure the placenta, there is either a lack 
of regulation (such as in some patients with severe preeclampsia) or 
too much activation (such as in antiphospholipid syndrome and sle, 
where there is constant exposure of antibodies that may overwhelm 
regulatory mechanisms). The presence of complement in placental 
tissue of a fetal loss might provide clues for an antibody mediated 
pathogenesis. This idea will be further explored in this thesis. 
complement and the brain
cerebral immunology and the consequences of 
cerebral complement activation Through which 
mechanisms could complement cause injury in the brain? To find 
answers to this question it is necessary to focus on the immuno- 
logy of the brain, which is essentially different from other organs.  
The cerebral microenvironment needs to be precisely regulated 
and strongly protected from invasion of microorganisms for 
optimal functioning. Since the brain has limited capacity for repair 
and regeneration of neurons, the immunological barriers in the 
brain help to minimize damage.61 This is done mainly through 
mechanisms at the interface where the blood meets the nervous 
tissue, better known as the blood-brain barrier. The blood-brain 
barrier is composed of polarized brain endothelial cells connected 
by tight intercellular junctions. The endothelial layer is further 
supported by the footprocesses of astrocytic glial cells.62 This con- 
struction limits the cellular permeability of plasma constituents 
(including immunoglobulins), whilst carefully regulating the  
uptake of nutrients and efflux of toxins and metabolites into,  
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Part 3 – This thesis
In sle and antiphospholipid syndrome, but also in pregnancy- 
associated morbidity, vital organs can be injured by means of anti-
body-mediated complement activation. The vast majority of these 
patients are young women of childbearing age. This impels efforts to 
further unravel these disease mechanisms and search for diagnostic 
tools and therapeutic targets. The complement system is a double-
edged sword. When excessively activated, its beneficial effects can 
become detrimental and cause serious organ damage. In this thesis 
we focus on the role of classical complement activation, and especially 
on the clinical significance of c4d in the following clinical settings:
* Complement induced endothelial injury in sle and antiphospho-
lipid syndrome
* Complement induced injury at the fetal-maternal interface 
aims of this thesis 
* To investigate the relation between c4d and microthrombotic 
injury in lupus nephritis
* To explore the presence of classical complement deposition in 
cerebral tissue of patients with sle, and investigate the associa- 
tion of c4d with thrombo-ischemic brain damage
* To determine the role of placental c4d in sle and Antiphospho-
lipid syndrome related adverse pregnancy outcome
* To explore the possibility of antibody mediated fetal loss in 
patients with recurrent miscarriage of unknown etiology 
* To set out the historical role of c4d as a biomarker in solid organ 
transplantation against novel insights, and explore whether c4d 
has potential as a biomarker for other clinical settings (such as 
autoimmunity and pregnancy) 
thesis outline This thesis is divided into two parts. The first 
part will uncover the role of classical complement activation in the 
development of endothelial injury and microthrombotic complica-
tions of sle and antiphospholipid syndrome. The second part will  
neuropsychiatric sle Between 20-70% of patients with sle 
develop nervous system involvement, and even in those without 
overt neurological symptoms, cognitive deficits can often be detected 
by careful testing.68 The culprit (or culprits) causing neuropsychiatric 
symptoms in sle remains an enigma with few therapeutic options. 
Both clinically and histologically, neuroinvolvement of sle seems 
to be caused by a vascular, thrombo-ischaemic pathomechanism. 
Microvascular occlusions with hyaline or platelet microthrombi, 
microinfarctions and small vessel vasculopathy are the most common 
findings in all neuropathological studies that have been performed so 
far.69-72 Affected vessels are virtually always arterioles and capillaries, 
with endothelial proliferation, hyalinization, and thickening of the 
vessel wall also known as ‘vasculopathy’.73 Interestingly, evidence of 
immunecomplex deposition in the small cerebral vessels has never 
been demonstrated.71 In contrast to the renal endothelium, the 
blood-brain barrier is better able to prevent trapping of immune-
complexes, which can probably be attributed to the tight junctions 
between adjacent endothelial cells.
As complement is a key event in many of the other organs that are 
involved in sle, this mechanism could play a similar role in cerebral 
lupus. Although immunecomplexes are not detected in cerebral  
vessels, any explanation for the mechanism of np-sle must take  
into account the role of antibodies and in particular that of anti- 
phospholipid antibodies.6;74 The latter can directly bind to endothe-
lial cells, and they can activate the classical complement cascade.6;55;75  
The small vessel injury observed in np-sle could be caused by 
complement activation at the blood-brain barrier. If complement 
activation is mutilating enough to damage the blood-brain barrier, 
it may even lead to entering of neurotoxic autoantibodies into the 
parenchyma, causing direct neuroinflammation. These mechanisms 
will be investigated further in this thesis. 
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The second part of the thesis is devoted to adverse pregnancy out- 
come in auto- and alloimmune settings. In chapters 6 and 7  
the role of placental complement is investigated in two clinical 
settings. First, chapter 6 evaluates pregnancies of patients with 
sle and antiphospholipid syndrome. This study describes the role 
of classical complement in inducing antiphospholipid antibody-
mediated fetal loss, showing that c4d has potential as a diagnostic 
marker to detect antibody-mediated morbidity in pregnancy.  
This prompted us to perform the studies described in chapter 7, 
in order to investigate whether the same mechanism could play a 
role in recurrent miscarriage of unknown etiology. Here, anti-hla 
or anti-paternal antibodies are likely candidates to cause placental 
insufficiency via a humoral immune-attack at the fetomaternal 
interface. 
Throughout the whole thesis c4d plays an important role as  
a disease marker and as an indicator of classical complement acti-
vation. For decades, c4d has been used as a marker for antibody 
mediated rejection in solid organ transplantation. Will c4d remain  
as diagnostic tool in solid organ transplantation, or will newer mole-
cular techniques replace it? Are findings in this thesis and in other 
work in this field interesting enough to start using c4d as a marker 
in pregnancy or in native renal disease? And finally: Is complement 
a target for treatment and could c4d be used as a marker to identify 
patients who would benefit from these treatments? These questions 
will be addressed in chapter 8, the general discussion, where the 
findings of this thesis will be summarized and placed in a more 
general perspective. This chapter is accompanied by several audio-
interviews with experts in the field who comment on controversies 
surrounding the use of c4d as a biomarker. The general discussion 
will be followed by a summary in Dutch.
focus on classical complement activation in adverse pregnancy out-
come related to sle and antiphospholipid syndrome, and in patients 
with recurrent miscarriage of unknown etiology. 
The role of complement in thrombosis and complicated preg- 
nancy cannot be investigated without attention being given to 
the antiphospholipid syndrome. Therefore, after this introductory 
chapter, the diagnosis and management of this relatively new disease 
is reviewed in chapter 3. The antiphospholipid syndrome overlaps 
with sle, and is a good example of an autoimmune disease in which 
complement activation is the consequence of antibody binding, 
leading to thrombosis and complications in pregnancy. This chapter 
highlights the difficulty of treating aps patients with a wide variety 
of distressing clinical symptoms and sets the clinical scene for the rest 
of the thesis. 
Interest in the subject was originally triggered when an unex-
pected association was observed between signs of earlier complement 
activation (complement factor c4d) and the presence of glomerular 
microthrombi in patients with lupus nephritis. This confirmed our 
suspicion that complement activation can induce endothelial injury 
to such an extent that thrombotic microangiopathy can develop. 
Chapter 4 describes these first experiments.30 
Neuropsychiatric involvement is a severe but poorly understood 
manifestation of sle in which microthrombotic injury is often 
observed. So far, studies in humans have failed to provide clues 
for interactions between autoantibody-mediated inflammation 
and thrombo-ischemic lesions observed in brains of sle patients. 
In line with our previous study in the kidney, we hypothesized 
that cerebral complement activation could play a role in inducing 
microthrombotic injury in np-sle. A nationwide search for brain 
tissue of sle patients provided a unique cohort to study deposition 
patterns of c4d and several other complement components. 
Furthermore, in this study we aimed to correlate post-mortem 
histopathology to ex-vivo7Tesla mri imaging in three brains of  
sle patients. The results of this study can be found in chapter 5. 
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Introduction
Antiphospholipid syndrome was first described 27 years ago in  
patients with systemic lupus erythematosus (sle) and positive  
anticardiolipin antibodies, who presented with a clotting syn- 
drome that affected arteries and veins.1 Female patients had a high 
risk of recurrent miscarriage and late fetal loss. The international 
classification criteria for this syndrome used today are based on 
those initial clinical observations.2
The syndrome is under-recognised and underdiag nosed and  
can have devastating consequences if untreated, mainly because of 
uncontrolled thrombosis. Difficulties in diagnosis are compounded  
by a lack of standardisation of diagnostic tests. Early recognition is 
crucial, because treatment can reduce mortality and morbidity  
in relatively young people who often present with diseases such  
as stroke, myocardial infarction, and deep vein thrombosis.
Because of its variable clinical presentation, patients with anti- 
phospholipid syndrome present to a variety of medical practitioners. 
Here, we introduce this complicated and intriguing syndrome, and 
provide basic guiding prin ciples for the recognition, diagnosis,  
and management of affected patients.
What is the antiphospholipid syndrome? 
Antiphospholipid syndrome is a systemic autoimmune disorder  
characterized by both arterial and venous thrombosis, adverse  
outcome in pregnancy (for mother and fetus), and raised titers  
of antiphospholipid antibodies. It occurs in isolation (primary 
antiphospholipid syndrome) in more than 50% of patients, but it 
can be associated with other autoimmune diseases. sle is the most 
common—20-35% of patients with sle develop secondary antiphos-
pholipid syndrome.2 An acute vari ant of the syndrome—catastrophic 
antiphospholipid syndrome—results in widespread thrombotic 
microangi opathy and multiple organ failure (Box 2).3 Classification 
criteria were last updated in 2006 (Box 1). A combination of clinical 
and laboratory findings is required to confirm the diagnosis.4 
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Who gets it? 
sle may affect up to 1 in 1000 women (depending on ethnic origin), 
and around 30% of those develop secondary antiphospholipid syn-
drome. The population prevalence of primary antiphospholipid 
syndrome is unknown, although it is estimated that this disease 
affects up to 0,5% of the general population.
Antiphopholipid syndrome occurs mainly in young women 
of fertile age, rarely occurs in children and only 12% of patients 
present over the age of 50. In a large international cohort of patients 
diagnosed with the syndrome the mean age at diagnosis was 34 + 13 
years sd. The male:female ratio was 1:3.5 for primary disease and 1:7 
for secondary diagnosis associ ated with sle.2 A recently reported, 
unique cohort of 121 pediatric cases (primary and secondary) had a 
mean age of 10.7 at disease onset (range 1.0-17.9), and a male:female 
ratio of almost 1:1.5 Patients who present after 50 are more often male 
and present more often with stroke and coronary heart disease.2 Less 
than 1% of patients with primary or secondary antiphospholipid 
syndrome develop the catastrophic form and in almost half of them, 
catastrophic antiphospholipid syndrome appears de novo, without 
prior thrombotic events.2
What are antiphospholipid antibodies and how are they 
associated with clinical symptoms?
Antiphospholipid antibodies form a heterogeneous group of auto-
antibodies directed at plasma proteins that bind to phospholipids.6 
Some antibodies from the antiphospholi pid family have a paradoxi- 
cal effect on coagulation: in vivo they are associated with recurrent 
throm bosis, but in vitro they increase phospholipid dependent 
clotting times, a phe nomenon known as ‘lupus anticoagulant’ 
activity. This peculiar phenomenon was named ‘Lupus anticoagulant’ 
and refers to the ability of certain antibodies to prolong phospholipid 
dependent clotting time. The so-called ‘lupus anticoagulant assay’ 
 – box 1 –
classification criteria for the antiphospholipid syndrome 
 
Antiphospholipid syndrome is present if at 
least one of the clinical criteria and one of 
the laboratory criteria that follow are met:
clinical criteria
Vascular thrombosis
One or more clinical episodes of arterial, 
venous, or small vessel thrombosis, in 
any tissue or organ. Thrombosis must be 
confirmed by objective validated criteria 
(i.e. unequivocal findings of appropriate 
imaging studies of histopathology). For 
histopathologic confirmation, thrombosis 
should be present without significant 
evidence of inflammation in the vessel wall.
 
Pregnancy morbidity
One or more unexplained deaths of a mor-
phologically normal fetus at or beyond the 
10th week of gestation, with normal fetal 
morphology documented by ultrasound  
or by direct examination of the fetus.
Or one or more premature births of a 
morphologically normal neonate before 
34th week of gestation because of: (i) 
eclampsia or severe preeclampsia defined 
according to standard definitions, or 
(ii) recognized features of placental 
insufficiency.
Or three or more unexplained consecutive 
spontaneous miscarriages before the 10th 
week of gestation, with maternal anatomic 
or hormonal abnormalities excluded and 
paternal and maternal chromosomal causes 
excluded.
laboratory criteria
Lupus Anticoagulant present in plasma, 
on two or more occasions at least 12 weeks 
apart, detected according to the guidelines 
of the International Society on Thrombosis 
and Haemostasis (Scientific Subcommittee 
on lupus anticoagulant/phospholipid –
dependent antibodies).10
Anticardiolipin antibody of IgG and/or 
IgM isotype in serum or plasma, present in 
medium or high titer (i.e. > 40 Gpl or Mpl, 
or > the 99th percentile), on two or more 
occasions, a least 12 weeks apart, measured 
by standardized elisa.
Anti-β™-glycoprotein I antibody of IgG 
and/or IgM isotype in serum or plasma, 
present in medium or high titer (i.e. > 40 
Gpl or Mpl, or > the 99th percentile), on two 
or more occasions, a least 12 weeks apart, 
measured by standardized elisa, according 
to recommended procedures.59
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Antiphospholipid antibodies are found in 1-5% of apparently healthy 
subjects. Prevalence increases with age and may be influenced by 
chronic disease, infections, malig nancies, and the use of certain drugs. 
Positivity in these conditions usually arises from IgM antibodies at 
low titres and is not associated with thrombosis or adverse pregnancy 
outcome.11 
Persistent positivity is rare. In a cross sectional study of 552 healthy 
blood donors, 6.5% had anticardiolipin IgG, but fewer than 2% still 
had increased titres nine months later.12 A definitive diagnosis of 
antiphospholipid syndrome requires the presence of clinical criteria 
and positive results for at least one of the three assays on at least two 
separate occasions 12 weeks apart because only persistent antiphos-
pholipid antibodies are clinically relevant.4;13 
The assays currently used for detecting antiphospholipid anti-
bodies show variable correlations with clinical symptoms. Well 
designed prospective diagnostic studies are scarce. Difficulties in 
interpreting clinical-serological studies arise from non-standardised 
assays, variable inclusion criteria, and broad definitions for case 
selection. Overall, the evidence supports the following:
* Lupus anticoagulant strongly associates with venous thrombosis, 
both in sle and in the general population (or 11).7 This effect is 
stronger in younger age groups (< 50).14
* Lupus anticoagulant strongly associates with stroke, both in sle 
and the general population. (or 8,1 95% CI 2.4–27.5) This effect is 
stronger in young age groups (<50).15;16 
* Lupus anticoagulant is strongly associated with fetal loss > 10 wks 
of gestation. (or 7,8 95% CI 2.30–26.45).8
* Lupus anticoagulant predicts venous thrombosis and fetal loss 
more strongly than anticardiolipin antibodies (or ranging from 
1,6-3,5).7;8
* The anticardiolipin elisa is considered to have high sensitivity 
but low specificity. It has a stronger association with morbidity  
in pregnancy than with thrombosis.8;17;18
* Studies that have investigated the relationship between anti-
β™glycoprotein I antibodies and clinical symptoms have shown 
 – box 2 –
the catastrophic antiphospholipid syndrome 
is a functional assay based on a combination of several clotting tests. 
Two other antibodies are useful for diagnosing antiphospholipid 
syndrome: anti cardiolipin antibodies and anti-β2 glycoprotein i 
antibodies (box 1), both of which can be detected by enzyme linked 
immunosorbent assays (elisas).4 
Antibodies with lupus anticoagulant activity are of major im - 
por tan ce clinically as two systematic reviews found them to be 
strongly correlated with thrombotic and obstetric complications  
of anti-phos pholipid syndrome.7;8 Table 1 describes assays for  
lupus anticoagulant, anticardiolipin antibodies, and anti-β2  
glyco-protein i antibodies. 
Unfortunately, agreement between laboratories for all of these 
assays is poor. A recent survey that evaluated lupus anticoagulant 
positive plasma samples found a false posi tive rate of 24%.9 This 
highlights the importance of good communication between the 
laboratory and the clinician when making a diagnosis and of 
ensuring that guidelines are followed.10
Management of catastrophic anti phos-
pho lipid syndrome is an extremely rare life 
threatening condition, characterized by the 
rapid development of multiple micro-
thrombi in various organ systems, typi-
cally the brain, kidneys, lung and skin.60 
Thrombocytopenia, hemolysis, schistocytes, 
and activation of the coagulation system 
are frequent laboratory findings and thus 
thrombotic thrombocytopenic purpura, he-
molytic uremic syndrome and disseminated 
intravascular coagulation are important 
differential diagnostic considerations. The 
mortality of the catastrophic antiphospho-
lipid syndrome approaches 50%.61 Figure 3 
gives examples of schistocutes and micro-
thrombi in the kidneys and the brain.
 Data on how to treat the catastrophic 
antiphospholipid syndrome is limited but 
current treatment regimes seem to have 
led to a marked reduction of the mortality 
when compared to historical case series.61 
Successful treatment regimes include 
anticoagulation, high dose corticosteroids 
and plasma exchange with or without 
intravenous immunoglobulins. Plasma 
exchange seems to be particularly useful in 
the setting of thrombotic microangiopathy. 
Possible precipitating disorders such as 
infection should be treated promptly. 
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is there an additional trigger? Most patients develop  
a discrete thrombotic event at a cer tain site in the body, suggesting 
that an additional trigger or risk factor—a ‘second hit’—is needed for 
the development of thrombosis. Infection, local endothelial damage, 
and pregnancy are possible candidates.
pregnancy Thrombosis in the placental vasculature was 
initially thought to be the main cause of adverse outcomes in 
pregnancy. However, placental thrombosis and infarction are 
not specific to antiphospholipid syndrome but occur in other 
conditions, such as non-antiphospholipid syn drome pre-eclampsia 
and hellp syndrome.28 In vitro and animal studies show ing that 
antiphospholipid antibodies can bind directly to trophoblast cells 
and cause direct cellular injury, defec tive invasiveness, and a local 
inflammatory response as a result of activation of the classical and 
alternative path ways of complement provided important insights 
into the pathophysiology of pregnancy loss.24;29 Moreover, they 
showed that the protective effect of heparin resulted from its anti-
complement activity and not only from its effects on coagulation.30 
Antiphospholipid antibodies seem to cause direct dysfunction of the 
trophoblast as well as activation of complement at the fetomaternal 
interface, resulting in an impaired exchange of blood components 
between mother and fetus, which can lead to early miscarriage, 
preeclampsia, intrauterine growth restriction or even intrauterine 
fetal death. 
How do patients with antiphospholipid syndrome 
present?
The clinical features of antiphospholipid syndrome are diverse  
and can affect all organ systems. Figure 1 gives an overview of the 
most common clinical findings. Venous thrombosis, along with  
its complications, is more common than arterial thrombosis.  
In a large cohort of 1000 patients deep vein thrombosis in the leg  
contradictory findings.8;13;19 The clinical relevance of isolated  
a anti-β™glycoprotein I antibodies remains uncertain.
* Patients with triple positivity for lupus anticoagulant, 
anticardiolipin and anti-β™glycoprotein I antibodies seem to 
have a particularly high risk for future pregnancy morbidity or 
thromboembolism (or = 34.4, 95% CI 3.5-335).20;21
* Established risk factors for thrombosis such as smoking (arterial 
disease) and oral contraception (venous thrombosis) contribute 
to a further increased risk of thrombosis in the presence of 
antiphospholipid antibodies.15 
* The risk of apparently healthy people with persistently positive 
antiphospholipid antibodies to eventually develop a clinical  
event, such as thrombosis or adverse pregnancy outcome  
remains unknown.
What is known about the aetiology and pathophysiology 
of antiphospholipid syndrome?
The cause of the production of autoantibodies to phospholipid  
binding proteins such as anti-β™-glycoprotein I is largely unknown.6;22 
effect on coagulation and inflammatory pathways 
Antiphospholipid antibodies affect the coagulation cas cade 
and inflammation. In a process mediated by β2 glyco protein I, 
antiphospholipid antibodies bind to platelets and endothelial 
cells, activating endothelial cells and induc ing a procoagulant 
state. Antibody binding also activates complement23, resulting 
in recruitment of other inflamma tory cells, activation of tissue 
factor, endothelial damage, and finally thrombosis.24 Although 
cerebral involvement is thought to be mainly thrombotic in nature, 
evidence now suggests that antiphospholipid antibodies may have 
more direct effects, causing neurological impairment unrelated to 
thrombosis through antibody-cellular interactions, pos sibly because 
of complement activation25 or a disrupted blood-brain barrier.26;27
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 – box 3 –
conditions that point to antiphospholipid syndrome
Thrombosis can occur anywhere in the renal vasculature, ranging 
from occlusion of the renal veins and arterial trunk to microthrombi 
in glomerular capillaries. The latter can cause rapid decline of renal 
function.2 In secondary antiphospholipid syndrome it is debated 
whether presence of antiphospholipid antibodies leads to a worsened 
outcome for traditional lupus nephritis. Although prospective 
studies have not addressed this matter so far, retrospective analyses 
provide good evidence for this.37
Haematological manifestations such as thrombocytopenia and 
haemolytic anaemia, and dermal symptoms such as livedo reticularis 
occur in 10-30% of patients although these features are not included 
in the classification criteria.2 Box 3 lists red and yellow flag conditions 
that indicate when antiphospholipid syndrome should be included 
in a differential diagnosis. 
maternal and fetal effects in pregnancy Obstetric cri-
teria used to define antiphospholipid syndrome are fetal loss after 10 
weeks’ gestation, three or more unexplained consecutive embryonic 
losses before the 10th week of gestation, and pre-eclampsia or features 
of placental insufficiency associated with the premature birth of a 
morphologically normal neonate before the 34th week of gestation.4
 
was the first symptom in 32%, and pulmonary embolism in 14%.2 
Other vesseIs such as renal veins, hepatic, subclavian, and retinal 
veins, cerebral sinuses and vena cava are more often affected than  
in non antiphospholipid syndrome related thrombosis.2 
The most common arterial thrombotic events are stroke and  
transient ischaemic attack, which are the initial clinical manifesta-
tion in 13% and in 7% of patients, respectively.2 Recurrent thrombotic 
events are common. The vascular pattern of recurrent thrombosis is 
fairly consistent for venous thrombosis (70% venous recurrence) and 
arterial thrombosis (90% arterial recurrence).31 
cerebral involvement Cerebral involvement is common in 
antiphospholipid syndrome32 and was highlighted in the original 
description of the syndrome.1 Cerebral ischaemia, migraine, cognitive 
dysfunction, seizures, chorea, transverse myeli tis, psychosis, 
depression, and Guillain-Barré syndrome have all been associated 
with the presence of antiphos pholipid antibodies.27 Despite a strong 
observed asso ciation between chronic headache, including migraine, 
and antiphospholipid syndrome 33, studies exploring the relationship 
between headache and antiphospholipid antibodies have shown 
contradictory results.34 An association has been reported between 
valvular heart disease and central nervous system manifestations of 
the syndrome, which suggests that cerebral emboli from valvular 
lesions may be a risk.35
other organ involvement The most common cardiac 
abnormality in patients with antiphospholipid syndrome is non-
bacterial thrombotic endocarditis characterized by adherent platelet-
fibrin thrombi on the endocardial surface of valves, which has been 
reported in 11.6% of patients during the evolution of disease.2;36 
Myocardial infarction is the presenting symptom of the syndrome 
in 2.8% of patients.2 Prospective studies have shown that presence of 
antiphospholipid antibodies is associated with an increased risk of 
myocardial infarction.15;17 
Red Flags
Unexplained deep vein thrombosis and/or 
pulmonary embolism under 50
Stroke under 50
Transient ischemic attack under 50
Recurrent thrombosis
Thrombosis in an unusual site 
Unexplained fetal loss after 10 weeks 
gestation
Severe and/or early preeclampsia 
Severe intrauterine growth restriction
Preeclampsia with severe thrombocytopenia
Cardiac valve disease (in combination with 
other symptoms in this box)





Recurrent early pregnancy loss
46 clinical significance of c4d in sle and antiphospholipid syndrome 47 iii • diagnosis and management of the antiphospholipid syndrome
– box 4 –
situations when you should test for antiphospholipid 
antibodies
Lupus anticoagulant and the persistent presence of anticardiolipin 
antibodies increase the risk of thromboembolic events in patients 
with sle. 45;46 Data on antiphospholipid antibodies can help when 
interpret ing new symptoms in these patients and may influence 
therapeutic decisions in situations with increased throm boembolic 
risk, such as surgery, pregnancy, puerperium, or the use of oestrogen 
containing drugs.
pregnancy  A recent prospective study of pregnant women  
with only one previous spontaneous abortion before the 10th week  
of gestation reported that the presence of antiphospholipid anti- 
bodies significantly increased the risk of embryonic loss, pre-
eclampsia, and intrauterine growth restriction in the next preg- 
nancy.38 However, after single pregnancy loss, most subsequent 
pregnancies are uneventful without treatment. Therefore, testing 
after one early miscarriage, or even testing all women who plan to 
become pregnant, is not advised. 43 
Other manifestations that are not stated in the criteria, but 
are sequelae of the syndrome, are pregnancy-related maternal 
thrombosis and unexplained intrauterine growth restriction.
Late fetal loss is strongly associated with presence of anti-
phospholipid antibodies, and particularly lupus anticoagulant. 
Prospective studies have shown that positive lupus anticoagulant 
and/or high titers of cardiolipin IgG increase the risk of recurrent 
adverse outcome in a subsequent pregnancy.38;39
Evidence for a causal association between antiphos pholipid 
antibodies and early miscarriage is limited.8 Early miscarriage is 
relatively common and has many causes, of which fetal chromosomal 
abnormalities are the most likely. Observational studies of the 
association between antiphospholipid syndrome and recurrent 
early miscarriage are likely to be heavily confounded, especially by 
inclusion of women with sporadic rather than recurrent miscarriage. 
Therefore international guidelines (Royal College of Obstetricians 
and Gynaecologist, European Society of Human Reproduction and 
Embryology) advise screening for antiphospholipid antibodies in 
women with more than three early miscarriages.40;41
Women with antiphospholipid syndrome have an increased 
incidence of early or severe pre-eclampsia, which often leads 
to iatrogenic preterm birth due to ter mination of pregnancy 
for maternal or fetal reasons. Pre-eclampsia with severe 
thrombocytopenia may also point towards the presence of the 
syndrome, and is a red flag condition (box 3). 42
Who should be tested for antiphospholipid antibodies?
Box 4 lists the indications for testing for antiphospholipid 
antibodies.43 
sle Testing for antiphospholipid antibodies is recommended in 
the initial evaluation of patients with sle and should be reevalu-
ated if new risk factors for thromboembolic events emerge.44
Thrombosis
Arterial thrombosis before the age of 50 
Unprovoked venous thrombosis before  
the age of 50 
Recurrent thrombosis
Thrombosis in an unusual site
Patients with both arterial and venous 
thrombotic events
Any patient admitted with thrombotic 
microangiopathy of unknown etiology
Obstetric manifestations
One or more unexplained fetal losses after 10 
weeks of gestation 
Unexplained severe intrauterine growth 
restriction 
Early and/or severe preeclampsia 
Three or more spontaneous miscarriages 
before 10 weeks of gestation
SLE patients
At baseline
Repeat testing prior to pregnancy, surgery, 
transplant and use of oestrogen-
containing treatments, or in the 
presence of a new neurological, vascular 
or obstetric event
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the results contradict those of observational studies, mean that 
treatment aims are still a point of ongoing debate.50 International 
guidelines and systematic reviews currently recommend aiming for 
an inr between 2 and 3. 47;48;54;55 
preventing obstetric complications Few well designed 
trials have been carried out and studied populations are heteroge-
neous, so the level of evidence for all treatment options is low. Table 
2 gives suggestions for primary and secondary prevention of throm-
bosis and adverse pregnancy outcome; these are based on the limited 
available evidence and our own experience.
preventing maternal thrombotic complications 
Warfarin crosses the placenta and is teratogenic in the first trimester 
of pregnancy so low molecular weight heparins are the agents of 
choice for antenatal thromboprophylaxis.41;56 Observational studies 
have shown that low molecular weight heparin is at least as effective 
as unfractionated heparin and safer. 41;56 Women who are on long 
term warfarin because of previous thrombosis should switch to 
heparin when trying to conceive or on confirmation of conception. 
The dose of heparin will depend on the woman’s clinical history and 
should be discussed with a haematologist.
preventing adverse pregnancy outcome A meta-analysis 
of intervention trials for recurrent (early) miscarriage have concluded 
that heparin with low dose aspirin reduces pregnancy loss by 54%.57 
No randomised controlled trials have investigated prevention  
in patients with a history of late miscarriage, fetal death, and intr a- 
uterine growth restriction. Most clinicians would consider treatment 
with low dose aspirin and heparin (mostly low molecular weight 
heparin) in such cases. In patients with antiphospholipid antibodies 
and a history of severe pre-eclampsia at least low dose aspirin (75-80 
mg once daily) is recommended.47
Glucocorticoids, cytotoxic agents, and intravenous immunoglo-
bulin have no confirmed benefit and may even be teratogenic.47
How to treat antiphospholipid syndrome
Antithrombotic agents aim to reduce the risk of recurrent thrombo-
embolism and are the mainstay of treatment. Recently guidelines  
on how to treat antiphospholipid syndrome subdivided patients 
into those with venous thrombosis, those with arterial thrombosis, 
and obstetric antiphospholipid syndrome.47 A treatment algorithm 
containing an overview of these guidelines is presented in figure 2. 
first episode For a first episode of unprovoked venous thrombo-
sis or thromboembolism associated with persistent positive anti -
phospholipid antibodies international guidelines recommend  
long term anticoagulation with vitamin K antagonists such as  
warfarin to reduce the risk of recurrence of a thrombotic event.48 
However, if a reversible risk factor for thromboembolism — such  
as surgery, immobilisation, oestrogen therapy, or pregnancy — is 
reliably eliminated indefinite anticoagulation may not be justified.47 
The only prospective study focusing on arterial cerebral events 
showed similar rates of recurrent thromboembolism and risk  
of major bleeding in patients treated with warfarin or low dose  
aspirin.49 However, inappropriate criteria for defining antiphos-
pholipid antibody positivity limit the generalisability of this study.50 
In patients with antiphospholipid syndrome and stroke, long term 
anticoagulation with warfarin or low dose aspirin is advised.
Two randomised controlled trials compared high inten sity 
anticoagulation (aimed at an international normalised ratio (inr) 
of 3.1-4) with moderate intensity anticoagula tion (inr 2-3) for the 
prevention of recurrent venous and arterial thrombotic events in 
non-pregnant adults with antiphospholipid syndrome. Both trials 
used oral warfa rin and found that high intensity treatment was 
no better at preventing thrombotic events.51;52 When results were 
pooled, the risk of bleeding was slightly increased in patients on high 
intensity treatment.53 The limitations of these trials (patients with 
arterial events were in the minor ity and many patients randomised 
to a target inr >3 did not achieve this target), and the fact that 
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a patient’s perspective 
methods 
sle In patients with sle and antiphospholipid antibodies, low  
dose aspirin may be considered for primary prevention of thrombo-
sis and pregnancy loss.58 In non-pregnant patients with sle and 
antiphospholipid syndrome associated thrombosis, long term anti-
coagulation with vitamin K antagonists is effective for secondary 
prevention of thrombosis. In pregnant patients with sle and 
antiphospholipid syndrome, combined unfractionated heparin  
or low molecu lar weight heparin and aspirin reduce pregnancy  
loss and thrombosis and should be considered.58 
catastrophic antiphospholipid syndrome Box 2 
summarises the management and characteristics of this rare 
manifestation of the syndrome. Figure 3 gives examples of typical 
histologic findings in patients with catastrophic antiphospholipid 
syndrome. 
Future challenges in for the management of patients with 
Antiphospholipid syndrome
 
A reliable diagnostic test is still needed. Antiphospholipid syndrome 
mimics many other conditions, which leads to misdiagnosis and  
thwarts efforts to perform studies of suf ficient size to give unequivo-
cal support for diagnostic and treatment strategies. However, left 
untreated the syndrome can have serious sequelae. We advise that  
any patient with a suspected antiphospholipid syndrome should  
be seen by a multidisciplinary team of specialists that ideally includes 
a rheumatologist, haematologist, neurologist, nephrologist, and 
obstetrician for diagnosis, treatment, and education. 
From the age of 16, I had frequent head-
aches, sometimes with double vision, and 
I occasionally had pins and needles in one 
hand. My general practitioner never found 
an obvious cause. At 21 I was diagnosed with 
a deep vein thrombosis in my left leg, after 
a minor car accident. I was treated with 
heparin and aspirin for a few months.
A year later I had a miscarriage at 9 weeks’ 
gestation. My platelets were low and did 
not improve. My gynaecologist sent me 
to a haematologist, who thought of the 
antiphospholipid syndrome. The blood test 
was positive. It was a double feeling: on the 
one hand I felt relieved to have a diagnosis 
that explained all my medical problems, 
but I suddenly had a disease that I had never 
heard of. My friends and family have dif-
ficulty understanding when I try to explain 
what antiphospholipid syndrome is. The 
most frustrating thing is that even some 
of the doctors I talk to have never heard of 
it. Two years ago they found out that two 
of my heart valves are leaking. I have had 
surgery for one valve recently, and one more 
operation is needed for the other. It is scary 
to think that if my anticoagulation therapy 
is stopped I will be at risk of developing 
things like a stroke. It is surreal to have to 
think about these things in your early 30s. 
Because of the heart valves I had to postpone 
further pregnancies. I hope for the best, and 
hope that with heparin treatment I’ll have a 
fair chance of becoming a mother one day.
A Meijer-Bezema, Stadskanaal, Netherlands
In cooperation with a trained librarian, 
a search strategy was composed. The 
following databases were searched for 
evidence from systematic reviews, clinical 
trials and prospective cohort studies: 
PubMed (1949 to January 2010), embase 
(OviD-version, 1980 to January 2010), 
Web of Science (1945 to January 2010), 
Cochrane Library (1990 to January 2010), 
cinahl (EbscoHost-version, 1982 to 
January 2010), and Academic Search Premier 
(EbscoHost-version (1865 to January 2010). 
All relevant keyword variations were 
used, not only keyword variations in the 
controlled vocabularies of the various 
databases, but the free text word variations 
of these concepts as well. In general, the 
search consisted of the combination of 
the following terms: ‘antiphospholipid 
syndrome’, ‘Hughes syndrome’, ‘antiphos-
pholipid antibodies’, ‘lupus anticoagulant’, 
‘anticardiolipin antibodies’, ‘anti β™-glyco-
protein i antibodies’ and ‘catastrophic 
antiphospholipid syndrome’. The results 
were limited to articles written in English. 
The search was performed on the 27th of 
January, 2010. 
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ongoing research and future challenges
tips for non specialists 
Pathologic mechanism
To clarify the relation between inflamma-
tion and thrombosis in antiphospholipid 
syndrome.
To further unravel the actions of different 
antiphospholipid antibodies on hemosta-
sis, endothelial activation and placental 
invasiveness.
Serology
To find more specific tests for antipho spho-
lipid antibodies that correlate better with 
clinical symptoms. Lupus anticoagulant 
inducing anti-β™glycoprotein i antibodies 
and anti-β™glycoprotein i domain i 
antibodies are promising new binding 
targets.6
Treatment
To identify the role of newer, preferably 
oral anticoagulants in antiphospholipid 
syndrome.
To identify the role of anti-inflammatory 
drugs in antiphospholipid syndrome 
(Rituximab, anti-complement agents, 
statins)
To perform well designed randomized con-
trolled trials in pregnancy related settings. 
Early recognition of antiphospholipid 
syndrome offers a chance for prevention 
of recurrent thrombosis, and prevention 
of recurrent maternal and fetal pregnancy 
morbidity.
A delayed diagnosis can cause permanent 
disability due to uncontrolled thrombosis 
formation, or death.
If you consider testing for antiphospholipid 
syndrome, perform all three laboratory 
tests mentioned in the classification criteria 
(box 1) or refer the patient to a specialist for 
testing. 
Try to obtain the first test results before 
starting with anticoagulation therapy,  
since anticoagulation therapy influences  
the outcome of the lupus anticoagulant test. 
A positive test is an indication to refer the 
patient to a specialist.
Antiphospholipid syndrome pregnancies 
are high risk pregnancies, and management 
at specialized centers is advisable.
Traditional risk factors for cardiovascular 
disease contribute further to the risk of 
thrombosis in antiphospholipid syndrome, 
even at young age. 
Try to support patients to stop smoking, 
normalize body weight and try to avoid oral 
contraception and hormone replacement 
therapy.
summary points 
continuing medical education resources  
Antiphospholipid syndrome is a relatively 
common autoimmune disorder that mainly 
affects young adults
If untreated, antiphospholipid syndrome 
can lead to permanent disability, severe ma-
ternal or perinatal morbidity, or even death
Symptoms can occur in virtually all organ 
systems
Venous thrombosis and stroke are the most 
common thrombotic manifestations
In pregnancy the syndrome is asso ciated 
with adverse maternal and fetal outcomes
The lupus anticoagulant test is the most 
useful because positivity correlates most 
strongly with clinical manifestations
Cardiac valvular disease is an important 
clinical manifestation and may contribute 
to the risk of strokes
For professionals
How I treat the antiphospholipid syndrome.47 
Excellent review about recent developments 
in treatment of antiphospholipid syndrome 
patients. 
How we diagnose the antiphospholipid syn-
drome.43 Excellent review about recent  
developments in diagnosing the anti-
phospholipid syndrome. 
Reducing the risk of thrombosis and embolism 
during pregnancy and the puerperium.41 
Greentop guidelines of the Royal College  
of Obstetricians and Gynecologists  
(rcog). http://www.rcog.org.uk/
Antithrombotic and thrombolytic therapy, 
and Antithrombotic therapy for venous 
thromboembolic disease, 8th edition.48;54 
Guidelines of the American College of  
Chest Physicians (accp) http://www.
chestnet.org/accp/
Investigation and medical treatment of recurrent 
miscarriage.40 Guidelines from the European 
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Youtube: Video in which Dr Graham 
Hughes of the London Lupus Center 
explains about antiphospholipid syndrome, 
and in which 2 patients tell about their 
experiences with recurrent miscarriage 
and stroke. (http://www.youtube.com/
watch?v=V3J8BLkZyhU)
Youtube: Video showing an excellent 
animation of deep vein thrombosis. (http://
www.youtube.com/watch?v=CETfozL0cQg)
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fig 2 treatment algorithm for antiphospholipid syndrome
Adapted, with permission obtained from ‘Blood copyright clearance centre’, Giannakopoulos et al, 
(2009); How I treat the antiphospholipid syndrome
fig 3 classic histological findings in a patient with   
 catastrophic antiphospholipid syndrome
(a) Cerebral microthrombi (arrows); the fibrin thrombi are stained blue by phosphotungstic acid 
haematoxylin. (b) Renal microthrombi, prominently present in a glomerulus (arrow). (c) Blood 
smear showing schistocytes (fragmented red blood cells), which are formed by fibrin strands that 
sever red blood cells as they try to move past a (micro)thrombus (arrows), and are indicative of 
microangiopathic haemolytic anaemia
fig 1 clinical manifestations of antiphospholipid syndrome
  
(Illustration by Folkert van Meurs)
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table 2 treatment of patients with persistent positive   
 antiphospholipid antibodies in pregnancy






Women (including  
patients with sle) with  
prior thrombosis 
• Graduated elastic compression 
stockings
• Weight adjusted, full-dose 
lmwh from < 6 wks gestation
• Graduated elastic compression 
stockings
• 6 weeks lmwh or warfarin* 
c
Women with late fetal loss  
(> 10 wks)
Low-dose aspirin  
and/or lmwh ***
at least 7 days lmwh  
or warfarin
c
Women with recurrent 
miscarriage (<10 wks)
Low-dose Aspirin  
plus lmwh 
at least 7 days lmwh  
or warfarin
a
Women with history of early 
and/or severe preeclampsia or 
intrauterine growth restriction
Low-dose Aspirin 
Consider additional lmwh ***
at least 7 days lmwh  
or warfarin
c
Women with persistently 
positive antiphospholipid 
antibodies without clinical 
symptoms 
Close surveillance at least 7 days lmwh  
or warfarin
c
Women with sle without 
previous obstetric or  
thrombotic complications
Low dose Aspirin ***  at least 7 days lmwh  
or warfarin
 c
Women with sle with previous 
obstetric complications
Low-dose Aspirin + lmwh ***  at least 7 days lmwh  
or warfarin
*  Warfarin crosses the placenta, is teratogenic and must be avoided in pregnancy 
**  Level a: Consistent randomized controlled trials and/or cohort studies / Level b: Consistent retrospective 
 cohort, exploratory cohort or case control studies or extrapolations from level a studies / Level c: Case-series 
 or extrapolations from level b studies / Level d: Expert opinion without explicit critical appraisal
***  If possible try to include patients in a Rct






Test Anticardiolipin elisa anti-β™glycoprotein i 
elisa
The lupus anticoagulant 
assay **
Test guidelines Pierangeli et al, 2008 59 no guidelines yet Pengo et al, 2009 10








Detects immunoglobulins that 
cause prolonged clotting times 
in vitro, but are associated with 
thrombosis in vivo. 
Relevant isotypes IgG +++, IgM + IgG+++, IgM + not applicable
What titers are 
considered positive?
Medium/High: > 99th 
percentile, or >40 gpl  
or mpl
Medium/High: > 99th 
percentile, or >40 gpl 
or mpl
not applicable
Is the test influenced 
by anticoagulation 
therapy?
no no yes: both heparin and warfarin 
influence the test-results, and 
testing under coagulation 
therapy is controversial.
Is there overlap with 
other tests?
yes, overlap with lupus 
anticoagulant
yes, overlap with lupus 
anticoagulant 
yes: anti-β™glycoprotein i and 
anticardiolipin antibodies can 
have an anticoagulant effect, 
but other antibodies like anti-
prothrombin and anti-annexin 
V antibodies can contribute to 
this effect too.
** A set of coagulation assays in three steps: Screening (identification of a prolonged clotting time), mixing 
(confirmation of an inhibitor and exclusion of factor-deficiencies) and confirmation (confirmation of phospholipid 
dependence of the inhibitor) 
58 clinical significance of c4d in sle and antiphospholipid syndrome 59 iii • diagnosis and management of the antiphospholipid syndrome
study of anticardiolipin antibodies as a risk 
factor for venous thrombosis in a general popu-
lation (the HUNT study). J Thromb Haemost 2006; 
4(1):44-49.
19 Galli M, Luciani D, Bertolini G, Barbui 
T. Anti-beta 2-glycoprotein I, antiprothrom-
bin antibodies, and the risk of thrombosis in 
the antiphospholipid syndrome. Blood 2003; 
102(8):2717-2723.
20 Ruffatti A, Tonello M, Del RT, Cavazzana A, 
Grava C, Noventa F et al. Antibody profile and 
clinical course in primary antiphospholipid 
syndrome with pregnancy morbidity. Thromb 
Haemost 2006; 96(3):337-341.
21 Ruffatti A, Tonello M, Cavazzana A, 
Bagatella P, Pengo V. Laboratory classification 
categories and pregnancy outcome in patients 
with primary antiphospholipid syndrome 
prescribed antithrombotic therapy. Thromb Res 
2009; 123(3):482-487.
22 Pierangeli SS, Chen PP, Raschi E, Scurati 
S, Grossi C, Borghi mo et al. Antiphospholipid 
antibodies and the antiphospholipid syndrome: 
pathogenic mechanisms. Semin Thromb Hemost 
2008; 34(3):236-250.
23 Oku K, Atsumi T, Bohgaki M, Amengual O, 
Kataoka H, Horita T et al. Complement activa-
tion in patients with primary antiphospholipid 
syndrome. Ann Rheum Dis 2009; 68(6):1030-1035.
24 Salmon JE, Girardi G, Holers VM. Comple-
ment activation as a mediator of antiphos-
pholipid antibody induced pregnancy loss 
and thrombosis. Ann Rheum Dis 2002; 61 Suppl 
2:ii46-ii50.
25 Davis WD, Brey RL. Antiphospholipid an-
tibodies and complement activation in patients 
with cerebral ischemia. Clin Exp Rheumatol 1992; 
10(5):455-460.
26 Meroni pl, Tincani A, Sepp N, Raschi E, 
Testoni C, Corsini E et al. Endothelium and the 
brain in cns lupus. Lupus 2003; 12(12):919-928.
27 Katzav A, Chapman J, Shoenfeld Y. cns 
dysfunction in the antiphospholipid syndrome. 
Lupus 2003; 12(12):903-907.
28 Sebire NJ, Backos M, El GS, Goldin RD, 
Regan L. Placental pathology, antiphospholipid 
antibodies, and pregnancy outcome in recur-
rent miscarriage patients. Obstet Gynecol 2003; 
101(2):258-263.
29 Di Simone N, Luigi MP, Marco D, Fiorella 
DN, Silvia D, Clara DM et al. Pregnancies com-
plicated with antiphospholipid syndrome: the 
pathogenic mechanism of antiphospholipid 
antibodies: a review of the literature. Ann N Y 
Acad Sci 2007; 1108:505-514.
30 Girardi G, Redecha P, Salmon JE. Heparin 
prevents antiphospholipid antibody-induced 
fetal loss by inhibiting complement activation. 
Nat Med 2004; 10(11):1222-1226.
31 Khamashta MA, Cuadrado MJ, Mujic F, 
Taub NA, Hunt BJ, Hughes GR. The manage-
ment of thrombosis in the antiphospholipid-an-
tibody syndrome. N Engl J Med 1995; 332(15):993-
997.
32 Sanna G, D’Cruz D, Cuadrado MJ. Cerebral 
manifestations in the antiphospholipid 
(Hughes) syndrome. Rheum Dis Clin North Am 
2006; 32(3):465-490.
33 Hughes GR. Migraine, memory loss, and 
‘multiple sclerosis “. Neurological features of the 
antiphospholipid (Hughes’) syndrome. Postgrad 
Med J 2003; 79(928):81-83.
34 Montalban J, Cervera R, Font J, Ordi J, Vi-
anna J, Haga HJ et al. Lack of association between 
anticardiolipin antibodies and migraine in 
systemic lupus erythematosus. Neurology 1992; 
42(3 Pt 1):681-682.
35 Krause I, Lev S, Fraser A, Blank M, Lorber 
M, Stojanovich L et al. Close association between 
valvar heart disease and central nervous system 
manifestations in the antiphospholipid syn-
drome. Ann Rheum Dis 2005; 64(10):1490-1493.
36 Roldan ca. Valvular and coronary heart 
disease in systemic inflammatory diseases: 
Systemic Disorders in heart disease. Heart 2008; 
94(8):1089-1101.
37 Daugas E, Nochy D, Huong DL, Duhaut P, 
Beaufils H, Caudwell V et al. Antiphospholipid 
references
1 Hughes GR. Thrombosis, abortion, cerebral 
disease, and the lupus anticoagulant. Br Med J 
(Clin Res Ed) 1983; 287(6399):1088-1089.
2 Cervera R, Piette JC, Font J, Khamashta MA, 
Shoenfeld Y, Camps MT et al. Antiphospholipid 
syndrome: clinical and immunologic manifesta-
tions and patterns of disease expression in a 
cohort of 1,000 patients. Arthritis Rheum 2002; 
46(4):1019-1027.
3 Asherson RA, Cervera R, de Groot PG, 
Erkan D, Boffa MC, Piette JC et al. Catastrophic 
antiphospholipid syndrome: international con-
sensus statement on classification criteria and 
treatment guidelines. Lupus 2003; 12(7):530-534.
4 Miyakis S, Lockshin MD, Atsumi T, Branch 
DW, Brey RL, Cervera R et al. International 
consensus statement on an update of the clas-
sification criteria for definite antiphospholipid 
syndrome (aps). J Thromb Haemost 2006; 4(2):295-
306.
5 Avcin T, Cimaz R, Silverman ED, Cervera 
R, Gattorno M, Garay S et al. Pediatric antiphos-
pholipid syndrome: clinical and immunologic 
features of 121 patients in an international 
registry. Pediatrics 2008; 122(5):e1100-e1107.
6 de Laat B, Mertens K, de Groot PG. Mecha-
nisms of disease: antiphospholipid antibodies-
from clinical association to pathological mecha-
nism. Nat Clin Pract Rheumatol 2008; 4(4):192-199.
7 Galli M, Luciani D, Bertolini G, Barbui T. 
Lupus anticoagulants are stronger risk factors 
for thrombosis than anticardiolipin antibodies 
in the antiphospholipid syndrome: a systematic 
review of the literature. Blood 2003; 101(5):1827-
1832.
8 Opatrny L, David M, Kahn SR, Shrier I, 
Rey E. Association between antiphospholipid 
antibodies and recurrent fetal loss in women 
without autoimmune disease: a metaanalysis. J 
Rheumatol 2006; 33(11):2214-2221.
9 Pengo V, Biasiolo A, Gresele P, Marongiu F, 
Erba N, Veschi F et al. Survey of lupus anticoagu-
lant diagnosis by central evaluation of positive 
plasma samples. J Thromb Haemost 2007; 5(5):925-
930.
10 Pengo V, Tripodi A, Reber G, Rand JH, Ortel 
TL, Galli M et al. Update of the guidelines for 
lupus anticoagulant detection. J Thromb Haemost 
2009; 7(10):1737-1740.
11 Petri M. Epidemiology of the antiphos-
pholipid antibody syndrome. J Autoimmun 2000; 
15(2):145-151.
12 Vila P, Hernandez MC, Lopez-Fernandez 
MF, Batlle J. Prevalence, follow-up and clinical 
significance of the anticardiolipin antibodies in 
normal subjects. Thromb Haemost 1994; 72(2):209-
213.
13 Danowski A, Kickler TS, Petri M. Anti-beta2-
glycoprotein I: prevalence, clinical correlations, 
and importance of persistent positivity in 
patients with antiphospholipid syndrome and 
systemic lupus erythematosus. J Rheumatol 2006; 
33(9):1775-1779.
14 de Groot PG, Lutters B, Derksen RH, Lisman 
T, Meijers JC, Rosendaal FR. Lupus antico-
agulants and the risk of a first episode of deep 
venous thrombosis. J Thromb Haemost 2005; 
3(9):1993-1997.
15 Urbanus RT, Siegerink B, Roest M, Rosend-
aal FR, de Groot PG, Algra A. Antiphospholipid 
antibodies and risk of myocardial infarction and 
ischaemic stroke in young women in the RATIO 
study: a case-control study. Lancet Neurol 2009; 
8(11):998-1005.
16 Saidi S, Mahjoub T, Almawi WY. Lupus anti-
coagulants and anti-phospholipid antibodies as 
risk factors for a first episode of ischemic stroke. J 
Thromb Haemost 2009; 7(7):1075-1080.
17 Levine SR, Salowich-Palm L, Sawaya KL, 
Perry M, Spencer HJ, Winkler HJ et al. IgG anti-
cardiolipin antibody titer > 40 Gpl and the risk 
of subsequent thrombo-occlusive events and 
death. A prospective cohort study. Stroke 1997; 
28(9):1660-1665.
18 Naess IA, Christiansen SC, Cannegieter SC, 
Rosendaal FR, Hammerstroem J. A prospective 
60 clinical significance of c4d in sle and antiphospholipid syndrome 61 iii • diagnosis and management of the antiphospholipid syndrome
Management of antiphospholipid antibody 
syndrome: a systematic review. JAMA 2006; 
295(9):1050-1057.
56 Bates SM, Greer IA, Pabinger I, Sofaer S, 
Hirsh J. Venous thromboembolism, thrombo-
philia, antithrombotic therapy, and pregnancy: 
American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines (8th Edition). 
Chest 2008; 133(6 Suppl):844S-886S.
57 Empson M, Lassere M, Craig J, Scott J. 
Prevention of recurrent miscarriage for women 
with antiphospholipid antibody or lupus 
anticoagulant. Cochrane Database Syst Rev 
2005;(2):CD002859.
58 Bertsias G, Ioannidis JP, Boletis J, Bombar-
dieri S, Cervera R, Dostal C et al. eular recom-
mendations for the management of systemic 
lupus erythematosus. Report of a Task Force of 
the eular Standing Committee for Interna-
tional Clinical Studies Including Therapeutics. 
Ann Rheum Dis 2008; 67(2):195-205.
59 Pierangeli SS, Harris EN. A protocol for 
determination of anticardiolipin antibodies by 
elisa. Nat Protoc 2008; 3(5):840-848.
60 Asherson RA, Cervera R, Piette JC, Font J, Lie 
JT, Burcoglu A et al. Catastrophic antiphospho-
lipid syndrome. Clinical and laboratory features 
of 50 patients. Medicine (Baltimore) 1998; 77(3):195-
207.
61 Bucciarelli S, Erkan D, Espinosa G, Cervera 
R. Catastrophic antiphospholipid syndrome: 
treatment, prognosis, and the risk of relapse. Clin 
Rev Allergy Immunol 2009; 36(2-3):80-84.
62 Garcia D, Crowther MA, Ageno W. Practical 
management of coagulopathy associated with 
warfarin. BMJ 2010; 340:c1813.
syndrome nephropathy in systemic lupus 
erythematosus. J Am Soc Nephrol 2002; 13(1):42-52.
38 Chauleur C, Galanaud JP, Alonso S, 
Cochery-Nouvellon E, Balducchi JP, Mares P et al. 
Observational study of pregnant women with a 
previous spontaneous abortion before the 10 ges-
tation week with and without antiphospholipid 
antibodies. J Thromb Haemost 2010; 8(4):699-706.
39 Rai RS, Clifford K, Cohen H, Regan L. High 
prospective fetal loss rate in untreated pregnan-
cies of women with recurrent miscarriage and 
antiphospholipid antibodies. Hum Reprod 1995; 
10(12):3301-3304.
40 Jauniaux E, Farquharson RG, Christiansen 
OB, Exalto N. Evidence-based guidelines for the 
investigation and medical treatment of recur-
rent miscarriage. Hum Reprod 2006; 21(9):2216-
2222.
41 Nelson-Piercy, MacCallum, Mackillop. Re-
ducing the risk of thrombosis and embolism in 
pregnancy and the puerperium. rcog Green-top 
Guideline No 37 2009.
42 Duckitt K, Harrington D. Risk factors for 
pre-eclampsia at antenatal booking: system-
atic review of controlled studies. BMJ 2005; 
330(7491):565.
43 Giannakopoulos B, Passam F, Ioannou Y, 
Krilis SA. How we diagnose the antiphospholipid 
syndrome. Blood 2009; 113(5):985-994.
44 Mosca M, Tani C, Aringer M, Bombardieri 
S, Boumpas D, Brey R et al. European League 
Against Rheumatism recommendations for 
monitoring patients with systemic lupus 
erythematosus in clinical practice and in obser-
vational studies. Ann Rheum Dis 2010.
45 Martinez-Berriotxoa A, Ruiz-Irastorza G, 
Egurbide MV, Garmendia M, Gabriel EJ, Villar 
I et al. Transiently positive anticardiolipin 
antibodies and risk of thrombosis in patients 
with systemic lupus erythematosus. Lupus 2007; 
16(10):810-816.
46 Tektonidou MG, Laskari K, Panagiota-
kos DB, Moutsopoulos HM. Risk factors for 
thrombosis and primary thrombosis prevention 
in patients with systemic lupus erythematosus 
with or without antiphospholipid antibodies. 
Arthritis Rheum 2009; 61(1):29-36.
47 Giannakopoulos B, Krilis SA. How I treat 
the antiphospholipid syndrome. Blood 2009; 
114(10):2020-2030.
48 Kearon C, Kahn SR, Agnelli G, Goldhaber 
S, Raskob GE, Comerota AJ. Antithrombotic 
therapy for venous thromboembolic disease: 
American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines (8th Edition). 
Chest 2008; 133(6 Suppl):454S-545S.
49 Levine SR, Brey RL, Tilley BC, Thompson 
JL, Sacco RL, Sciacca RR et al. Antiphospholipid 
antibodies and subsequent thrombo-occlusive 
events in patients with ischemic stroke. JAMA 
2004; 291(5):576-584.
50 Ruiz-Irastorza G, Hunt BJ, Khamashta MA. 
A systematic review of secondary thrombopro-
phylaxis in patients with antiphospholipid 
antibodies. Arthritis Rheum 2007; 57(8):1487-1495.
51 Crowther MA, Ginsberg JS, Julian J, Den-
burg J, Hirsh J, Douketis J et al. A comparison of 
two intensities of warfarin for the prevention 
of recurrent thrombosis in patients with the 
antiphospholipid antibody syndrome. N Engl J 
Med 2003; 349(12):1133-1138.
52 Finazzi G, Marchioli R, Brancaccio V, 
Schinco P, Wisloff F, Musial J et al. A random-
ized clinical trial of high-intensity warfarin vs. 
conventional antithrombotic therapy for the 
prevention of recurrent thrombosis in patients 
with the antiphospholipid syndrome (Waps). J 
Thromb Haemost 2005; 3(5):848-853.
53 Crowther M, Crowther MA. Intensity of 
warfarin coagulation in the antiphospholipid 
syndrome. Curr Rheumatol Rep 2010; 12(1):64-69.
54 Hirsh J, Guyatt G, Albers GW, Harrington 
R, Schunemann HJ, American College of Chest 
Physician. Antithrombotic and thrombolytic 
therapy: American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines (8th 
Edition). Chest 2008; 133(6 Suppl):110S-112S.
55 Lim W, Crowther MA, Eikelboom JW. 
                           general
          
      part one
c4d and thrombotic
                part two
c4d and adverse  





            appendices
65 iv • potential for glomerular c4d as an indicator of thrombotic microangiopathy  
        in lupus nephritis
Abstract
 
objective In patients with systemic lupus erythematosus (sle) 
and lupus nephritis, the presence of antiphospholipid antibodies 
(apl) is considered to be an indication of increased risk of thrombotic 
microangiopathy, a serious complication of sle. Previous studies 
have demonstrated a critical role for activation of the classical 
pathway of complement that leads to thrombotic injury in the 
presence of apl. This study was undertaken to investigate whether 
c4d deposition in lupus nephritis is related to circulating apl and the 
presence of renal microthrombi.
methods Deposition patterns of c4d in 44 renal biopsy samples 
obtained from 38 patients with biopsyproven lupus nephritis were 
determined by staining with a polyclonal anti-c4d antibody.  
A phosphotungstic acid–hematoxylin stain was used to identify  
fibrin microthrombi. Clinical data (serum creatinine levels and 
presence or absence of apl) were obtained and correlated with 
findings in the renal biopsy specimens. Patients were categorized  
as having apl (n = 20) or not having apl (n = 18).
results A strong relationship between the intensity of glomerular 
c4d staining and the presence of microthrombi was found (P < 0.002). 
Intense glomerular c4d deposition was present in 7 of 8 biopsy 
samples showing renal microthrombi. Neither c4d deposition nor 
the presence of microthrombi was correlated with apl status.
conclusion Our findings suggest that activation of the classical 
pathway of complement plays a pathogenic role in the development 
of renal tissue injury leading to thrombosis, irrespective of the type of 
circulating antibodies present. Immunodetection of glomerular c4d 
deposition in renal biopsy samples could be a convenient method of 
identifying patients at risk of thrombotic microangiopathy.
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that platelet-bound c4d, a sensitive marker for the classical path- 
way of complement activation, is highly specific (though not sen-
sitive) for the presence of apl in sle patients. Those investigators 
suggested that platelet-bound c4d may provide clues to the patho- 
genic mechanisms responsible for the thrombotic and vascular 
complications of sle.17
c4d is a marker of humoral rejection in renal transplant biopsy 
samples, and its presence can be interpreted as a footprint of the 
classical pathway of complement activation and thus of alloanti- 
body-induced damage.18 In the transplanted kidney, humoral 
rejection is associated with glomerular and interstitial changes,  
in which thrombotic lesions may also occur.19 A mechanism similar 
to humoral rejection possibly occurs in sle, in which many different 
autoantibodies produce an analogous situation. Few reports have 
described c4d depositions in nontransplanted kidneys.
c4d positivity has been reported in membranous nephropathy 
and membranoproliferative glomerulonephritis and even in 
normal kidneys, suggesting that c4d positivity need not always be 
representative of activation of the classical pathway of complement.20 
c4d was detected by Kim and Jeong 21 in glomeruli in 21 cases of lupus 
nephritis, and the intensity of c4d staining correlated with the extent 
of immune complex depositions. In that study, the apl status of the 
patients was unknown, and the presence of microthrombi was not 
investigated.
The recent finding of c4d expression on platelets from sle 
patients17, as well as the results of recent work on complement-  
and apl-mediated thrombosis, support the notion of a possible role 
of c4d in the pathogenesis of thrombosis in sle. We hypothesized 
that immunodetection of c4d in renal biopsy samples could facilitate 
detecting sle patients at risk of the development of thrombotic 
complications. In the present study, we investigated the relationship 
between c4d deposition in renal biopsy samples, the presence of 
microthrombi in biopsy samples, and apl status in patients with 
lupus nephritis.
Introduction
Lupus nephritis develops in up to 60% of patients with systemic  
lupus erythematosus (sle) during the course of the disease.1  
Standard clinical practice is to perform a renal biopsy if clinical 
parameters suggest renal involvement; the lupus nephritis class2 
can be determined from the biopsy and has an impact on both the 
choice of treatment and the patient’s prognosis. In renal biopsy 
specimens obtained from sle patients, evidence of  thrombotic 
microangiopathy is occasionally detected.
Although the occurrence of thrombotic microangiopathy in 
patients with sle is rare, about 3% according to various studies3-6, 
clinicians are well aware of the serious complications. In its most  
fulminant form, thrombotic microangiopathy presents with mul-
tiple fibrin thrombi in glomeruli and/or arterioles and capillaries  
and is accompanied by a severe decline in renal function.7 sle 
patients with thrombotic microangiopathy also exhibit extrarenal 
complications, including thrombocytopenia, microangiopathic  
hemolytic anemia, neurologic manifestations, and even multiple  
organ failure.8
Thrombotic microangiopathy in sle patients is typically 
associated with the presence of antiphospholipid antibodies (apl), 
namely anticardiolipin antibodies (acl) and lupus anticoagulant 
(lac).8-11 However, apl are detected in up to 40% of sle patients12-14, 
and in many patients with high apl titers thrombotic microangio-
pathy never develops4;10 Conversely, thrombotic microangiopathy  
has been reported in several sle patients without apl.8 These ob- 
servations are consistent with suggestions that other factors are 
necessary to trigger the endothelial damage leading to thrombotic 
events.
Recently, the role of complement in apl-induced thrombosis  
has been thoroughly investigated. Pierangeli et al have shown  
that activation of the complement cascade is necessary for apl-
mediated thrombophilia.15-16 In addition, Navratil et al17 reported 
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Vector, Peterborough, uk). Sections were washed with pbs (pH 
7.4) between each step (3 times for 5 minutes each time). Finally, 
sections were counterstained with Mayer’s hematoxylin, air-dried, 
cleared in xylene, and coverslipped. A renal specimen from a humoral 
allograft rejection patient with c4d-positive staining confirmed by 
immunofluorescence was used as a positive control. Consecutive 
sections were stained for fibrin with Mallory’s phosphotungstic 
acid–hematoxylin. Fresh frozen tissue sections were incubated with 
fluorescein isothiocyanate–conjugated polyclonal antibodies directed 
against human IgA, IgG, IgM, c3, and c1q (Dako). 
quantification of morphology, immuno-
histochemical staining, histochemical staining, 
and immunofluorescence The biopsy specimens were  
scored by a renal pathologist (imb) who had no prior knowledge 
of the clinical and laboratory findings in the patients. Peritubular 
capillary c4d staining was scored as 0 or 1, where 0 represented the 
absence of c4d in peritubular capillaries, and 1 represented positive 
peritubular capillary c4d staining in any area of the biopsy sample. 
c4d positivity in arterioles was scored as 0 or 1, where 0 represented 
the absence of c4d, and 1 represented the presence of c4d.
Glomerular c4d staining was scored semiquantitatively using 
the following scoring system: 0 (no glomerular staining), 1 (mild to 
moderate glomerular staining), and 2 (intense glomerular staining). 
Typical examples of the different intensities of glomerular c4d 
staining are shown in Figures 1a–c. Consecutive sections were 
stained with phosphotungstic acid–hematoxylin and carefully 
examined for the presence of arterial and/or arteriolar thrombosis 
and glomerular microthrombi.
A glomerular microthrombus stained with phosphotungstic acid–
hematoxylin is shown in Figure 1d. Positive identification of at least 
1 microthrombus, either in glomeruli, interstitial capillaries, or small 
arterioles, was scored as 1. Absence of microthrombi was scored as 0. 
Intensity of glomerular staining for IgG, IgA, IgM, c3, and c1q was 
semiquantitatively scored as 0, 1, or 2.
Patients and methods
patients We retrospectively studied 38 patients with clinically 
evident sle who visited the outpatient clinic at the Department 
of Nephrology and Internal Medicine of the Leiden University 
Medical Center between 1983 and 2006. All patients met at least 4 of 
the American College of Rheumatology criteria for sle22, and lupus 
nephritis was confirmed in all patients by >1 renal biopsy. The biopsy 
specimens were reevaluated and classified according to the most 
recent modification of the World Health Organization classification 
from the International Society of Nephrology/Renal Pathology Society 
(isn/rps).2 Follow-up biopsy samples were available for 4 patients. 
Three of these patients had 2 biopsies, and 1 patient had 4 biopsies. 
The medical records of all patients were reviewed independently of 
the analysis of pathologic features. Most clinical data were available, 
although some were missing for the older cases. All patients were 
investigated for the presence of apl as defined by the Sapporo criteria 
for antiphospholipid syndrome (aps).23 In the present study, patients 
were categorized as having apl (n = 20) or not having apl (n = 18). An 
overview of the clinical data is given in Table 1.
biopsy samples Biopsy samples were fixed in 10% buffered formalin 
and embedded in paraffin. Paraffin sections (4 micrometer thick) were 
placed on positively charged slides and kept in a stove at 60°C for 1 hour. 
Sections were deparaffinized and rehydrated through a series of xylene 
and graded alcohols. Endogenous peroxidase was blocked in 3% h™o™ 
for 30 minutes. Antigen retrieval was performed by boiling the slides in 
a microwave at 1,000W for 10 minutes in 10 mM citrate buffer (pH 6.0).
The primary rabbit anti-human c4d polyclonal antibody (bi-
rc4d; Biomedica Gruppe, Vienna, Austria) was applied at a dilution 
of 1:50 in 1% bovine serum albumin/phosphate buffered saline (bsa/
pbs), and slides were incubated overnight at room temperature. 
The slides were then incubated with anti-rabbit EnVision (K5007; 
DakoCytomation,Glostrup, Denmark) for 30 minutes, and staining 
was visualized with the Vector Nova Red Substrate Kit (sk-4800; 
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statistical analysis Categorical variables were compared using 
Fisher’s exact test or the chi-square test. For the statistical analysis of 
immunofluorescence data, we used the nonparametric Spearman’s 
rank correlation. For the analysis of creatinine level and gfr, we used 
the Kruskal-Wallis one-way analysis of variance (anova). All analyses 
were performed using spss software, version 12.0.1 (spss, Chicago, 
il). P values less than 0.05 were considered significant.
Results
Relationships between the presence of apl, the presence of micro-
thrombi, and c4d staining. Forty-four renal biopsy samples from 
38 patients with lupus nephritis were examined. For patients with 
multiple biopsy samples, only the first biopsy sample in which 
lupus nephritis was diagnosed was analyzed. The mean (+/-sd) age 
of patients at the time of biopsy was 31.9 +/- 11.2 years (range 14–66 
years). Twenty patients (52.6%) were positive for apl, according to the 
Sapporo criteria. IgG acl was present in 17 of 36 patients (47%), and 
lac was present in 10 of 31 patients (32%). A significant relationship 
was found between the presence of microthrombi and the intensity of 
glomerular c4d staining. In 15 renal biopsy samples, intense glomer-
ular c4d staining was observed. Of these biopsy samples, 7 had mi-
crothrombi, whereas microthrombi were absent in almost all other 
biopsy samples (P <0.002, by Fisher’s exact test) (Table 2). Within the 
renal tissue specimens, microthrombi were found almost exclusively 
in glomeruli. In some cases, microthrombi were also found in the in-
terstitial arterioles and capillaries. Thrombi were typically not found 
in areas of active inflammation. Among the 8 patients with biopsy 
specimens showing microthrombi, 5 were positive for apl, compared 
with 15 of 30 patients without microthrombi. This difference was not 
statistically significant.
Neither the intensity of glomerular c4d staining nor the deposi-
tion of c4d in peritubular capillaries was related to apl status (Table 
3). Glomerular c4d staining and c4d in peritubular capillaries were 
laboratory evaluation Standard methods were used to 
determine the levels of antinuclear, anti-dna, antiextractable 
nuclear antigen, and anti-c1q antibodies. c3, c4, and c1q levels 
were also determined by standard protocols. Levels of IgG and IgM 
acl were determined using the Varelisa Cardiolipin Antibodies 
enzyme-linked immunosorbent assay kit (Phadia, Nieuwegein, 
The Netherlands). Laboratory diagnosis of lac was performed in 
citrated plasma prepared by double centrifugation. Two different 
phospholipid-dependent coagulation assays were used. An activated 
partial thromboplastin time (aptt) was measured, and, if the aptt 
was prolonged, patient plasma was mixed with normal plasma 
(automated aptt reagent; BioMerieux, Marcy l’Etoile, France) at 
a 1:1 ratio to test for the presence of an inhibitor. Persistence of a 
prolonged aptt clotting time indicated the presence of an inhibitor. 
Furthermore, the presence of lac was tested using a dilute Russell’s 
viper venom time (drvvt)–based assay (la screen/la Confirm;  
Life Diagnostics, Frenchs Forest, Australia). If the drvvt obtained 
using the la Screen reagent in the patient sample was prolonged  
>20% compared with normal plasma, studies with normal plasma 
were performed to exclude possible clotting factor deficiencies.  
If the drvvt remained prolonged after mixing, then the phospho- 
lipid dependency of the possible inhibitor was tested with the la 
Confirm reagent, which contains a high phospholipid concentra- 
tion. Normalization of drvvt with the la Confirm reagent 
confirmed the presence of lac.
clinical follow-up The glomerular filtration rate (gfr) was 
estimated for all patients at the time of biopsy, as well as during 
yearly followup visits, using the Modification of Diet in Renal Disease 
(mdrd) formula.24 Followup data were used to investigate whether 
renal biopsy findings at presentation were related to renal outcome. 
Data regarding the end points of occurrence of end-stage renal failure 
requiring dialysis and the date and cause of death were obtained  
from medical records. 
72 clinical significance of c4d in sle and antiphospholipid syndrome 73 iv • potential for glomerular c4d as an indicator of thrombotic microangiopathy  
        in lupus nephritis
patients had all positive results, while 1 patient had no peritubular 
capillary staining in either sample). Likewise, followup biopsies 
showed equally intense glomerular c4d staining at all time points. 
The patient with 4 biopsy samples showed both intense glomerular 
c4d staining and positive peritubular capillaries in all biopsy samples 
(Figure 2). In the diagnostic evaluation for this patient, microthrombi 
were first detected on the third biopsy. Additional stainings made for 
the purpose of the present study showed that microthrombi were also 
present in the first biopsy sample. During the course of the disease, 
results of tests for acl and lac were consistently negative. Because 
the clinical history of this patient was very illustrative of our results 
regarding the combination of intense glomerular c4d staining with 
the presence of microthrombi, we briefly present the case history 
here. 
case history The patient, a 27-year-old woman, presented 
with butterfly exanthema, alopecia, and renal involvement with 
proteinuria and active urinary sediment, and sle was diagnosed. 
Positive antinuclear factor and anti–double-stranded dna 
antibodies were present, and no apl were found. The first renal 
biopsy specimen obtained indicated lupus nephritis class v, and 
prednisone therapy and azathioprine were initiated. At age 28 
years, a second renal biopsy specimen obtained, showing a diffuse 
proliferative glomerulonephritis compatible with lupus nephritis 
class iv (a/g). Additionally, renal vein thrombosis developed, but 
the patient was still negative for apl. She was treated with vitamin 
K antagonists as anticoagulant therapy. Pulse cyclophosphamide 
(cyc) was administered, and the patient’s condition stabilized. 
Because apl did not seem to play a role, anticoagulant therapy 
was terminated after 2 years. Because the patient’s renal function 
continued to decline during the following 2 years, and proteinuria 
continued to increase during pulse cyc and prednisone therapy, a 
third renal biopsy specimen was obtained. Intra- and extracapillary 
proliferative lupus nephritis class iv (a/c) and evidence of a 
thrombotic microangiopathy were found. Shortly thereafter, 
not related to the presence of acl or lac alone, or to the isn/
rps classification for lupus nephritis. c4d positivity in arterioles 
occurred in only 3 patients, and none of these arterioles contained 
thrombi. Relationship between glomerular c4d staining and the 
presence of antibodies (IgG, IgA, IgM), c3, and c1q. Table 4 shows 
the relationship between immune complex deposits, glomerular 
c4d, and apl. Consistent with results previously reported by Kim 
and Jeong21, we found that increased intensity of c4d deposition was 
significantly correlated with the presence of capillary c3 (r = 0.348, P 
= 0.023). We also found a nearly significant correlation between the 
intensity of c4d staining and the presence of capillary IgG (r = 0.316, 
P = 0.064). There was also a nearly significant correlation between the 
intensity of c4d staining and the presence of apl(r = 0.315, P = 0.054).
results of clinical follow-up The serum creatinine level 
and the gfr were available for all patients over at least 3 years of 
followup and for some patients for up to 15 years of followup. Of 
the 38 patients, 4 died before the study started, and of those, 3 had 
developed endstage renal failure requiring dialysis. Of the 3 patients 
who died with end-stage renal failure, 2 had biopsies showing renal 
microthrombi and intense c4d staining.
Two other patients had developed end-stage renal failure by the 
time our study started. In these patients, renal biopsy did not show 
microthrombi, but in 1 patient the biopsy did show intense c4d 
staining. The mean (+/-sd) gfr after 3 years of followup was 73 +/-  
38 ml/minute in the group with no c4d staining (n = 5), 68 +/- 22 ml/
minute in the group with mild c4d staining (n = 18), and 62 +/- 23 ml/
minute in the group with intense staining (n = 15). There were no 
statically significant differences between these 3 groups (P = 0.34  
by Kruskal-Wallis one-way anova).
follow-up biopsy findings Multiple biopsy samples were 
available for 4 patients. Three patients each had 2 biopsies, and 1 
patient had 4 biopsies. Follow-up biopsies showed consistently 
positive or negative staining in peritubular capillaries (3 of 4  
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pathway, c4d is also involved in the lectin pathway. Therefore, 
we cannot exclude the possibility that c4d deposition partly 
reflects activation of the lectin pathway due to, for example, IgM 
autoantibodies.25
The case report presented in this study illustrates that c4d 
deposition can be found in the kidney years prior to the time when 
actual thrombotic microangiopathy is revealed. Regarding the 
clinical outcome in the patients in the present study, there appeared 
to be a trend toward a less favorable renal outcome in the group of 
patients whose biopsy samples showed more intense c4d staining. 
However, this trend did not reach statistical significance. Of the 
5 patients in whom end-stage renal failure developed, 2 had renal 
microthrombi and 3 had intense c4d staining, suggesting that the 
presence of intense c4d staining may be related to a less favorable 
clinical outcome. Based on the findings of our study, positive c4d 
staining in a renal biopsy sample from a patient with lupus nephritis 
should raise suspicion of thrombotic complications, even in the 
absence of apl. However, further studies are needed to define the 
clinical implications of c4d deposition as a biopsy finding, because in 
this retrospective study, our results were obviously biased by several 
factors that were uncontrolled, such as ongoing disease activity at 
the time of measurement and co-medication. Our findings therefore 
indicate the need for future prospective and controlled studies in 
larger groups of patients, in order to investigate the potential of c4d 
staining in the renal biopsy specimen to predict the serious clinical 
complication of thrombotic microangiopathy in sle and aps. 
Our study was initiated by the results of the recent study by 
Navratil et al17, which showed a specific relationship between platelet 
c4d and the presence of apl in sle. Platelet c4d was detected in 18% 
of 105 patients with sle, and was 100% specific for a diagnosis of sle 
compared with healthy controls, and 98% specific for sle compared 
with patients with other diseases. The authors suggested that, apart 
from indicating that platelet-bound c4d may be a biomarker for 
sle, their findings provided a clue to the pathogenic mechanisms 
responsible for the myriad thrombotic and vascular complications 
the patient presented with upper body ataxia and aphasia. These 
neurologic complications were most likely associated with the 
thrombotic microangiopathy in combination with active sle. The 
patient remained negative for apl, but complement values were 
very low. She was treated with 10 plasmapheresis sessions and 
hemodialysis, and her gfr declined to 15 mmoles/liter. At age 39 
years, prolonged hemodialysis was started. Two years later, acute 
neurologic deterioration and respiratory distress occurred, and the 
patient was admitted to the intensive care unit, where she died, 
likely due to diffuse alveolar hemorrhage in the lungs and bleeding 
in and around multiple organs during active lupus nephritis. At 
autopsy, the kidneys showed extensive chronic damage, classified as 
lupus nephritis class iv-C (g). In the brain, diffuse chronic and global 
ischemia was detected, accompanied by a few vessels in the white 
matter with intraluminal thrombi and extensive cerebral gliosis. For 
the present study, all of the kidney biopsy specimens obtained from 
the patient were stained for c4d, and all of them were positive for 
similar high-intensity glomerular c4d staining (Figure 2).
Discussion
We observed a striking relationship between the intensity of glo-
merular c4d deposition and the presence of renal microthrombi 
in lupus nephritis. This report describes the novel finding of the 
presence of c4d in lesions indicative of thrombotic microangio- 
pathy in nontransplant biopsy specimens. It is likely that activa- 
tion of the classical pathway of complement is a crucial pathogenic 
intermediate in the development of thrombosis in lupus nephritis. 
In the group of patients included in the present study, there was no 
definitive relationship between c4d deposition and the presence 
of apl. The presence of apl was not correlated with the presence of 
microthrombi. This suggests that additional factors, such as other 
autoantibodies that have not yet been identified and assessed, may 
trigger activation of the classical pathway of complement in these 
patients. Although its function is closely related to the classical 
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course, namely when a microthrombus was detected on the third 
renal biopsy specimen, which was obtained 7 years after disease 
presentation. Earlier tests for apl were negative, which contributed 
largely to the decision to stop oral anticoagulant therapy after renal 
vein thrombosis. The patient experienced severe renal and neurologic 
complications, which were confirmed at autopsy to have been 
caused by microthrombi. In this patient, c4d staining was notably 
intense in all biopsy samples, as shown in Figure 2, and could have 
indicated the risk of a thrombotic microangiopathy much earlier 
in the time course of the disease. Our results further suggest the 
potential for c4d staining in guiding the therapeutic strategy, such 
as the earlier and prolonged use of immunosuppressive therapy or 
anticoagulant therapy. Recently, immunoreactivity to c4d protein 
was reported to be significantly stronger in the placentas of patients 
with apl than in the placentas of healthy controls.30 These findings 
are consistent with the results of murine studies by Girardi et al31; 32, 
indicating that low molecular weight heparin, even at doses that do 
not interfere with coagulation, protects pregnancies against apl-
induced damage mor thrombosis, because it blocks the activation 
of complement. Interestingly, anticoagulant treatment without 
any anticomplement effect was not protective, suggesting that 
anticoagulation in and of itself is not sufficient for patients with aps-
related miscarriage. If complement is indeed a critical factor in the 
development of endothelial damage and microthrombi in kidneys 
of patients with sle and/or aps, the possibility that treatment with 
heparin at subcoagulant doses could have beneficial effects in these 
patients should be investigated. Notably, the patient described in 
the case history presented in this study was treated with vitamin k 
antagonists as anticoagulant therapy after renal vein thrombosis 
and received several plasmapheresis sessions when thrombotic 
microangiopathy was discovered, but this therapeutic intervention 
was not successful. She never received heparin during the course of 
her disease.
A shortcoming of the present study regards the detection of micro- 
thrombi in renal biopsy specimens. Given their relatively sparse 
of lupus associated with apl. Thus far, the exact role of apl in the 
development of lupus-related thrombotic microangiopathy has not 
been elucidated. The ability of apl to activate endothelial cells in vitro 
and in vivo, induce platelet activation, and interact with elements of 
the coagulation cascade has been well established.26 These findings 
indicate that apl seem to play an important role in the initial phase 
of a cascade leading to thrombotic events. In addition to this, many 
studies have shown complement activation to be essential. The det-
rimental role of complement is underlined in experimental studies, 
such as that by Nangaku et al27, demonstrating that thrombotic mi-
croangiopathy is prevented if c5b–9 (the membrane attack complex) 
is temporarily inhibited. Pierangeli et al15 demonstrated that c3- and 
c5-deficient mice were resistant to apl-induced thrombosis. How 
would complement activation result in a thrombotic event? A novel 
finding is the role of tissue factor activation as an inducer of throm-
bosis downstream of complement. It was recently demonstrated that 
apl-induced complement activation and downstream signaling via 
c5a receptors in neutrophils lead to the induction of tissue factor,  
a key initiating component of the blood coagulation cascade28.  
Another study identified tissue factor as an important mediator  
of the c5a-induced oxidative burst in neutrophils in the setting  
of apl-induced fetal injury29. These findings are interesting in light 
of our results, since they may explain why such a strong relationship 
was found between the presence of c4d and microthrombi in this 
study. In patients with sle, aps may become clinically apparent only 
after a major thrombotic event. In many hospitals, patients with sle 
are not routinely tested for apl but are tested only ‘on clinical indica-
tion.’ In some instances, the detection of microthrombi in the renal 
biopsy specimen is the first clue that thrombotic microangiopathy 
is present. However, the detection of microthrombi in renal biopsy 
specimens is not very sensitive, which is likely due to sampling error.
We have illustrated the difficulty of identifying and managing 
thrombotic microangiopathy in an sle patient in the case history 
presented in this study. In this patient, the presence of thrombo- 
tic microangiopathy became evident fairly late in the clinical 
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thrombosis in lupus nephritis. Furthermore, we propose that c4d 
may be an important additional tool in the evaluation of renal biopsy 
specimens obtained from patients with sle. Future prospective 
studies are needed to investigate this possibility. Our findings 
also have therapeutic implications, in that staining renal biopsy 
specimens for c4d could be an easy and elegant method of identifying 
patients with lupus nephritis who are at risk of thrombotic 
microangiopathy.
 
presence, it is likely that microthrombi are easily missed in the small 
tissue sample obtained at renal biopsy. Therefore, we cannot exclude 
the possibility that renal microthrombi were missed due to sampling 
error in the 8 patients whose biopsy samples showed intense 
glomerular c4d staining but no thrombotic lesions when stained 
with phosphotungstic acid–hematoxylin. It is also possible that some 
focal microthrombi were missed in patients whose biopsy samples 
showed only mild or no staining for c4d. 
In this study, only 1 patient had renal microthrombi in the 
absence of c4d deposition. In future studies, more patients should be 
included, and thrombotic microangiopathy should be investigated 
more closely, by examining more biopsy slides or by taking 
into account other clinical parameters indicative of thrombotic 
microangiopathy.
Importantly, not all patients with sle and apl develop thrombotic 
microangiopathy. According to Harris and Pierangeli33, a ‘second 
hit,’ e.g., infection or trauma, is necessary to trigger thrombosis at 
the vessel site where apl have deposited. Conversely, not all patients 
with sle and thrombotic microangiopathy have apl. This suggests 
that the deposition of antibodies other than apl may lead to a 
thrombotic event, or that apl are only transiently present in some 
sle patients. Although the etiology of neither situation is completely 
understood, it seems wise to look at complement deposition, and 
deposition of c4d in particular, in all patients with lupus nephritis. 
Because activation of the classical pathway of complement is 
likely to be a marker of endothelial damage leading to thrombotic 
microangiopathy in lupus nephritis, c4d immunodetection may 
be a useful tool in determining whether patients are at risk of this 
complication. In our experience, the serologic detection of apl is  
only marginally related to evidence of microthrombi in the kidney.  
Of 8 patients with microthrombi, apl were found in 5, and of 
30 patients without microthrombi, apl were present in 15. This 
difference was not statistically significant. The results of the present 
study strongly support the notion that activation of the classical 
pathway of complement is a crucial factor in the development of 
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fig 1  different intensities of glomerular c4d staining in lupus  
 nephritis
Renal biopsy samples obtained from patients with lupus nephritis, showing different intensities 
of glomerular C4d staining and a glomerular microthrombus. A, No glomerular C4d staining. B, 
Mild to moderate glomerular C4d staining. C, Intense glomerular C4d staining. D, A glomerular 
microthrombus stained bright blue with a phosphotungstic acid–hematoxylin stain for fibrin. 
(Original magnification X400.)
fig 2  four biopsy samples of one patient
Four renal biopsy samples obtained from a patient with lupus nephritis complicated by a thrombotic 
microangiopathy during the disease course. The patient was negative for antiphospholipid antibod-
ies. Glomerular C4d staining intensity was uniformly strong in all biopsy samples.  
(a) First biopsy sample in which lupus nephritis was diagnosed. Microthrombi were not detected.  
(b) Biopsy sample obtained after development of renal vein thrombosis and a decline in renal func-
tion. (c) Biopsy sample showing an intensely stained glomerulus. Thrombotic microangiopathy was 
diagnosed, and neurologic complications developed. (d) Biopsy sample obtained at autopsy, showing 
extensive chronic damage. C4d deposition was still detectable. (Original magnification X400.)
 
table 1 clinical characteristics and laboratory findings 
in the 38 patients with lupus nephritis* 
  
Age at biopsy, mean ± sd (range) years 31.9 ± 11.2 (14–66)
Sex, no. female 35








Immunologic disorders, no. (%) positive‡
 Antiphospholipid antibody disorders§ 20 (53)
 Anticardiolipin antibodies, IgG 17 (47)
 Anticardiolipin antibodies, IgM 11 (32)
 Lupus anticoagulant 10 (32)
 Antinuclear antibodies 34 (90)
 Anti-ema antibodies 22 (59)
 Anti-dsdna antibodies 28 (74)
 Anti-C1q antibodies 8 (33)
Serum creatinine level, median (range) μmoles/liter 95.0 (56–485)
gfr, median (range) μmoles/liter 70.1 (9.6–119.4)
Serum c3 level, median (range) μmoles/liter 45.5 (1–115)
Serum c4 level, median (range) μmoles/liter 17.0 (2–46)
Serum C1q level, median (range) μmoles/liter 11.5 (1–21)
* isn/rps = International Society of Nephrology/Renal Pathology Society;  
 anti-dsDNA = anti–double-stranded dna; gfr = glomerular filtration rate. 
†  Subclasses are not shown.    
‡  IgG anticardiolipin antibodies were tested in 36 patients; IgM anticardiolipin antibodies were  
 tested in 34 patients; lupus anticoagulant was tested in 31 patients; anti–extractable nuclear  
 antigen (anti-ena) antibodies were tested in 37 patients; and anti-C1q antibodies were tested  
 in 24 patients.    
§  Defined by the Sapporo criteria, specifically by the presence of IgG anticardiolipin antibody or  
 lupus anticoagulant 
a cb d
a cb d
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table 2 relationship of glomerular c4d staining to the presence 
 of microthrombi in the 38 patients with lupus nephritis* 
  
no detectable microthrombi 
(n = 30)
microthrombi present      
(n = 8)





* Values are the number of patients. P < 0.002 for the presence of microthrombi in samples with 
intense staining versus samples with no staining or mild to moderate staining. 
table 3 relationship of c4d staining and presence of 
 microthrombi to apl status in the 38 patients with 
 lupus nephritis* 
patients with apl  
(n = 20)
patients without apl 
(n = 18)
c4d peritubular capillary staining   
Positive 10 12
Negative 10 6
c4d glomerular staining   
No staining 1 4
Mild to moderate staining 9 9
Intense staining 10 5
Presence of microthrombi   
Microthrombi present 5 3
No detectable microthrombi 15 15
* Values are the number of patients. apl = antiphospholipid antibodies
table 4 relationship between immune complex deposits, glomeru-
 lar c4d staining, and the presence of antiphospholipid  







igg igm iga c3 c1q
1 0 0 0 0      
2 0 0 0 0      
3 0 0 0 1 2 2 2 2 2
4 0 0 0 0 2 1 1 2 1
5 0 1 0 0 1 1 2 1 2
6 1 0 0 0 1 1 0 2 1
7 1 0 0 0 1 0 1 0 0
8 1 0 0 0 1 2 2 2 2
9 1 0 0 0 1 1 1 0 1
10 1 0 0 0 1 2 1 1 2
11 1 1 0 0 1 1 1 1 1
12 1 1 0 0 2 2 1 1 1
13 1 1 0 0 1 1 1 1 1
14 1 0 0 0 1 1 0 1 0
15 1 0 0 0 0 1 0 1 1
16 1 0 0 0 2 2 1 2 2
17 1 0 0 0 2 1 1 2 1
18 1 1 0 0 0 1 1 1 1
19 1 1 0 0 2 2 1 2 2
20 1 1 0 0 1 1 2 2 2
21 1 1 0 0      
22 1 1 1 0 1 1 1 1 1
23 1 1 0 0 1 1 1 1 1
24 2 0 0 1 2 2 1 2 0
25 2 0 0 0 1 1 1 1 1
26 2 0 0 0 2 2 2 2 2
27 2 0 0 1 2 2 1 2 2
28 2 0 1 0 2 1 0 2 1
29 2 1 0 1 2 2 2 2 2
30 2 1 0 0 0 1 1 1 1
31 2 1 0 0 1 0 2 2 1
32 2 1 0 1 2 2 2 2 2
33 2 1 0 0 2 2 1 2 2
34 2 1 0 0 2 2 1 2 2
35 2 1 0 1 2 2 2 2 2
36 2 1 1 1 2 0 1 2 2
37 2 1 0 1 2 2 1 2 2
38 2 1 0 0 1 2 2 1 2
* Values are the score. Glomerular C4d staining of each sample was scored on a scale of 0–2, where 0 = no glomerul 
ar staining, 1 = mild to moderate glomerular staining, and 2 = intense glomerular staining. Samples were given 
a score of 1 or 0 for the presence or absence, respectively, of antiphospholipid antibodies (aPL), arteriolar C4d, and 
microthrombi. The intensity of immunofluorescence for IgG, IgM, IgA, C3, and C1q was scored on a scale of 0–2.  
Data on IgG IgM, IgA, C3, and C1q were not available for patients 1, 2, and 21.
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Abstract
objective Neuropsychiatric (np) involvement is a poorly 
understood manifestation of systemic lupus erythematosus (sle). 
Studies in humans have failed to provide clues for interactions 
between autoantibody-mediated inflammation and thrombo-
ischemic lesions observed in brains of np-sle patients. We 
hypothesized that cerebral complement activation could induce 
microthrombotic injury in np-sle. Furthermore, we aimed to 
correlate post-mortem histopathology to ex-vivo7 Tesla mri imaging 
in three brains of sle patients.
methods A nationwide search for autopsy material from sle 
patients resulted in brain tissue from 16 patients with np-sle and 18 
patients with sle. Brains from 24 previously asymptomatic patients 
who died from acute cardiac events served as controls. Paraffin 
embedded tissue of the cerebral cortex was stained for complement 
components of the classical- and lectin pathway. Of three np-sle 
patients, whole formalin fixed brains were available for mri analysis. 
results Cerebral complement deposition was strongly associated 
with both sle and np-sle compared to controls (P<0,001) and c1q 
and c4d deposits were typically seen in small vessels affected by 
vasculopathy. Microthrombi were exclusively found in np-sle and 
were associated with c4d deposition (P=0,029). mri analysis revealed 
that the majority of small vessel injury was found in the vicinity of 
white matter hyperintensities.
interpretation Cerebrovascular complement activation is 
common in sle patients but not in controls, and deposits of c4d 
are closely associated to microthrombotic injury. These findings 
provide a novel explanation for the interaction between circulating 
autoantibodies and the development of thrombo-ischemic lesions 
observed in np-sle. Complement activation has potential as a novel 
therapeutic target in np-sle. 
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glomerular microthrombi in lupus nephritis.11 This is in line with 
findings in antiphospholipid syndrome (aps)12-14 and atypical 
hemotylic uremic syndrome (hus)15 where there is good evidence 
that complement activation can induce endothelial activation, 
endothelial injury and (micro)thrombosis.13;16;17 We hypothesize that 
this mechanism could also be responsible for the vascular pathology 
observed in np-sle. 
To test this hypothesis we performed a nationwide search for 
cerebral autopsy material of sle patients with and without np 
symptoms. In this unique cohort we investigated the presence of 
complement depositions and their correlation to thrombo-ischemic 
lesions. As a secondary aim, we questioned whether our post-mortem 
findings can be potentially detected clinically by correlating ex- vivo 
imaging with 7 Tesla mri with post-mortem histology of three 
brains of sle patients.
Methods
 
palga search for cerebral tissue of sle patients  
To study the role of complement in np-sle we conducted a nation–
wide search for cerebral autopsy-tissue from sle patients with and 
without clinical signs of neuropsychiatric involvement. For this 
purpose we used the Dutch palga system (www.palga.nl), a unique 
histopathology data network, encompassing data from the archives  
of all sixty-four pathology laboratories in The Netherlands.18 Our  
search parameters included ‘sle’, ‘Systemic Lupus Erythematosus’, 
‘Lupus’ and ‘Cerebral autopsy’, which led to 296 hits from the palga  
database. We subsequently excluded patients who only had cuta-
neous or discoid lupus erythematosus, and included all patients  
with systemic le of which cerebral autopsy tissue was available.  
This resulted in 48 appropriate cases. Of 14 cases paraffin blocks  
were no longer available or tissue quality was too poor for analysis. 
Finally, 34 formalin-fixed tissue samples from autopsied sle cases 
were retrieved from 12 Dutch pathology laboratories for analysis. 
Introduction
 
Systemic lupus erythematosus (sle) is a severe systemic autoim- 
mune disease that primarily affects women of childbearing age.1  
The presence of circulating auto-antibodies and immune com- 
plexes is the hallmark of sle, and disease manifestations can occur  
in virtually all organ systems.2 The devastating consequences 
of cerebral involvement of sle are commonly referred to as 
neuropsychiatric sle (np-sle).3 np-sle develops in about 50-70% 
of sle patients who may show symptoms varying from stroke to 
psychosis.4;5 Due to the heterogeneity of the condition and the 
lack of both etiological insight and evidence based therapeutic 
interventions, the clinical management of these patients is complex.
In the extensive work-up of patients with suspected np-sle, 
magnetic resonance imaging (mri) of the brain plays a prominent 
role4 although the interpretation is often hampered by a so-called 
‘clinicoradiological paradox’: Some patients with sle and severe neu-
rological symptoms only show minor abnormalities on mri, whereas 
the reverse also occurs. In a recent systematic analysis of mri findings 
in the setting of np-sle, absence of mri abnormalities despite signs 
and symptoms of active disease was found in 42% of all patients.  
Overall, the most common mri findings were white matter hyper- 
intensities, suggestive of cerebral hypoperfusion and infarction.6 
The few studies on histopathological findings in brains obtained 
from sle patients with neuropsychiatric symptoms showed that 
the most prominent pathological lesions were related to ischemic 
injury in the vicinity of small vessels.3;7-10 Microthrombosis, 
microinfarction, and microhemorrhage were present in the majority 
of cases. These findings suggest a thrombo-ischemic pathofysiology, 
whereas sle is known as a disease with an autoantibody-mediated 
inflammatory nature. So far, studies in humans have failed to provide 
clues for interactions between autoantibody- mediated inflammation 
and the thrombo-ischemic lesions observed in the brain. 
We recently demonstrated that the intensity of classical com- 
plement activation in glomeruli corresponds to the presence of 
90 clinical significance of c4d in sle and antiphospholipid syndrome 91 v • nationwide autopsy study links complement to thrombo-ischemia  
       in neurolupus
cerebral and cerebellar hemispheres were sectioned in the coronal 
plane. Regions of interest were dissected into tissue blocks, processed 
using standard tissue processing methods and embedded in paraffin.
histology and immunohistochemistry Sections of 
all tissue blocks were stained with haematoxylin and eosin using 
standard methodologies. To study cerebral complement activation, 
we investigated the presence of c1q (representing activation of the 
classical pathway), Mannose Binding Lectin (mbl) (representing 
activation of the mbl pathway) and c4d (a split product of c4 which 
binds covalently to the target tissue, and is widely used as a tissue 
biomarker for antibody mediated endothelial injury. In transplant 
pathology c4d-staining is incorporated in the standard work-up  
for diagnosing antibody mediated rejection of a renal allografts.20) 
immunohistochemistry Immunohistochemistry was 
performed after deparaffinized sections were subjected to antigen 
retrieval by edta-tris (pH 9.0) or 10 mM citrate buffer (pH 6.0)
(waarom twee methods). Sections were subsequently stained 
with antibodies to c1q (Dako Cytomation, Denmark, 1:800), 
c4d (Biomedica Gruppe, Austria, 1:50) and mbl (Sigma-Aldrich 
Biotechnology, 1:500). Staining was visualized with appropriate 
secondary antibodies and diaminobenzidine as the chromagen. 
Finally, sections were counterstained with haematoxylin. Optimal 
antibody dilutions and incubation times for the different antibodies 
were pre-determined by means of titration on positive control 
sections.
quantification of histopathologic morphology and 
immunohistochemistry All sections were evaluated by an ex-
perienced neuropathologist who was blinded to the patients’ clinical 
data. Each case was scored separately for the presence (1) or absence (0) 
of microinfarction, macroinfarction, large hemorrhage, microbleeds, 
cerebral infection and vasculitis. Vasculopathy was defined as endo-
thelial cell proliferation, thickening of the vessel wall and narrowing 
patients We studied brain tissue of 34 patients (27 females, 7 
males) with sle. All patients fulfilled the 1982 American College of 
Rheumatology (acr) revised criteria for sle.19 Cases were divided in 
patients with neuropsychiatric symptoms that could be attributed 
to sle (np-sle group, n=16) and patients without neuropsychiatric 
symptoms or with neuropsychiatric symptoms that were evidently 
caused by other factors than sle such as medication toxicity or 
infection (sle group, n=18). Classification of patients in different 
groups was performed by two rheumatologists with extensive 
experience in diagnosing np-sle (msb and TH) using the available 
patient data from clinical records and autopsy reports. 
The following neuropathological symptoms (acr case definitions) 
were present in our np-sle group: Cerebrovascular disease (n=11), 
movement disorder (chorea) (n=2), seizures and seizure disorders 
(n=2), acute confusional state (n=2), cognitive disorder (n=2), plexopa-
thy (1) and psychosis (n=1). There were 11 patients with one symptom, 
4 patients with 2 symptoms and 1 patient with 3 symptoms. 
In our sle group, 3 patients had neuropsychiatric symptoms 
that could be evidently attributed to other factors than sle. One 
patient suffered large a intracerebral hemorrhage associated with 
anticoagulant treatment, one patient had a severe cerebral mycotic 
infection in association with high dose immunosuppressive therapy 
for class iv lupus nephritis and a third patient died from a uremic 
coma following acute renal failure caused by fulminant lupus 
nephritis. 
Control cases were identified from the archives of the Leiden 
University Medical Centre (lumc) and the Reinier de Graaff Hospital 
(Delft, the Netherlands), which included previously healthy patients 
who died from acute cardiac events confirmed by autopsy (control 
group, n=24). An overview of the clinical characteristics of all patients, 
derived from the autopsy-reports and from clinical data when 
available, is given in table 1.
brain tissue For post-mortem preservation, the brain and spinal 
cord were fixed in 10% neutral buffered formalin for 14 days. The 
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failure due to active sle and diffuse thrombotic complications. 
Cerebral autopsy revealed atrophy of the cerebral cortex, laminar 
cortical necrosis, old and recent micro- and macroinfarctions and 
diffuse vasculopathy.
* patient 2. np-sle, acute neurological deterioration 
and vasculitis This 38-year-old man with a 10-year history 
of sle was admitted in a subcomatose condition, a state which 
had developed the night before. His sle was associated with skin 
lesions, pleuritis, pericarditis, arthritis and hypocomplementemia. 
Antinuclear and anti-dsdna were positive, antiphospholipid 
antibodies were negative. All cerebrospinal fluid cultures at 
admission were negative. Premortem ct and mri (1,5T) imaging 
did not show any abnormalities. Upon clinical diagnosis of np-
sle the patient was treated with high dose immunosuppression 
(cyclophosphamide and prednisone). However, the clinical 
course was complicated by the development of an opportunistic 
pulmonary infection with Klebsiella pneumonia and the patient 
died from respiratory distress at the intensive care unit. Autopsy 
revealed venous abnormalities compatible with venous vasculitis 
(invasion of lymphocytes within the vascular wall and fibrinoid 
necrosis), and diffuse vasculopathy. 
* patient 3. sle, acute myocardial infarction and 
no neuropsychiatric symptoms This 63-year-old 
female patient with a 30-year history of sle complicated by 
arthritis, glomerulonephritis, pleuritis and skin lesions died 
from a myocardial infarction. During the course of her disease 
she never had neuropsychiatric symptoms. She was positive for 
antinuclear antibodies and anti-dsdna antibodies, and negative 
for antiphospholipid antibodies.
post-mortem neuroimaging and evaluation of acquired 
images Directly after autopsy formalin fixed brains were sectioned 
into approximately 1 centimeter thick coronal sections and stored 
of the capillary lumen, and was scored semiquantitatively as ‘no 
vasculopathy’ (total absence of vasculopathy in all low powerfields), 
‘mild vasculopathy’ (1-2 vessels showing vasculopathy per low 
powerfield) or ‘diffuse vasculopathy’ (several vessels showing 
vasculopathy in all low powerfields). 
Positivity for immunohistochemical stainings was scored by  
two independent observers blinded to the patients’ clinical data.  
A similar semi-quantitative scoring system was used for c1q and 
c4d, which both mainly stained positive on endothelial cells of small 
vessels in the white and grey matter. c1q and c4d depositions were 
scored as ‘no staining’ (total absence of c1q or c4d staining in all 
low powerfields), ‘mild staining’ (1-2 vessels showing c1q or c4d 
positivity per low powerfield) or ‘diffuse staining’ (several vessels 
showing c1q or c4d positivity in all low powerfields). mbl was 
never positive in a vascular pattern, but deposited on single cells 
throughout the grey and white matter. Therefore, mbl-positive  
cells were scored as present (1) or absent (0). 
whole formalin fixed brains: clinical case histories
In three subjects, whole formalin fixed brains were available that per-
mitted direct comparison of postmortem mri with cerebral histopa-
thology. Detailed case histories of these patients are given below. 
* patient 1. np-sle, antiphospholipid syndrome 
and cerebrovascular disease This 57-year-old female 
patient with a 28-year history of sle complicated by arthritis, 
endocarditis, epilepsy, cerebral infarctions and antiphospholipid 
syndrome, suffered an epileptic attack at home and was admitted 
in a confusional state. mri imaging (1,5T) of 2 weeks before her 
death revealed diffuse cortical atrophy, multiple old cortical 
infarcts and diffuse white matter hyperintensities. She developed 
a myocardial infarction, severe pulmonary embolism, acute renal 
failure and multiple cerebral infarctions. Antinuclear, anti-dsdna 
and antiphospholipid antibodies were repeatedly positive. There 
was no sign of cns infection. She died in a coma from multiorgan 
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handled in a coded fashion, according to Dutch national ethical 
guidelines (Code for Proper Secondary Use of Human Tissue, Dutch 
Federation of Medical Scientific Societies).
statistical analysis Categorical variables were compared using 
the Chi-square test and its trend version (linear-by-linear analysis). 
Differences in quantitative parameters between groups were assessed 
using one-way anova (for data normally distributed) or the non-
parametric Kruskall Wallis-test (for non-normally distributed data). 
All analyses were performed using spss statistical software package 
(version 16.0; Chicago, il). A p-value equal to or less than 0,05 was 
considered statistically significant.
Results
light microscopy and neuropathology The prepon-
derance of pathology was found in the cerebral cortex, equally 
distributed over white and grey matter. Cases (np-sle and sle) 
differed significantly on all histological parameters from controls, 
in which neuropathological abnormalities were rarely present. 
When comparing cases with and without neuropsychiatric symp-
toms, microinfarction (P=0,016), macroinfarction (P=0,002) and 
vasculitis (P=0,048) were more often present in np-sle than in sle. 
Microthrombi were exclusively found in patients with np-sle, in 7 
out of 16 patients (44%) (P=0,002) (figure 1). 
The presence of vasculopathy and its distribution in either  
a focal or diffuse pattern differed significantly among the three 
groups (i.e. patients with np-sle, sle and controls) in a chi-square 
linear by linear association analysis (p<0.00001). Whereas focal 
vasculopathy was present in all groups in circa 40-60% of subjects, 
diffuse vasculopathy was almost uniquely present in patients with 
np-sle, and significantly more often than in sle patients without 
neuropsychiatric symptoms (P=0,001) (figure 2). Diffuse vasculopathy 
occurred in 9/16 patients with np-sle (56%) and in only 1/18 sle 
patients (6%). Diffuse vasculopathy was not observed in controls.
accordingly. Prior to imaging, remnants of the dura and vasculature 
were removed from the pial surface, and residual formalin was  
washed out by immersion in phosphate buffered saline (pbs) for at 
least one day to partially restore transverse relaxation parameters.21 
The brain specimens were placed in between two adjustable 
polymethyl methacrylate plates (170 mm long, 80 mm wide) and 
immersed in a proton free fluid (Fomblin Lc55, Solvay). Postmortem 
mri was acquired at a whole body 7 T system (Philips Healthcare,  
Best, The Netherlands) using a Nova Medical transmit coil with 16 
channel receive array. 
A modified protocol described before was used with echo times  
(te) ranging from 20 – 40 ms.22 After visual inspection the protocol 
with a te of 35 ms was chosen for displaying the best image quality 
and contrast, and was subsequently used for imaging of all other brain 
specimens. Scan parameters were: Voxel resolution 0.3 x 0.3 x 0.3 mm3 
for a 3d T™*-weighted gradient echo sequence with repetition time / 
te / flip angle = 60 ms / 35 ms / 10°. The number of slices was adjusted 
to match the size of the brain specimen and varied between 60 and 80 
slices, resulting in an approximate scan duration of 2h30min, 7 signal 
averages were acquired to obtain sufficient image quality. 
Images were concurrently reviewed by two neuroradiologists  
with extensive experience in np-sle (MvB and be) who identified 
areas of interest. 
histological analysis of postmortem mri scanned 
brains After radiological analysis, tissue blocks of those areas that 
were selected on postmortem mr images were sampled, embedded 
in paraffin and stained with haematoxylin and eosin. The neuro-
pathologist then independently prepared a report detailing the 
histopathological changes in each sampled area, and pathological 
lesions were correlated to mri findings.
ethical considerations Tissues and patient data were used 
according to the guidelines of the ethics committee of the lumc. 
Patient anonymity was strictly maintained. All tissue samples were 
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(17%). Focal deposition of c4d was present in 11 patients with np-sle 
(69%) and 14 patients with sle (78%). Between sle and np-sle there 
was no significant difference (P=0,800). c4d deposition in controls 
occurred in 6 out of 24 controls in a focal pattern. In all other controls, 
c4d deposits were negative. The different staining intensities in 
patients and controls are given in figure 4b.
 
mbl mbl did not deposit in a vascular pattern and as a consequence 
co-localization between mbl and c1q/c4d never occurred. How- 
ever, mbl positivity was observed on star-shaped cells, most likely 
astrocytes. These mbl-positive cells were detected both in patients 
and controls (no statistically significant difference, data not shown) 
Examples of mbl-positive cells are given in figure 3g and 3h. 
complement deposition, microthrombi and micro- 
infarction To find out whether complement deposition was  
associated with histological lesions that were associated to np-sle, 
the relation between c1q and c4d and presence of microthrombi,  
micro- and macro-infarction, vasculitis and vasculopathy was inves-
tigated. Of those, only the presence of microthrombi was significantly 
related to the presence of c4d staining (p=0,029, table 3) All cases with 
cerebral microthrombi showed focal or diffuse c4d staining. Three 
had a diffuse c4d staining pattern whereas the other four had a focal 
c4d staining pattern. Because microthrombi uniquely occurred in 
the np-sle patient group, the association between c4d and micro-
thrombi within this group was analysed separately, and was signi- 
ficant in a linearbylinear association chi square analysis (p=0.029).
relation between c4d and c1q in sle and np-sle  
To gain more insight in the cascading events of classical comple- 
ment activation, staining-patterns of c1q and c4d were correlated 
to each other, within patient groups with sle and np-sle. In 
general, diffuse c1q staining was present more often than diffuse 
c4d staining (35% vs 15%). Patients with positive c4d staining (focal 
or diffuse) had co-localized c1q deposits in 29 out of 30 positive cases 
In total, vasculitis was present in 6 patients, of which 5 in the  
np-sle-group and 1 in the sle group (P=0,048). Every patient with 
np-sle and vasculitis also had vasculopathy (4 in a diffuse pattern, 
1 in a focal pattern). Vasculitis was associated with cerebrovascular 
disease in 4 patients, and acute confusional state in one case. The 
patient with vasculitis with sle (without np-sle) had a severe 
mycotic infection in association with immunosupression. 
Typical histological examples of vasculopathy and cerebral 
microthrombi are shown in figure 3a and b respectively. 
immunohistochemistry Staining patterns for c1q, c4d and 
mbl were investigated in all tissue samples. In figure 3c-h typical 
examples of immunohistochemical staining in cases and controls  
are shown.
c1q c1q deposition was observed on endothelial cells of small 
vessels, as shown in figure 3d. Vessels in tissue of np-sle and  
sle patients both had significantly more c1q depositions than 
controls (Table 2, P<0,001). A diffuse staining pattern for c1q was 
present in 12 cases, of which 5 (31%) with np-sle and 7 with sle  
(38%). In controls diffuse c1q depositions never occurred. Focal 
deposition was present in 11 np-sle cases (69%) and 10 sle cases 
(56%). All cases of np-sle showed diffuse or focal c1q deposition, 
whereas total absence of c1q was seen only once in sle. Between 
sle and np-sle there was no significant difference (P=0,531) with 
respect to c1q deposits. Nine out of 24 controls (38%) had detectable 
c1q depositions in a focal deposition pattern. In all other controls 
c1q deposits were undetectable. An overview of the different staining 
intensities in patients and controls is given in figure 4a. 
c4d c4d depositions were also observed on endothelial cells, as 
shown in figure 3f. Similar to c1q, small vessels in tissue of np-sle 
and sle patients both showed significantly more c4d depositions 
than controls (Table 2, P<0,001). A diffuse staining pattern was present 
in 5 patients, of which 2 patients with np-sle (13%) and 3 with sle 
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* patient 2: histopathology As no abnormalities were 
identified on mri, pathological sections were taken from various 
areas in the cortex. All sections revealed severe vasculopathy (figure 
5, patient 2c and d). Furthermore, as described in the original 
autopsy-report, several venes and venules showed invasion of 
lymphocytes within the vascular wall, associated with fragmented 
nuclei and fibrinoid material (figure 5, patient 2e) No intracascular 
microthrombi, infarctions or gliosis lesions were discovered. 
* patient 3: post mortem mr imaging Imaging studies 
revealed a prominent virchow robin space (figure 5, patient 3a) 
Furthermore, a linear perivascular white matter hyperintensity 
was discovered in the internal capsule. Another white matter lesion 
was identified in the frontal white matter (figure 5, patient 3b). 
* patient 3: histopathology Sections taken from the frontal 
white matter lesion showed a mild vasculopathy, but no other 
abnormalities. Vasculopathy was seen throughout all other 
sections as well in a similar focal distribution pattern (figure 5, 
patient 3c and d).
Discussion
 
The understanding of mechanisms involved in np-sle is poor.  
This lack of insight has major consequences for both patients and 
clinicians, mainly because there is no gold standard for diagnosis  
and no targeted treatment options. Our aim was to test the hypoth-
esis that complement activation is involved in the pathofysiology  
of np-sle. With this study we are the first to show that vascular  
depositions of c1q and c4d, both components of the classical path-
way of complement, were detected in cerebral vessels of patients 
with sle and were present significantly more often in sle and 
np-sle than in controls. Thrombo-ischemic injury was closely 
associated to np-sle. Interestingly, cerebral microthrombi were 
associated with the presence of c4d, and were found exclusively in 
(97% overlap). Conversely, patients with positive c1q (focal or diffuse) 
had co-localized c4d in 28 out of 33 cases (85% overlap) In table 4 it 
can be appreciated that for both the sle and the np-sle group the 
distribution of c1q and c4d are similar. 
post mortem mri scans and correlations with histo-
pathology and immunohistochemistry Results of post 
mortem mr Imaging of two np-sle patient and one sle patient  
are shown in figure 5. 
* patient 1: post mortem mr imaging Imaging studies 
revealed extensive confluent periventricular and deep white 
matter lesions with notable sparing of u-fibers (figure 5, patient 
1a and b). Furthermore, central lacunes were identified in the 
deep white matter suggesting tissue loss as can be seen in lacunar 
infarction. The white matter lesions peripheral to the confluent 
white matter lesions and adjacent to the deep white matter lesions 
had a perivascular distribution.
* patient 1: histopathology Sections taken from both deep 
and periventricular white matter lesion showed areas of recent 
and older micro- and macroinfarction. In one deep white matter 
lesion multiple microthrombi (figure 5, patient 1c and d) were 
identified. In all sections prominent vasculopathy in both grey and 
white matter was found (figure 5, patient 1 E). Vasculopathy was 
seen within white matter hyperintensities and infarcted areas, but 
also in normal appearing white and grey matter. Furthermore, vast 
areas of the atrophied cortex, especially in proximity of infarctions, 
showed laminar necrosis (figure 5, patient 1f)
* patient 2: post mortem mr imaging Imaging studies 
revealed normal gray and white matter differentiation (figure 5, 
patient 2a and b) Several linear hyperintensities were characteristic 
of normal Virchow Robin spaces (figure 5, patient 2a). The white 
matter in patient 2 was homogenous compared to the white 
matter in patient 1 and there was a normal cortical thickness. 
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disturbance. Thus far it has not been possible to link the work of 
Diamond et al to the thrombo-ischemic injury observed in human 
np-sle cases.
With our study a new pathogenic factor in the form of com-
plement activation enters the field. Our findings suggest that the 
constant exposure of autoantibodies to the cerebral endothelium 
of lupus patients causes continuous complement activation and 
endothelial injury in all sle patients. Complement may activate 
endothelial cells leading to upregulation of adhesion molecules 
such as icam-1, e-selectin, p-selectin and VcaM promoting 
coagulation and proliferation. This mechanism, which has been 
also described in conditions like hus30, post-transplant ischemia-
reperfusion damage31 and severe malaria32, provides a model for the 
development of small vessel injury and vasculopathy seen in sle.33 
Furthermore, the effect of complement on the cerebral endothelium 
may damage the blood-brain barrier. In experimental lupus it was 
shown by Alexander et al that c5a indeed is able to alter blood-brain 
barrier integrity34 and that inhibition of the c5a receptor alleviates 
neurological symptoms.35 If complement fulfills this role also 
in the human brain, this may explain the passage of neurotoxic 
autoantibodies in sle, causing a neuroinflammatory state. 
The fact that we observed complement activation in sle patients 
with and without neuropsychiatric symptoms may explain the 
clinically well-known ‘lupus fog’ of the brain of which many patients 
complain, but which is not incorporated in the acr ’99 criteria as an 
official form of neuro-involvement of sle. Apparently, a second hit is 
necessary for overt clinical disease as defined in the acr ’99 criteria.36 
Infection, pregnancy, medication toxicity15, or defects in complement 
regulatory mechanisms15;37 have been described as triggering factors. 
Whether these also play a role in np-sle could be subject for further 
studies. 
Three ‘whole’ human brains of patients with sle were subjected 
to 7Tesla mri imaging to investigate whether microvascular and 
thrombo-ischemic injury could be detected. High field mri exami-
nations can provide images at a higher spatial resolution, resulting  
patients with np symptoms. Our data support a pathogenic mech-
anism where sle-related autoantibodies bind to endothelial cells of 
small vessels in the brain leading to local activation of the classical 
complement cascade, widespread vasculopathy, impaired cerebral 
perfusion, and finally, development of cerebral microthrombi and 
microinfarction.
The role of complement activation in the development of throm-
bosis and ischemia has been extensively studied outside the field 
of sle. In the setting of antiphospholipid syndrome, both animal 
studies and studies in humans have shown that complement 
activation is essential for the development of antiphospholipid 
antibody-mediated thrombosis13 and antiphospholipid anti-
body mediated fetal loss23, the latter being characterized by 
placental infarction and fetal growth restriction.14 By using 
comple ment deficient mice, or blocking complement activation 
pharmacologically, it was possible to reduce or even prevent the 
development of thrombosis.24;25 In a non auto-immune model of 
hypoxic-ischemic brain injury in neonatal mice, Ten et al showed  
that significantly greater neurologic damage developed after an 
induced hypoxic-ischemic insult in wild type mice compared with 
c1q deficient mice.26 The infarct volume that developed in the wild 
type mice was more than twice as large as in c1q deficient mice. This 
study provides strong evidence that hypoxic-ischemic brain injury 
can be mediated by c1q deposition. Given the fact that we observed 
c1q deposits in the majority of sle patients, this mechanism might 
also contribute to cerebrovascular injury seen in sle and np-sle.
Studies in animal models are less explicit about the histopathology 
of experimental np-sle, which in these studies is defined by altered 
animal behavior. The group of Diamond et al provided a body of 
evidence focusing on the role of autoantibodies in the development 
of neuropsychiatric symptoms. They demonstrated that anti-
dsdna antibodies derived from human sle patients can enter the 
murine brain through a lipopolysaccharide induced breach in the 
blood-brain barrier and can cross-react with nmda receptors on 
neurons.27-29 In mice, this led to impaired cognition and emotional 
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in more detailed information of microvascular injuries. Interestingly, 
in our patients (2 with np-sle and 1 with sle, figure 5) even high 
resolution mr imaging could not detect the majority of small vessel 
injury observed histologically. Microvascular injury (vasculopathy, 
microinfarctions, microbleeds) were most prominently found in 
the vicinity of white matter hyperintensities. In our opinion, white 
matter hyperintensities in sle patients should therefore not be 
considered innocent, but instead might mark the initial phase of 
vascular damage that could eventually lead to np-sle. Prospective 
studies on the role of 7Tesla mri in the detection of these lesions in 
sle and np-sle should be performed to further unravel this issue. 
Currently, neurological involvement of sle is a poorly understood 
manifestation of the disease causing major decline in quality of life  
of young patients. np-sle is often treated with aggressive 
immunosuppression, which is beneficial in some but certainly  
not all patients.4;38 Our findings demonstrate that complement 
activation is present in patients with sle and np-sle and suggest 
that this mechanism may contribute to the development of throm-
bo-ischemic injury and potentially disruption of the blood brain 
barrier, thus facilitating antibody-mediated neuroinflammation. 
Eculizumab is the first complement inhibitor that is already used 
extensively in other settings of complement-mediated disease with 
fewer side effects than high dose corticosteroids or cyclosporine.39  
We therefore suggest complement as a promising target for 
treatment in np-sle. 
fig 1 histological parameters in np-sle, sle and controls
 
Figure 1 shows the presence of different histological parameters in brain tissue of patients with sle, 
neuropsychiatric sle (np-sle) and controls. Microthrombi, microinfarction, macroinfarction and 
vasculitis were present statistically significantly more often in np-sle compared to sle. None of 
these parameters were present in brains of controls. 
fig 2 vasculopathy in np-sle, sle and controls
Figure 2 shows the results of semi-quantitative scoring of vasculopathy in brain tissue of patients 
with sle, neuropsychiatric sle (np-sle) and controls. Vasculopathy was defined as endothelial cell 
proliferation, thickening of the vessel wall and narrowing of the capillary lumen, and was scored 
semiquantitatively as ‘no vasculopathy’ (total absence of vasculopathy in all low powerfields), ‘mild 
vasculopathy’ (1-2 vessels showing vasculopathy per low powerfield) or ‘diffuse vasculopathy’ (several 
vessels showing vasculopathy in all low powerfields). Diffuse vasculopathy was present significantly 
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fig 3 histopathological findings and immunohisto - 
 chemical staining patterns
Figure 3a-h shows different histopathological findings and immunohistochemical staining patterns 
(Magnification of all images: 40x). Figure 3a gives a typical example of vasculopathy with thickening 
of the vessel wall without an inflammatory infiltrate. Figure 3b shows a typical example of a cerebral 
microthrombus. An example of the observed linear intravascular deposition pattern for c1q is given 
in 3d (c1q positive staining in an np-sle patient). Figure 3e (negative c4d staining) and F (positive 
c4d staining) show that c4d has a similar deposition pattern as c1q. mbl never co-localized with c1q 
or c4d, but instead stained positive in cases and controls in star-shaped cells suggestive for astrocytes. 
Examples of mbl staining are shown in figure 3f and 3g. 
fig 4  staining patterns of c1q and c4d in np-sle, sle  
 and controls
Figure 4 shows staining-patterns of c1q and c4d. Both were scored semiquantitatively as ‘no staining’ 
(total absence of c1q or c4d staining in all low powerfields), ‘mild staining’ (1-2 vessels showing 
c1q or c4d positivity per low powerfield) or ‘diffuse staining’ (several vessels showing c1q or c4d 
positivity in all low powerfields). Both c1q   (figure 4a) and c4d (figure 4b) were present equally 
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fig 5 post mortem 7tesla mri and corresponding 
 histopathological lesions
 
Figure 5 shows the findings of post mortem mri and corresponding histopathological 
lesions in three sle patients of whom whole formalin-fixed brains were available. 
Patient 1: sle and antiphospholipid syndrome, with epilepsy and multiple infarctions. 
Figure 1a: Extensive confluent periventricular and deep white matter lesions (*). Figure 
1b: Deep white matter lesions with sparing of u-fibers (*) and white matter lesions with 
a perivascular distribution (arrow). Figure 1c-f: Sections taken from both deep and peri-
ventricular white matter lesion showed areas of recent and older micro- and macroin-
farction and thrombo-ischemic injury. Figure 1c shows an example of microinfarction 
and 1d shows examples of multiple microthrombi found in the vicinity of white matter 
lesions. Figure 1e: Prominent vasculopathy in both grey and white matter was found in 
all areas. Vasculopathy was seen within white matter hyperintensities and infarcted ar-
eas, but also in normal appearing white and grey matter. Figure 1f: Evidence of laminar 
necrosis found in vast areas of the cortex. 
 
Patient 2: sle with an acute confusional state.  
Figure 2a-b. Normal grey and white matter differentiation. Several linear hyperintensi-
ties were characteristic of normal Virchow Robin spaces (2a, arrow). Figure 2c-e: As no 
abnormalities were identified on mri, pathological sections were taken from various 
areas in the cortex. All sections revealed severe vasculopathy (2c-d). Figure 2e: Several 
venes and venules showed signs of venous vasculitis. 
 
Patient 3: sle without neuropsychiatric symptoms 
Figure 3a shows a prominent Virchow Robin space, and normal grey and white mat-
ter differentiation. Figure 3b shows a white matter lesion that was identified in the 
frontal white matter. Sections taken from the frontal white matter lesion showed mild 
vasculopathy (Figure 3c). However, vasculopathy was seen throughout all other (normal 
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table 1 patient characteristics
 np-sle (n=16) sle (n=18) controls (n=24)
Number of Females (%) 15 (94) 12 (67) 10 (42)
Mean age at death in years (sd) 44 (14) 46 (19) 47 (17)
Neuropsychiatric symptoms (acr 99 criteria)
Cerebrovascular disease (%) 11 (69) 2 (11) 0 (0)
Movement Disorder (%) 2 (12) 0 (0) 0 (0)
Seizures and seizure disorders (%) 1 (6) 0 (0) 0 (0)
Acute confusional state (%) 2 (12) 1 (6) 0 (0)
Cognitive dysfunction (%) 1 (6) 0 (0) 0 (0)
Psychosis (%) 1 (6) 0 (0) 0 (0)
No Neuropsychiatric symptoms (%) 0 (0) 15 (83) 24 (100)
Primary versus secondary np-sle
Primary np-sle (%) 16 (0) 0 (0) 0 (0)
Secondary np-sle (%) 0 (0) 3 (17) 0 (0)
Neurological infection (%) 3 (19) 5 (28) 0 (0)
Weight brain (sd) 1308 (177) 1290 (137) 1437 (171)
table 2 c1q and c4d staining in patients versus controls
 np-sle (n=16) sle (n=18) controls (n=24) p value
No c1q staining n (%) 0 (0) 1 (6) 15 (63)
Focal c1q staining n (%) 11 (69) 10 (55) 9 (37)
Diffuse c1q staining n (%) 5 (31) 7 (39) 0 (0) P< 0,001
No c4d staining n (%) 2 (12) 2 (11) 18 (75)
Focal c4d staining n (%) 11 (69) 14 (78) 6 (25)
Diffuse c4d staining n (%) 3 (19) 2 (11) 0 (0) P< 0,001
table 3 correlation between c4d and microthrombi in 
np-sle and sle patients
microthrombi absent microthrombi present*
No c4d deposition 4 0
Mild c4d deposition 21 4
Diffuse c4d deposition 2 3
*p = 0,029
table 4 correlation between c1q and c4d in sle and np-sle




No c1q staining 0 1 0
Focal c1q staining 2 7 1
Diffuse c1q staining 0 6 1




No c1q staining 0 0 0
Focal c1q staining 2 7 2
Diffuse c1q staining 0 4 1
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Abstract
introduction Recurrent miscarriage, fetal growth restriction 
and intrauterine fetal death are frequently occurring complications 
of pregnancy in patients with systemic lupus erythematosus (sle) 
and anti phos pholipid syndrome (aps). Murine models show that 
complement activation plays a pivotal role in antiphospholipid 
antibodymediated pregnancy morbidity. However, the exact 
pathways of complement activation and their potential role in 
human pregnancy are insufficiently understood. Given the anti- 
body-mediated nature of sle and aps in which pregnancy losses  
are pertinent, we hypothesized that the classical pathway would  
play a major role in inducing fetal loss. 
methods To gain more insight into the contribution of different 
complement pathways to fetal outcome, pregnant c57bl/6 
mice and mice deficient in c1q and factor d were injected with 
antiphospholipid antibodies or normal human IgG. Mice-placentas 
were subsequently stained with an anti-c4 antibody and anti-normal 
human IgG to determine presence of classical complement activation 
and IgG binding. Findings in mice were validated in 88 human 
placentas from 83 women (sle and aps cases versus controls), which 
were immunohistochemically stained for c4d, c1q, properdin and 
mbl. Staining patterns were compared to pregnancy outcome.
results In murine placentas of mice pre-treated with 
antiphospholipid antibodies, increased c4 deposition was observed, 
which was associated with adverse fetal outcome but not with 
IgG binding. In humans, diffuse c4d staining at the fetomaternal 
interface was present almost exclusively in patients with sle and/
or aps (p < 0.001) and was related to intrauterine fetal death (p = 0.03). 
conclusion Our data show that presence of c4d in murine and 
human placentas is strongly related to adverse fetal outcome in the 
setting of sle and aps. The excessive deposition of c4d supports the 
concept of severe autoantibody-mediated injury at the fetomaternal 
interface. We suggest c4d as a potential biomarker of autoantibody-
mediated fetal loss in sle and aps. 
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Introduction
 
Recurrent miscarriage, fetal growth restriction and intrauterine fetal  
death (iufd) are devastating complications of pregnancy that occur  
20 to 40 times more often in patients with systemic lupus erythema-
tosus (sle) and antiphospholipid syndrome (aps) than in healthy 
pregnant women.1;2 Presence of circulating antiphospholipid anti-
bodies (apl) which is a prerequisite for aps and occurs in 40% of sle 
patients, is strongly associated with thrombosis and fetal loss.3
The increased risk of thrombosis in the presence of apl suggests 
that thrombosis of the uteroplacental vasculature could be an 
important cause of pregnancy morbidity. However, thrombotic 
lesions are not significant and even not always detectable in 
placentas of patients with apl-mediated fetal loss.4 Recent 
studies in complement deficient murine models 5-8 suggested 
that complement activation plays a pivotal role in apl-mediated 
fetal loss, shifting the focus more towards inflammation as the 
primary causative mechanism.9;10 However, the exact pathways of 
complement activation and their potential role in human pregnancy 
are insufficiently understood. We hypothesized that classical com-
plement activation is the main responsible pathway in sle and 
aps related pregnancy morbidity, based on an antibody-mediated 
allo-response at the fetomaternal interface. We therefore investigated 
the role of classical, alternative and mannose binding lectin (mbl) 
pathway activation in a murine model of apl-mediated fetal injury 
and in human placentas of pregnancies affected by sle and aps.  
As a marker for classical pathway activation we used c4d, a marker  
for classical complement activation.
In transplantation pathology, c4d is widely used as a biomarker  
to diagnose antibody-mediated allograft rejection.11 As a degradation 
product of c4, one of the main components of the classical com ple-
ment cascade, c4d has the ability to bind covalently to cell surfaces 
and basement membranes near sites of c4 activation. Covalently 
bound c4d is anchored to the tissue, and remains attached much 
longer than the antibodies that originally activated the classical 
pathway. This makes c4d a highly stable marker, and has led to c4d 
being referred to as ‘a footprint’ of antibody-mediated tissue injury.12
In a mouse model of apl-mediated fetal loss we first studied 
murine placentas with an anti-c4 antibody to determine presence of 
classical complement activation. Observations in mice were validated 
by investigating the presence c4d deposits in placentas of patients 
with sle and/or aps in relation to pregnancy outcome, compared 
to healthy and disease controls. In additional studies we confirmed 
that placental c4d depositions reflect specific involvement of classical 
pathway activation, and are not derived from lectin or alternative 
pathway activation.
Materials and methods
mouse model of antiphospholipid antibody-induced 
fetal loss Adult mice (6-8 weeks), c57bl/6 mice (Jackson Labora-
tories, Bar Harbor, ME, usa) and mice deficient in c1q and factor d 
(c1qfdko) 13 (generously provided by Greg Stahl, Harvard University) 
were used in all experiments.
On days 8 and 12 of pregnancy, females were treated with i.p. 
injections of human IgG-containing apl (apl-IgG) (10 mg) or normal 
human IgG (nh-IgG) (10 mg) as previously described.5;14 Apl-IgG 
were obtained from patients with aps [characterized by high titer apl 
antibodies (>140 Gpl units), nh-IgG was obtained from healthy non-
autoimmune individuals.
Mice (c57bl/6 and c1qfdko) were sacrificed on day 8, 2h after 
apl-IgG injection (cases, n=5) or nh-IgG injection (controls, n=5), 
uteri were dissected and deciduas and placentas were harvested. 
Another group of cases (n=5) and controls (n=5) were euthanized on 
day 15 of pregnancy to harvest placentas. Resorption sites that result 
from loss of a previously viable embryo were counted as previously 
described.5;14
For immunohistochemical studies, deciduas from day 8 and 
placentas from day 15 of pregnancy were fixed in paraformaldehyde 
4%, frozen in o.c.t. compound, and cut into 10 µm sections. Sections 
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were stained for c4d with a rat monoclonal anti-c4 antibody 
(c4 antibody [16d2] (ab11863) Abcam, Cambridge, ma, usa) at a 
dilution 1/50. This antibody reacts with murine c4, c4b and c4d. 
As a positive control we used a kidney of a mouse injected with fb1 
(mouse monoclonal-apl that activates complement). As a positive 
control we used a kidney that belonged to a mouse injected with fb1 
(mouse monoclonal antiphospholipid antibody from M. Monastier 
that activates complement). This antibody (specificity, isolation, 
etc) was described in studies in pregnancy and renal thrombotic 
microangiopathy. The control mouse received mouse IgG. 
An hrp-labeled secondary antibody and dab as substrate or a 
fitc-labeled secondary antibody were used to develop the reaction.  
For fluorescence staining gold antifade reagent with dapi (Invitro-
gen, Carisbad, ca, usa) was used.
Day 15 placentas were also stained with anti-human IgG (Sigma-
Aldrich, St Louis, mo) at a dilution 1/150.
All animal studies were approved by the institutional Animal  
Care and Use Committee of the Hospital for Special Surgery or  
Weill Medical College of Cornell University and York College,  
City University of New York, New York.
 
patients and placentas We studied 88 placentas from 83 
women who delivered at the Obstetrical Department of the  
Leiden University Medical Centre (lumc) between 1995 and 
2009. Women were subdivided into three groups: The case-group 
consisted of 21 patients with a confirmed diagnosis of sle and/or 
aps, from which we selected all available placentas (26 placentas of 
21 patients). Multiple placentas were available from 4 patients in 
the case group. For statistical analysis, only the placenta of the first 
pregnancy was taken into account. All patients in the case group 
were tested for antiphospholipid antibodies (lupus anticoagulant 
and anticardiolipin antibodies) according to the most recent 
guidelines.15;16
For a first control group (live-birth controls) we included 40 
placentas of pregnancies that resulted in live births in the same 
period as above. These placentas represented pregnancies ranging 
from completely normal to relatively complicated, including both 
maternal and fetal morbidity. None of the patients had preeclampsia 
or Hemolysis Elevated Liver enzymes and Low Platelets (hellp) 
syndrome.
For a second control group (iufd-controls) we included 22 pla-
centas of pregnancies that resulted in iufd by various causes other 
than sle or aps. Fetal losses in this group were mainly caused by  
fetal chromosomal abnormalities.
An overview of the clinical characteristics of all patients, derived 
from the case-records of the lumc, is given in table 1.
All tissue samples were handled in a coded fashion, according  
to Dutch national ethical guidelines (Code for Proper Secondary Use 
of Human Tissue, Dutch Federation of Medical Scientific Societies). 
routine histopathology and immunohisto-
chemistry Placentas were fixed in 4% buffered formalin and  
embedded in paraffin. Paraffin sections were routinely stained with 
he. To study complement activation, immunohistochemical stain-
ing was performed for c4d (BI-Rc4d, Biomedica Gruppe, Austria),  
c1q (Dako Cytomation, Denmark), mbl (Sigma-Aldrich Biotech- 
nology) and properdin (primary antibody kindly provided by the  
department Nephrology, Leiden, the Netherlands). Optimal anti- 
body dilutions and incubation times for the different antibodies were 
pre-determined by means of titration on positive control sections. 
c4d Endogenous peroxidase activity was blocked. Antigen retrieval 
was performed with 10 mM citrate buffer (pH 6.0). A polyclonal rabbit  
anti-human c4d antibody (Biomedica Gruppe, Austria), was applied 
at a dilution of 1:80 in 1% bsa/pbs, and slides were incubated for one  
hour at room temperature. The slides were then incubated with a  
secondary antibody (anti-rabbit EnVision, K5007, Dako Cytomation, 
Denmark) for 30 minutes. Staining was visualized with diamino-
benzidine (Dako Cytomation, Denmark) and counterstained with 
Haematoxylin.
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A tissue sample from a renal biopsy of a patient with humoral 
rejection with c4d-positive staining served as a positive control.
 
c1q Endogenous peroxidase activity was blocked. Antigen retrieval 
was performed in edta-tris (pH 9.0). A polyclonal rabbit anti-
human polyclonal c1q antibody (Dako Cytomation, Denmark) was 
applied at a dilution of 1:700 in 1%bsa/pbs, and slides were incubated 
for one hour at 37 C. The slides were then incubated with a secondary 
antibody (anti-rabbit EnVision, K5007, Dako Cytomation, Denmark) 
for 30 minutes. Staining was visualized with diaminobenzidine (Dako 
Cytomation, Denmark) and counterstained with Haematoxylin. 
Tonsil tissue served as a positive control. 
mbl Endogenous peroxidase activity was blocked. Antigen retrieval 
was performed with 10 mM citrate buffer (pH 6.0). A polyclonal rabbit 
anti-human mbl antibody (Sigma-Aldrich Biotechnology) was 
applied at a dilution of 1:250 in 1% bsa/pbs, and slides were incubated 
for one hour at room temperature. The slides were then incubated 
with a secondary antibody (anti-rabbit EnVision, K5007, Dako 
Cytomation, Denmark) for 30 minutes. Staining was visualized with 
diaminobenzidine (Dako Cytomation, Denmark) and counterstained 
with Haematoxylin. Liver tissue served as a positive control. 
properdin Endogenous peroxidase activity was blocked. Antigen 
retrieval was performed with 10 mM citrate buffer (pH 6.0). The slides 
were subsequently blocked with 5% heat-inactivated normal human 
serum in 1% bovine serum albumin/phosphate-buffered saline (bsa/ 
pbs) for 45 min at room temperature. A polyclonal rabbit anti-human 
properdin antibody (kindly provided by the department Nephrology, 
Leiden, the Netherlands) was applied at a dilution of 1:800 in 1%bsa/
pbs overnight. The slides were then incubated with a secondary 
antibody (anti-rabbit EnVision, K5007, Dako Cytomation, Denmark) 
for 30 minutes. Staining was visualized with diaminobenzidine (Dako 
Cytomation, Denmark) and counterstained with Haematoxylin. A 
kidney with membranous nephropathy was used as a positive control. 
quantification of placental morphology and 
immunohistopathology Sections were evaluated by  
two experienced pathologists who scored the slides blinded  
to the patients’ clinical data. Differences in scorings were resolved  
by re-reviewing the sections and coming to consensus. Each placenta 
was scored separately for the presence or absence of histopathological 
changes associated with decreased uteroplacental perfusion: Acute 
and/or chronic deciduitis, decidual necrosis, increased syncytial 
knots, accelerated villous maturity, accellerated maturity, avascular 
villi, villous infarcts, retroplacental hematomas, intervillous thrombi 
and decidual vasculopathy.17;18
Positivity for immunohistochemical stainings was scored semi- 
quantitatively. A random area of 1 x 1 cm was selected from each  
tissue sample for scoring. Staining intensity around syncytiotro-
phoblast was scored as 0, 1, or 2, with 0 representing the total absence 
of staining, 1 representing focal positive staining, and 2 representing 
diffuse staining of all syncytiotrophoblast cell- and basement mem-
branes within this area. Intravillous endothelial staining was scored 
on a 0, 1, 2 scale, with similar definitions as above.
statistical analysis Categorical variables were compared 
using the Chi-square test. Differences in quantitative parameters 
between groups were assessed using one-way anova (for data 
normally distributed) or Kruskal Wallis H one-way analysis (for data 
not normally distributed). All analyses were performed using spss 
statistical software package (version 16.0; Chicago, il). A p-value less 
than 0.05 was considered statistically significant.
Results
mouse model of apl-igg treated mice
c4 deposition in apl-igg treated mice versus controls
Placentas from the surviving fetuses in apl -treated mice showed 
increased c4 deposition in the labyrinth (Figure 1bii, iii, iv) when 
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compared to placentas from nh-IgG treated mice (Figure 1aii, iii, 
iv). The labyrinth is the area of active feto-maternal exchange in the 
murine placenta, equivalent to chorionic villi in humans.
Specifically, c4 deposition was observed on the trophoblast  
giant cells (tgc) (Figure 1bi). These cells are crucial for implantation 
and invasion of the conceptus into maternal decidua of the uterus. 
Abnormalities in these cells can cause placental defects and com-
promised pregnancies 19;20 and can explain the high resorption 
frequency observed in embryos from apl-treated mice.5;14
c4 deposition in c1q- and factor d-deficient mice
To rule out that c4d positivity was caused by lectin pathway activa-
tion we studied pregnancy outcomes in mice that are deficient for 
complement component c1q and factor d (Figure 1c). Mice deficient 
in the classical pathway component c1q and the alternative pathway 
component factor d were protected from apl-induced fetal injury. 
The fetal resorption frequency in these mice was not different from 
that calculated in nh-IgG treated mice with uneventful preg nancies 
(Figure 1c). No c4 deposition was observed, neither in deciduas nor 
in placentas from c1qfdko mice treated with apl (data not shown).
igg deposition To study if complement deposition coincidences 
with apl-binding in apl-treated mice with increased fetal loss, we 
stained for human IgG in day 15 placentas from surviving fetuses. In 
contrast with the robust c4a deposition observed in these placentas, 
no IgG staining was found.
clinical data Patients in all groups were of similar age. In the 
case group of patients with sle and/or aps, 15 patients met the 
American College of Rheumatology criteria for sle21, 12 patients  
met the classification criteria for aps22, and 6 patients had both sle 
and aps (see table 1).
None of the patients in the live-born control group had been tested 
for apl. In the iufd-group all patients with an iufd of unknown 
etiology were tested for apl. None of the patients met the laboratory 
criteria for aps. Other patient and pregnancy characteristics are 
shown in table 1.
histopathological findings in cases versus controls
Retroplacental hematomas and intervillous thrombi were infrequent 
and not increased either in placentas from patients with sle and/or 
aps, compared to both control groups. Villous infarction and acceler-
ated maturity occurred more often in placentas from patients with 
sle/aps than in both control groups. Figure 2 shows the incidence  
of various histopathological findings in all placentas. 
detection of complement components and 
their association with clinical parameters
c4d When present, c4d showed positivity at the fetomaternal 
interface, on the maternal side of the syncytiotrophoblast, either  
in a focal or a diffuse staining pattern. Typical examples of c4d 
staining patterns are shown in figure 3a-C. A diffuse c4d staining 
pattern in the placenta was strongly associated with sle and/or  
aps (p < 0.001) (figure 3M). Within the case group, diffuse c4d staining 
was associated with iufd (p < 0.03) (figure 3n). Detailed information 
on c4d staining in the cases versus controls is shown in table 2.
Diffuse c4d staining around all syncytiotrophoblast cell- and 
basement membranes (figure 3c) was found in 12 placentas: Ten 
were from patients with sle and/or aps, of whom 5 had a pregnancy 
resulting in iufd, 4 pregnancies were characterized by severe 
intrauterine growth retardation and/or preeclampsia and one of the 
patients had an uncomplicated pregnancy, which was her first live 
born child after 4 late miscarriages. Two of the 12 placentas that were 
diffusely positive for c4d were from patients from the control group 
with iufd: Both patients had an unexplained iufd. One patient 
was negative for apl, the other appeared to have circulating apl 
(anticardiolipin IgG antibodies) when she was tested three months 
after delivery. A diffuse or focal positive c4d staining pattern was 
never found in the control group with live-born children (p<0.001). 
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Detailed information on focal and absent c4d staining patterns is 
given in table 2.
c1q c1q was present in both intravillous endothelial cells and 
around the syncytiotrophoblast cells (Figure 3d-F), and was never 
completely negative, neither in cases nor controls (data not shown).  
In cases of diffuse c4d deposition around syncytiotrophoblast cells, 
c1q clearly co-localized with c4d depositions.
properdin Properdin was almost uniquely positive in intra-
villous endothelial cells, and showed minor positivity around 
syncytiotrophoblast cells in only 2 cases of live birth controls. It did 
not co-localize with c4d deposition (figure 3g-I). Diffuse properdin 
staining occurred almost at a similar rate in live born placentas and  
in placentas in the sle/aps group (33% and 28% respectively). 
Properdin positivity was negatively associated with iufd: In only  
2 out of 22 iufd cases a diffuse staining pattern was observed.
mbl In all cases mbl deposition was absent (figure 3j-l), whereas 
liver tissue that was used as a positive control was evidently positive. 
mbl also did not occur in c4d positive placentas, or in placentas of 
patients with prolonged rupture of membranes.
patients of which multiple placentas of subsequent 
pregnancies were available Multiple placentas were 
available from 4 patients in the case group (see table 3) 
The first patient was diagnosed with sle and had four subse - 
quent pregnancies, of which the first ended in an early miscarriage 
(no tissue available), the second and third ended in intrauterine 
fetal loss and the fourth was a live birth. For the first fetal loss an 
explanation or cause was never found, the second fetus died because 
of congenital heartblock in the presence of maternal anti-ssa and 
anti-ssb antibodies. In her fourth pregnancy she gave birth to a 
healthy child. This patient did not have antiphospholipid antibodies 
at any point in time and her placentas were negative for c4d every 
time. The next patient had sle and secondary antiphospholipid 
syndrome. She had three pregnancies of which two placentas were 
available. All three pregnancies ended in live births, but with seve- 
rely growth restricted children and severe maternal preeclampsia 
during the first and second pregnancy. In the third pregnancy she 
was treated with aspirin and heparin. Her first placenta was not 
available, she had diffuse c4d staining in the second, and focal c4d 
staining in the third placenta. The last two patients had primary 
antiphospholipid syndrome. One patient had three pregnancies 
of which two (the first and third pregnancy) ended in intrauterine 
fetal death, accompanied by severe growth retardation and maternal 
hellp syndrome. Both placentas were diffusely positive for c4d. 
Her second pregnancy, of which no placenta was available, ended in 
a live birth but with maternal hellp syndrome complicated by liver 
infarction. The other patient also had three pregnancies, all of which 
ended in intrauterine fetal death accompanied by severe fetal growth 
retardation. Only the last two placentas were available, which were 
both diffusely positive for c4d.
Discussion
 
aps and sle are autoantibody mediated autoimmune diseases in 
which severe pregnancy morbidity is pertinent. The present study 
demonstrated that c4d deposits were present in areas of active 
fetomaternal exchange in the murine placenta of mice pre-treated 
with human apl-IgG, and absent in those treated with nh-IgG. 
c4d deposits in murine placentas were associated with an increased 
fetal absorption rate (figure 1). Observations in mice were validated 
in human placentas, where placental c4d deposition was frequently 
and almost exclusively present around syncytiotrophoblast cells of 
placentas from patients with sle and/or aps. Its presence in human 
placentas was strongly related to adverse pregnancy outcome in sle 
and aps patients. In patients without sle or aps but with iufds 
diffuse c4d staining was rare. c4d staining was always negative in 
placentas from patients with live births (figure 3, table 2). Our data 
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support the concept of a severe autoantibody-mediated immune 
response at the fetomaternal interface, leading to impaired fetal 
outcome.
To rule out that c4d deposition is a reflection of lectin pathway 
activation we studied the deposition patterns of mbl. In the mice-
experiments, mice deficient in the classical pathway component c1q 
and the alternative pathway component factor d were protected from 
apl-induced fetal injury. No c4 deposition was observed in placentas 
from these mice. mbl was not detectable in human placentas, and did 
not co-localize with c4d. These observations indicate that it is very 
unlikely that the lectin pathway is involved in the pathogenesis of 
fetal losses induced by apl.
Direct exposure of trophoblast to the maternal blood puts 
these cells at risk of being attacked by complement activation 
products, both in the setting of maternal autoimmune disease as 
in normal pregnancies. Our data indicate that deposition of early 
classical pathway component c1q is most likely a non-pathological 
phenomenon. The observed presence of c1q in placentas of 
controls could reflect the physiological presence of maternal IgG 
and IgM. It is not surprising that this usually does not lead to full 
blown activation of the complement cascade, because of the many 
complement regulatory mechanisms normally present at the level 
of the syncytiotrophoblast.6 Alternatively, it was previously shown 
that decidual endothelial cells can synthesize c1q and express it on 
their surface in physiological situations. 23;24 Bulla et al showed that 
deposition of c1q in the placenta was not necessarily associated with 
the presence of IgG, IgM or c4.23 The clear association of c4d  
(a complement split-product more downstream than c1q) with sle 
and aps related pregnancy morbidity as presented in this study, may 
be regarded as evidence of a severe antibody-mediated allo-response, 
where the complement inhibitory mechanisms are surpassed and fail 
to suppress the evolving events in the complement cascade.
Evidence from mouse-models suggested that a large part of the 
apl-mediated placental damage is caused by amplification of the 
classical pathway by the alternative pathway.25 However, we found 
properdin, a membrane bound marker of alternative pathway 
activation, in placentas of both patients with sle and aps as well as 
in live-birth controls, making no distinction between a good or bad 
pregnancy outcome. Interestingly, properdin depositions are found 
within the vessels of the villi, and do not co-localize with c4d deposits 
at the maternal side of the syncytiotrophoblast. This means that 
properdin must originate from the fetal complement system26, and 
may reflect a general state of fetal distress, rather than being directly 
related to the c4d depositions.
Although the clinical implications of apl are well known, testing 
for their presence remains difficult and only highly specialized 
laboratories can provide reliable test results.27;28 c4d stainings are 
performed in most clinical pathology laboratories and a diffuse 
c4d staining pattern in the placenta is easy to recognize (figure 3c). 
We therefore propose that placental c4d staining could be a useful 
additional tool to further strengthen the diagnosis of aPl-mediated 
fetal loss, for instance in the work-up of a first late miscarriage or fetal 
death. This might even have implications for treatment with heparin, 
as it was shown in animal models that heparin prevents apl-induced 
fetal loss by inhibiting complement activation.29 Alternatively, 
it would be interesting to explore whether targeted inhibition of 
complement activation would be beneficial for pregnancy outcome, 
similar to the findings in mice models.5;7
The analogy between pregnancy and transplantation was made as 
early as 1953, when Peter Medawar introduced the concept of ‘the fetal 
allograft’.30 In transplantation, humoral allograft rejection has gained 
much attention since the discovery of c4d.11 Our data demonstrate 
that complicated pregnancies of patients with autoimmune diseases 
such as aps, share several pathofysiological aspects with humoral 
rejection. Both apl and donor-specific antibodies to donor-hla bind 
at the frontier where cells from the one individual (mother or host) 
meet the other (fetus or graft). 
Interestingly, both in pregnancy and in transplantation we 
find no histological evidence for the binding of the antibodies 
themselves, whereas c4d remains attached and is easily detectable 
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both in mice placentas at day 8 and 15, and in human placentas of 
various gestational age. In day 15 placentas of apl-treated mice, we 
did not find nh-IgG deposition, whereas it was previously published 
that nh-IgG can be detected in day 8 placentas of similarly treated 
mice.31 This shows that these antibodies do bind at the fetomaternal 
interface initially, but do not remain attached longer than a few 
days, whereas c4d is detectable throughout the whole pregnancy. 
From the transplant setting, it is known that this phenomenon can 
be explained by the relatively weak binding capacity of antibodies, 
compared to the covalent binding of c4d which anchors to the 
damaged tissue.11 In this study a parallel between the humoral 
rejection and pregnancy is now found in the form of c4d deposition, 
indicating that c4d might be a more reliable and long lasting marker 
of placental antibody-mediated tissue injury.
In human placentas, we demonstrated that 62% of patients with 
sle/aps have a focal or a diffuse c4d staining pattern. However 
38% of these patients do not show any deposition of c4d, while 
their pregnancy outcomes are also impaired, either by growth 
restriction, preeclampsia or even fetal death. There are two important 
explanations for this situation. Firstly, as we take only a small part 
of the placenta for analysis, c4d positivity present in a focal, patchy 
pattern through the whole placenta can be missed due to sampling 
error. In future studies, the effect of more extensive tissue sampling 
could be investigated. Secondly, it is evident that in any pregnancy, 
many more than c4d-related causes can lead to iufd or impaired 
pregnancy outcome. For instance, anti-ssa or anti-ssb antibodies 
can cause a congenital heart block and subsequently, fetal death, 
by travelling through the placenta into the fetal circulation. This 
is a totally different mechanism for sle-related iufd in which no 
trophoblastic c4d deposition is expected. Furthermore, there is 
always a chance for fetal chromosomal abnormalities, and in such 
cases no diffuse c4d deposition is expected as we have illustrated in 
our iufd control group.  
 
In conclusion, we have shown that classical complement activation plays a 
major role in apl- mediated fetal injury, and that placental c4d deposition is a 
reflection of classical complement activation.  
c4d is strongly associated to impaired fetal outcome, both in a mouse model 
of apl- mediated fetal loss and in human pregnancy affected by sle and aps. 
Especially in women with a first pregnancy resulting in iufd, placental c4d 
staining has potential as a diagnostical tool  
to detect apl-mediated fetal loss. Further prospective studies need  
to confirm if c4d positivity in a previous iufd or late miscarriage  
can be considered as a biomarker of a future complicated pregnancy.
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fig 1a-b increased c4 deposition in apl-igg treated mice   
 versus nh-igg controls
Figure 1bi, ii, and iii show increased c4 deposition in the labyrinth (lab) compared to figure 1ai, i, 
and iii. The labyrinth is the area of active feto-maternal exchange in the murine placenta. The equiva-
lent to this area in humans is the chorionic villi. c4 deposition was observed on the trophoblast giant 
cells (tgc) of apl-IgG treated mice (Figure 1bii and iii). In contrast, minimal c4d staining was found 
in placentas from nh-IgG-treated mice (Figure 1ai, ii, iii).  
Figure 1c shows fetal resorption frequency in c1q- and factor d-deficient mice. Mice deficient in the 
classical pathway component c1q and the alternative pathway component factor d are protected 
from apl-induced fetal injury. The fetal resorption frequency in these mice was not different from 
that calculated in nh-IgG treated mice with uneventful pregnancies. No c4 deposition was observed 
neither in deciduas nor in placentas from c1qfdko mice treated with antiphospholipid antibodies 
(data not shown). 
fig 2 bar graph of specific placental histological   
 scores as described in the result section
This figure gives an indication of the abundance of various lesions in different groups.  
The differences between groups is represented with (∗) indicating a p-value of < 0.05 
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fig 3 immunohistochemical staining patterns in human   
 placentas
 c4d c4d c4d
 negative staining focal staining diffuse staining
Panels 3a-l: typical examples of immunohistochemical staining patterns of c4d, c1q, 
Properdin and mbl of placentas. Vertically the panels are organized in such a way that 
each column represents the same placenta. Horizontally the different immunohisto-
chemical stainings are shown. The first column represents a c4d negative placenta of a 
patient with a live birth. The middle column represents a placenta of a patient with an 
iufd, with a focal c4d staining pattern. In the third column a placenta of a patient with 
sle and secondary aps is shown which is diffusely positive for c4d. The pregnancy was 
accompanied by severe maternal preeclampsia and severe fetal growth retardation. 
 
Panels 3a-c: Typical examples of different c4d staining intensities of villous syncy- 
tiotrophoblast cell and basement membranes observed in patients with sle and/or  
aps compared to controls. Panels demonstrate the different staining intensities by  
which the placentas were scored: (a) ‘no placental c4d staining’, (b) ‘focal placental  
c4d staining’, and (c) ‘diffuse placental c4d staining’. In (c) it is clearly shown that  
c4d depositions are found on the maternal side of the placental syncytiotrophoblast, 
and not within the fetal vasculature.  
 
Panels 3d-f: Typical examples of placental c1q staining. Interestingly, c1q was not 
unique for c4d positive placentas, but was observed frequently in non-c4d positive  
placentas too. This phenomenon is illustrated in figure (d), where a c4d negative  
placenta is evidently c1q positive. However, panel (f) shows that c1q does co-localiza-
tion with c4d in a c4d positive placenta, confirming that c4d originates from classical 
pathway activity.  
 
Panels 3g-i: Typical examples of properdin staining, in which properdin deposits on 
endothelial cells of the fetal vessels. Properdin deposition is not corresponding with the 
sites of c4d deposition, suggesting that classical complement activation does not neces-
sarily lead to properdin deposition – i.e. alternative pathway activation.  
 
Panels j-l: In all cases mbl deposition was absent, further confirming that the mbl 
pathway does not contribute to the deposition of c4d in the setting of sle and apl-
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m: Shows the association of diffuse c4d staining with iufd in sle/aps cases.  
The differences between groups is represented with (∗) indicating a p-value of <0.05 and 
(∗∗) indicating p-value of < 0.01. 
 
n: Bar graph of c4d staining in sle/aps cases versus control groups. Figure 3 gives an 
indication of the abundance of diffuse c4d staining in the sle/aps case group and the 
striking absence of diffuse c4d in the live birth controls.  
table 1 patient characteristics






Mean maternal age in years (sd) 29,7(4) 30,5 (6) 31,5 (6)
Mean gravidity (sd) 2,3 (1,5) 2,6 (1,6) 2,2 (0,87)
Mean parity (sd) 0,6 (1,1) 1,3 (1,4) 0,8 (0,8)
Previous live birth (%) 5 (24) 11 (50) 15 (38)
Previous miscarriage or fetal loss (%) 8 (38) 6 (27) 14 (35)
Gestational age at delivery (wk + day) (sd in days) 32 + 6 (4) 25 + 3 (8) 37 + 1 (7)
 Delivery at < 24 wk (%) 4 (19) 14 (64) 0
 Delivery at 24-38 wk (%) 17 (81) 6 (27) 20 (50)
 Delivery at 38-42 (%) 5 (24) 2 (9) 20 (50)
Intrauterine fetal death (%) 6(29) 22(100) 0
Fetal distress (%) 6(29) 0 11(27)
Mean birth weight (grams) (sd) 1639,3 (1060) 901,3 (1203) 2534,5 (981)
Placental weight (grams) (sd) 306,8 (173) 230,2 (205) 472,9 (139)
Heparin therapy during pregnancy (%) 8 (38) 0 0
Comorbidity
 sle (%) 15 (71) 0 0
 sle and aps (seconday aps) (%) 6 (28) 0 0
 aps, no sle (primary aps) (%) 6 (28) 0 0
 Lupus anticoagulant (%) 8 (38) 0 0
 Anticardiolipin antibodies, IgG (%) 10 (48) 0 0
 Preeclampsia (%) 5 (24) 0 0
 hellp syndrome (%) 2 (10) 0 0
 Normal pregnancy and delivery (%) 2 (10) 0 14 (35)
 Unexplained intrauterine fetal death (%) 0 5 (23) 0
 Infant congenital abnormalities (%) 0 12 (55) 3 (8)
*  Systemic Lupus Erythematosus and antiphospholipid syndrome
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No c4d deposition (%) 8 (38) 13 (59) 40(100)  
Focal c4d deposition (%) 3 (14) 7 (32) 0
Diffuse c4d deposition (%) 10 (48) 2 (9) 0 P < 0.001
No properdin deposition (%) 8 (38) 19 (86) 17 (43)  
Focal properdin deposition (%) 6 (29) 2 (9) 12 (30)
Diffuse properdin deposition (%) 7 (33) 1 (5) 11 (28) P < 0.918
** Systemic Lupus Erythematosus and aps
*  iufd control group  





gravidity c4d staining fetal outcome weeks  
& days
1 sle* g1 no tissue available early miscarriage < 10
g2 no c4d staining iufd*** of unknown etiology 18
g3 no c4d staining iufd, congenital heart block in  
the presence of anti-ssa and  
anti-ssb antibodies
31
  g4 no c4d staining Live birth 38 + 1
2 sle + aps** g1 no tissue available Live birth, iugr† 37 + 2
g2 diffuse c4d staining Live birth, iugr and severe 
Preeclampsia
38 + 4
  g3 focal c4d staining Live birth, iugr 38 + 3
3 Primary aps g1 diffuse c4d staining iufd, severe iugr and maternal 
hellp ‡ syndrome. 
23 + 2
g2 no tissue available live birth, hellp syndrome and 
maternal liver infarction
37
g3 diffuse c4d staining iufd, severe hellp syndrome 28 + 2
4 Primary aps g2 no tissue available iufd of unknown etiology 21 + 4
g3 diffuse c4d staining iufd, severe iugr 18 + 1
  g4 diffuse c4d staining iufd, severe iugr 26 + 1
*  Systemic lupus erythematosus
**  Antiphospholipid syndrome
***  Intrauterine fetal death
†  Intrauterine growth retardation
‡  Hemolysis Elevated Liver enzymes and Low Platelets
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background The conceptus represents a foreign body to 
the maternal immune system. This ‘natural’ allograft is usually 
not rejected. In analogy with solid organ transplantation, we 
hypothesized that antibody-mediated rejection, characterized by 
activation of the classical complement system, could play a role 
in women with unexplained recurrent miscarriage. We therefore 
investigated the presence of placental c4d deposition, a marker 
for classical complement activation, as well as the presence of anti-
hla class I and II antibodies in women with recurrent miscarriage 
compared to control subjects.
methodology and principle findings We studied 
placental c4d deposition in 38 women with unexplained recurrent 
miscarriage (cases), a first control group of 22 women who 
experienced one spontaneous miscarriage but subsequently had 
live births and a second control group of 67 women who underwent 
elective termination of pregnancy. c4d depositions were found at 
the maternal side of the syncytiotrophoblast and a diffuse staining 
pattern was strongly associated with recurrent miscarriage (p=0,004) 
when compared tot control subjects. Presence of anti-hla class I and 
II antibodies was determined in 28 out of 38 women in the recurrent 
miscarriage-group, of whom 11 (39%) had a positive titer for anti-
hla class I or II antibodies. Of those, 9 of 11(82%) had focal or diffuse 
placental c4d depositions, whereas in the 17 patients without anti-
hla antibodies diffuse placental c4d was present in only 4 patients 
(23%) (p=0,003).
conclusions Placental c4d is present significantly more often in 
patients with unexplained recurrent miscarriage compared to control 
subjects. c4d deposition is found at the fetal-maternal interface, and 
may be interpreted as a footprint of antibody mediated trophoblast 
injury. We identified 9 out of 39 patients with unexplained recurrent 
miscarriage who had both placental c4d deposits and positive titers 
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for anti-hla antibodies. This combination strongly suggests an 
antibody-mediated immune response, and might embody a new 
pathophysiologic mechanism responsible for recurrent miscarriages. 
Introduction
 
About 1-3% of all couples will be confronted with recurrent miscar-
riage, which is defined as >3 consecutive miscarriages within 20  
weeks of gestation.1 In any recognized pregnancy there is a chance  
of miscarriage of about 10-15%. The large majority of these spora- 
dic miscarriages are caused by fetal chromosomal aneuploidies.2  
In recurrent miscarriage, maternally derived underlying causes  
can be identified in a substantial proportion of women. Examples of 
such causes are uterine anomalies, endocrine disorders, autoimmune 
disorders such as sle or antiphospholipid syndrome, thrombophilia 
or balanced translocations in the maternal (and/or paternal) dna. 
However, in more than 50% of woman suffering from recurrent 
miscarriage, no causal factor can be identified.1 This burden of 
continuous uncertainty has major impact on the lives of women  
and their partners. For clinicians, the lack of both etiological 
insight and evidence based therapeutic interventions makes the 
management of these patients complex and sometimes frustrating.
In analogy with solid organ transplantation it has been 
hypothesized that recurrent miscarriage of unknown etiology is 
a form of maternal anti-fetal allograft rejection. In the transplant 
world, allo-antibody mediated rejection (humoral rejection) has 
gained much attention since the discovery of the biomarker c4d 
in the early nineties.3;4 c4d is a tissue-biomarker for classical 
complement activation, a powerful component of human innate 
immunity that plays an essential role in inducing tissue injury  
in many allo- and autoimmune settings. When antibodies (allo-  
or autoantibodies) bind or deposit, the classical complement path-
way is activated via a cascade of enzymatic reactions. The formation 
of potent anaphylactoxins c5a and c3a and the formation of the 
membrane attack complex are the main results of this process.  
c4d is a non-functional split product of classical complement 
activation that covalently attaches to cells and tissues. While 
antibodies dissociate over time, c4d stays anchored to the tissue, 
thereby acting as a footprint of recent antibody mediated tissue 
injury. Nowadays c4d is routinely used by transplantation 
pathologists all over the world.5
We have recently demonstrated that c4d is abundantly present 
in placentas of women with autoimmune mediated pregnancy 
losses caused by sle and antiphospholipid syndrome.6 Placental 
c4d was found at the fetal-maternal interface, and was strongly 
associated with intrauterine fetal death and severe forms of 
preeclampsia.7-10 The concept of excessive complement activation 
as an important mediator of maternal anti-fetal immunity has 
shown to be relevant in settings other than autoimmune disease 
too. Lee et al recently published that c4d in fetal cord endothelium 
was associated with circulating maternal anti-hla I antibodies in 
a setting of spontaneous preterm birth.11 Furthermore, a recent 
cohort study of patients with severe preeclampsia demonstrated 
that 19% of women had mutations in complement regulatory genes. 
It was shown that such mutations are responsible for inadequate 
inhibition of complement activation at the fetal-maternal interface, 
serving as a basis for impaired trophoblast functioning and placental 
development. 
In recurrent miscarriage of unknown etiology both auto- and al-
loantibodies could theoretically be involved. Auto-antibodies could 
for instance be antiphospholipid-like antibodies that are not picked 
up by current assays but have a similar effect on trophoblast cells. 
Allo-antibodies could be anti-hla antibodies directed against fetal 
inherited paternal hla antigens. We hypothesized that if an ongo- 
 ing antibody-mediated process is responsible for miscarriage, c4d 
should be present at the fetal-maternal interface. We therefore aimed 
to investigate the presence of c4d deposition on trophoblast tissue  
of patients with unexplained recurrent miscarriage compared to con-
trol subjects. To further unravel the disease mechanism, we related 
placental c4d with the presence of circulating anti-hlaantibodies in 
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a subgroup of women, with the hypothesis that antibody-mediated 
rejection of the fetal allograft may indeed be responsible for a propor-
tion of women with unexplained recurrent miscarriage.
Material and methods
ethics statement All tissue and serum samples were handled 
in a coded and anonymized fashion, according to the Dutch National 
Ethical guidelines (Code for Proper Secondary Use of Human Tissue, 
Dutch Federation of Medical Scientific Societies). This national 
guide line or code makes it possible to perform research with human 
material that came available within the framework of patient care. 
Subsequently, this human material can be used for research purposes 
when properly coded and anonymized. 
patients We studied products of conception of 127 women, who 
were divided into three groups: A case-group of 38 patients with 
recurrent miscarriage of unknown etiology, a first control group of 22 
healthy women with one spontaneous miscarriage who subsequently 
had normal pregnancies and live births, and a second control group 
of 67 women who underwent an elective termination of pregnancy 
due to medical reasons (i.e. fetal chromosomal anomalies) or social 
reasons. 
The case-group consisted of 38 women diagnosed with recurrent 
miscarriage of unknown etiology, who were selected from a popu-
lation of women enrolled in a clinical trial performed at the Leiden 
University Medical Center (Habenox trial, trial register number 
nvt0095962).12 The Habenox trial investigated the effect of anticoag-
ulant treatment on pregnancy outcome in women with unexplained 
recurrent miscarriage or thrombophilia. Recurrent miscarriage was 
defined as three or more consecutive first trimester miscarriages 
(<13 weeks), two or more second trimester miscarriages (13-24 weeks) 
or one third trimester miscarriage combined with at least one first 
trimester miscarriage. Patients with thrombophilia, defined as  
factor v Leiden mutation, prothrombin gene mutation, protein c  
or s deficiency, high factor viii or presence of antiphospholipid anti-
bodies were excluded for the current study. Other exclusion criteria 
were history of thromboembolism or bleeding disorders, allergy 
to aspirin or enoxaparin, uterine anomalies, cervical insufficiency, 
untreated thyroid disease, poorly treated diabetes mellitus, parental 
chromosomal abnormalities and pregnancies achieved by assisted 
reproductive techniques. We included all women of whom tissue 
samples of miscarriages were available in the archives of the pathol-
ogy department of the Leiden University Medical Center, Leiden, the 
Netherlands. 
For a first control group (sporadic miscarriage group) we included 
22 tissue samples of miscarriages from women who experienced one  
spontaneous miscarriage, but subsequently had live births and un-
eventful pregnancies. None of the patients had a history of preeclamp-
sia or Hemolysis Elevated Liver enzymes and Low Platelets (hellp) 
syndrome, or any of the other exclusion criteria used in the case group. 
For a second control group (elective termination of pregnancy 
group) we included 67 tissue samples of elective terminations of 
pregnancy, of which 21 terminations were performed for medical 
reasons (i.e. fetal chromosomal anomalies) and 46 for social reasons. 
Of 13 cases in this group we received tissue samples from an abortion 
clinic, therefore, of these patients we have no clinical information 
other than the gestational age of the pregnancy. 
An overview of the clinical characteristics of all patients, derived 
from the case-record files, is given in table 1.
tissue samples of miscarriages and elective termina-
tions of pregnancy Products of conception were fixed in 4% 
buffered formalin and embedded in paraffin. Paraffin sections were 
routinely stained with he. To study classical complement activation, 
immunohistochemical staining was performed for c4d (BI-Rc4d, 
Biomedica Gruppe, Austria). Optimal antibody dilutions and incuba-
tion times for the different antibodies were pre-determined by means 
of titration on positive control sections. Endogenous peroxidase 
activity was blocked. Antigen retrieval was performed with 10 mM 
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citrate buffer (pH 6.0). A polyclonal rabbit anti-human c4d antibody 
(Biomedica Gruppe, Austria), was applied at a dilution of 1:80 in 1% 
bsa/pbs, and slides were incubated for one hour at room tempera-
ture. The slides were then incubated with a secondary antibody (anti-
rabbit EnVision, K5007, Dako Cytomation, Denmark) for 30 minutes. 
Staining was visualized with diaminobenzidine (Dako Cytomation, 
Denmark) and counterstained with Haematoxylin. 
quantification of morphology and immunohisto-
pathology Sections were evaluated by two experienced observers 
(imb and dc) who scored the slides blinded to the patients’ clinical 
data. Differences in scorings were resolved by re-reviewing the sec-
tions and coming to consensus. Positivity for c4d was scored semi-
quantitatively. Staining intensity around syncytiotrophoblast was 
scored as 0, 1, or 2, with 0 representing the total absence of staining,  
1 representing focal positive staining, and 2 representing diffuse 
staining of all syncytiotrophoblast cell- and basement membranes. 
Typical examples of staining patterns are given in figure 1.
serology: anti-hla antibodies and antibody specific-
ity Serum samples from 28 patients from the recurrent miscarriage 
group were available for analysis. The samples were procured from 
µ80µC storage and a Lambda Antigen Tray class i & ii elisa (One 
Lambda, Canoga Park, ca) was carried out to detect the presence  
of hla class I and class II IgG antibodies. The elisa was conducted 
according to protocol with OD readouts at 630 nm. 
statistical analysis Categorical variables were compared using 
the Chi-square test and its trend version (linear-by-linear analysis). 
Differences in quantitative parameters between groups were assessed 
using one-way anova (for data normally distributed) or the non-
parametric Kruskall Wallis-test (for non-normally distributed data). 
All analyses were performed using spss statistical software package 
(version 16.0; Chicago, il). A p-value less than 0,05 was considered 
statistically significant.
Results
clinical characteristics of cases and control 
subjects Table 1 shows the clincial characteristics of the study 
population. Differences between women with unexplained recurrent 
miscarriages and control subjects were observed in maternal age 
and gravidity (both p<0.05). Women from the recurrent miscarriage 
group were treated with anticoagulant therapy during pregnancy in 
25 out of 38 cases (67%). The medication used was a prophylactic dose 
of low molecular weight heparin (lmwh) in 15 cases (40%), aspirin 
in 10 cases (27%) or a combination of both in 6 cases (16%). None of 
the women with sporadic miscarriage used any medication during 
pregnancy. In the elective termination of pregnancy-group this 
information was not available. 
immunohistochemical c4d staining in cases versus 
control subjects Immunohistochemistry was performed on 
trophoblast tissue from miscarriage material from the three study-
groups. When c4d was present on trophoblast tissue, positivity was 
detected at the fetal-maternal interface, on the maternal side of the 
syncytiotrophoblast, either in a focal or a diffuse staining pattern. 
Typical examples of c4d staining patterns are shown in figure 1a-c. 
The presence of placental c4d and its distribution in either a focal 
or diffuse pattern differed significantly among the three groups in 
a chi-square linear by linear association analysis (p<0.004). A diffuse 
c4d staining pattern in the placenta was present in 10 of 38 of women 
with unexplained recurrent miscarriage (26%), compared to 3 out of 
22 in the sporadic miscarriage group (13%) and 7 out of 67 in elective 
abortions (10,4%)(p<0,004). Detailed information on c4d staining in 
cases versus control subjects is given in table 2. 
anti-hla antibodies and their relation with c4d  
Table 3 shows the relationship between anti-hla seropositivity 
and presence of c4d in placental tissue. In total, serum samples of 
28 women with unexplained recurrent miscarriage were analysed. 
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Seropositivity for anti-hla class I or II IgG antibodies was detected  
in 11 cases. Of those, 9 women (82%) also had placental c4d deposits  
in a focal or diffuse pattern. In 17 women without detectable anti-




Recurrent miscarriage is a devastating complication of pregnancy, 
affecting a large population of women worldwide. Many disease 
mechanisms for this multifactorial disorder have been identified,  
but in 50% of couples no underlying cause can be found.1 For many 
years it has been questioned whether the fetus can indeed be 
interpreted as an ‘allograft’ and thus, miscarriage as ‘rejection’.1;13  
In this study we demonstrate that antibody-mediated rejection of  
the fetal allograft may indeed be present in a subgroup of women 
with so far unexplained recurrent miscarriages. 
c4d, a biomarker of classical complement activation and  
a footprint of antibody-mediated injury, was present in areas 
of active fetal-maternal exchange at the maternal side of the 
syncytiotrophoblast. Placental c4d in a diffuse staining pattern 
was present significantly more often in women with unexplained 
recurrent miscarriages compared to two control groups. Moreover, 
presence of c4d was associated to the presence of anti-hla class i or 
ii antibodies in the recurrent miscarriage group. Taken together, our 
data support the concept of an antibody-mediated immune response 
at the fetal-maternal interface, leading to miscarriage in a certain 
subgroup of patients with so far unexplained recurrent miscarriages. 
Antibody deposition is present in the placenta under physiological 
conditions but because the placenta is strongly protected from 
spontaneous complement activation by regulatory mechanism 
such as Decay Accelerating Factor (daf), Membrane Cofactor 
Protein (mcp) and cd59, this usually does not lead to extensive 
tissue damage.14-16 Therefore, excessive complement deposition 
as we observed in certain women with recurrent miscarriage can 
be interpreted as a sign of local dysregulation of the placental 
complement system. In other words, there must be either ‘excessive 
complement activation’, or ‘inadequate complement regulation’. 
Too much complement activation may be caused by excessive 
antibody deposition.6;17 Antiphospholipid antibodies are likely 
candidates, as they are associated with placental complement acti-
vation and impaired pregnancy outcome.6 However, all women in  
our recurrent miscarriage population were tested for anticardiolipin 
IgG, IgM and lupus anticoagulant and were excluded from the study 
if any of these antibodies were positive.12 Allo-antibodies could  
also be involved. Recently, Nielsen et al described that anti-hla 
antibodies are related to a reduced live birth rate in women with 
recurrent miscarriage.18 Interestingly, we found anti-hla class i  
and ii antibodies in serum samples of women with unexplained 
recurrent miscarriage, and demonstrated their potential trace at  
the fetal-maternal interface via c4d deposition. These antibodies  
are most likely directed against inherited paternal antigens expres- 
sed on trophoblast cells. Up to 30% of women have circulating anti-
hla antibodies during pregnancy, which usually do not predispose 
to higher risk of adverse pregnancy outcome, miscarriage or pre-
eclampsia.19;20 However, from transplantation settings we know 
that only some allo-antibodies cause rejection, depending on their 
antigenicity, their ability to activate complement and their avidity 
for the antigenic target. Furthermore, presence and detection of 
anti-hla antibodies could also be a marker for a broader antibody 
response. This was shown previously in hla identical family 
transplantations, where the presence of anti-hla antibodies  
was a risk factor for worse outcome, although clearly anti-hla anti- 
bodies themselves could not have caused any harm.21 The specific 
allo-antibodies involved in recurrent miscarriage should be subject 
for further studies. 
Apart from excessive activation, inadequate complement regu-
lation at the fetal-maternal interface may also play a role. It was 
recently shown in a group of women with sle and antiphospholipid 
syndrome, that up to 19% of patients who develop severe preeclampsia 
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have genetic mutations in genes encoding for complement regula- 
tory proteins that are necessary to prevent damage of host tissue 
due to uncontrolled activation of complement.22 These mutations 
were first described in populations with atypical Hemolytic Uremic 
Syndrome (ahus) where they lead to widespread microthrombotic 
injury. In the study by Salmon et al, patients with these mutations 
developed severe forms of preeclampsia, intrauterine growth restric-
tion and even third trimester intrauterine fetal death. They did not 
have signs of microthrombotic injuries in organs other than the 
placenta and did not present as hus cases. It is possible that genetic 
defects in complement regulation may cause recurrent miscarriages. 
The excessive deposition in placental tissue of some of our patients is 
in line with this concept.
At present there is no evidence based treatment for women 
with unexplained recurrent miscarriage. None of the published 
randomized controlled trials investigating the effect of lmwh and 
aspirin in this population could detect a beneficial effect of these 
interventions on live birth rate.12;23;24 In our population a substantial 
proportion of women was using lmwh, aspirin, or a combination of 
both at time of miscarriage. In our study, we could not find a relation 
between use of anticoagulation and presence of c4d, or presence of 
anti-hla antibodies (data not shown). Clearly the current group is 
too small to draw definite conclusions.
Recurrent miscarriage, as is demonstrated by this study, is not a 
condition with a single cause. Progress in understanding the many 
different mechanisms that may lead to recurrent miscarriage is 
urgently needed. This is not a condition with a single cause, and the 
trials described above illustrate that searching for a single treatment 
for all patients is likely futile. Unraveling possible pathofysiological 
mechanisms for recurrent miscarriage in order to define patient 
tailored treatment strategies is essential. Our findings possibly 
identify a subgroup of patients in which complement activation plays 
an important role. This is especially interesting in the light of animal 
studies by Girardi et al, showing that heparin is beneficial in patients 
with antiphospholipid antibodies because it inhibits complement 
activation, and not because of its effects on the coagulation cascade.25 
Patients with recurrent miscarriage and evidence for excessive 
complement activation at the fetal-maternal interface could be the 
’positive responders’ to treatment with heparin or lmwh. Whether 
a positive c4d stain in placental tissue of a patient with multiple 
miscarriages may guide treatment is an interesting subject for 
further investigations.
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Mean maternal age in years (sd) 33,5 (5,4) 31,9 (6,7) 28,6 (7,7)
Mean gravidity (sd) 4,2 (2,1) 2,1 (1,0) na
Mean parity (sd) 0,8 (0,8) 1 (1,1) na
Previous miscarriage or fetal loss (%) 100 0 na
Gestational age at miscarriage or  
abortion (wks) (sd in wks)
10,7 (3,8) 10,5 (2,0) 9,149 (3,1)
> 4 miscarriages n(%) 26 (68) 0 na
Heparin therapy during pregnancy n(%) 15 (40) 0 na
Aspirin during pregnancy n(%) 10 (27) 0 na
Aspirin and heparin during pregnancy n(%) 6 (16) 0 na
na = No information available 
 
table 2 recurrent miscarriage and c4d staining 
 







Recurrent miscarriage n(%) 16 (42,1) 12 (31,6) 10 (26,3) 38
Spontaneous miscarriage n(%) 7 (31,8) 12 (54,6) 3 (13,6) 22
Abortion on request n(%) 45 (67,2) 15 (22,4) 7 (10,4) 67
P < 0,004 (Chi squared linear by linear analysis) 
table 3 c4d and anti-hla antibodies in 28 patients with  
 unexplained recurrent miscarriage
 negative 
anti-hla  
class i or ii
positive 
anti-hla  
class i or ii
No or focal c4d deposition 13 2
Diffuse c4d deposition 4 9
17 11
P = 0,004
fig 1 examples of immunohistochemical staining   
 patterns of placental c4d
a. Diffuse c4d staining on trophoblast tissue derived from miscarriage material. c4d 
stains red and is positive at the fetal-maternal interface. Every fetal villus is fully covered 
with c4d deposits. No staining is visible within fetal villi, suggesting a maternal origin 
of complement activation.  
b. Focal c4d staining. Between 10% and 50% of fetal villi show signs of c4d deposition. 
Some parts of the trophoblast layer stain positive, but other parts remain negative.  




154 clinical significance of c4d in sle and antiphospholipid syndrome 155 vii • c4d as a footprint of maternal anti-fetal immunity in recurrent miscarriage
references
1 Branch DW, Gibson M, Silver RM. Clinical 
practice. Recurrent miscarriage. N Engl J Med 
2010; 363(18):1740-1747.
2 Sullivan AE, Silver RM, LaCoursiere DY, Por-
ter TF, Branch DW. Recurrent fetal aneuploidy 
and recurrent miscarriage. Obstet Gynecol 2004; 
104(4):784-788.
3 Collins AB, Schneeberger EE, Pascual MA, 
Saidman SL, Williams WW, Tolkoff-Rubin N et 
al. Complement activation in acute humoral 
renal allograft rejection: diagnostic significance 
of c4d deposits in peritubular capillaries. J Am 
Soc Nephrol 1999; 10(10):2208-2214.
4 Colvin RB. Dimensions of antibody-mediat-
ed rejection. Am J Transplant 2010; 10(7):1509-1510.
5 Sis B, Mengel M, Haas M, Colvin RB, Hal-
loran PF, Racusen LC et al. Banff ‘09 meeting 
report: antibody mediated graft deterioration 
and implementation of Banff working groups. 
Am J Transplant 2010; 10(3):464-471.
6 Cohen D, Buurma A, Goemaere NN, Girardi 
G, le CS, Scherjon S et al. Classical complement 
activation as a footprint for murine and human 
antiphospholipid antibody-induced fetal loss. J 
Pathol 2011.
7 Salmon JE, Girardi G, Holers VM. Comple-
ment activation as a mediator of antiphos-
pholipid antibody induced pregnancy loss 
and thrombosis. Ann Rheum Dis 2002; 61 Suppl 
2:ii46-ii50.
8 Pierangeli SS, Vega-Ostertag M, Liu X, 
Girardi G. Complement activation: a novel 
pathogenic mechanism in the antiphospholipid 
syndrome. Ann N Y Acad Sci 2005; 1051:413-420.
9 Girardi G, Salmon JB. The role of comple-
ment in pregnancy and fetal loss. Autoimmunity 
2003; 36(1):19-26.
10 Cohen D, Berger SP, Steup-Beekman GM, 
Bloemenkamp KW, Bajema IM. Diagnosis and 
management of the antiphospholipid syndrome. 
BMJ 2010; 340:c2541.
11 Lee J, Romero R, Xu Y, Kim JS, Topping V, 
Yoo W et al. A signature of maternal anti-fetal 
rejection in spontaneous preterm birth: chronic 
chorioamnionitis, anti-human leukocyte 
antigen antibodies, and c4d. ploS One 2011; 
6(2):e16806.
12 Visser J, Ulander VM, Helmerhorst FM, 
Lampinen K, Morin-Papunen L, Bloemenkamp 
KW et al. Thromboprophylaxis for recurrent 
miscarriage in women with or without throm-
bophilia. HAbeNOX: a randomised multicentre 
trial. Thromb Haemost 2011; 105(2):295-301.
13 Guleria I, Sayegh MH. Maternal acceptance 
of the fetus: true human tolerance. J Immunol 
2007; 178(6):3345-3351.
14 Grennan DM, McCormick JN, Wojtacha D, 
Carty M, Behan W. Immunological studies of the 
placenta in systemic lupus erythematosus. Ann 
Rheum Dis 1978; 37(2):129-134.
15 Johnson PM, Natvig JB, Ystehede UA, Faulk 
WP. Immunological studies of human placentae: 
the distribution and character of immunoglob-
ulins in chorionic villi. Clin Exp Immunol 1977; 
30(1):145-153.
16 Bulla R, Bossi F, Agostinis C, Radillo O, Co-
lombo F, De SF et al. Complement production by 
trophoblast cells at the feto-maternal interface. J 
Reprod Immunol 2009; 82(2):119-125.
17 Shamonki JM, Salmon JE, Hyjek E, Baergen 
RN. Excessive complement activation is as-
sociated with placental injury in patients with 
antiphospholipid antibodies. Am J Obstet Gynecol 
2007; 196(2):167-5.
18 Nielsen HS, Witvliet MD, Steffensen R, 
Haasnoot GW, Goulmy E, Christiansen OB et 
al. The presence of hla-antibodies in recurrent 
miscarriage patients is associated with a reduced 
chance of a live birth. J Reprod Immunol 2010; 87(1-
2):67-73.
19 Harris RE, Lordon RE. The association of 
maternal lymphocytotoxic antibodies with 
obstetric complications. Obstet Gynecol 1976; 
48(3):302-304.
20 Balasch J, Ercilla G, Vanrell JA, Vives J, 
Gonzalez-Merlo J. Effects of hla antibodies on 
pregnancy. Obstet Gynecol 1981; 57(4):444-446.
21 Opelz G. Non-hla transplantation im-
munity revealed by lymphocytotoxic antibodies. 
Lancet 2005; 365(9470):1570-1576.
22 Salmon JE, Heuser C, Triebwasser M, 
Liszewski MK, Kavanagh D, Roumenina L et al. 
Mutations in complement regulatory proteins 
predispose to preeclampsia: a genetic analy-
sis of the promisse cohort. ploS Med 2011; 
8(3):e1001013.
23 Clark P, Walker ID, Langhorne P, Crichton 
L, Thomson A, Greaves M et al. SPIN (Scottish 
Pregnancy Intervention) study: a multicenter, 
randomized controlled trial of low-molecular-
weight heparin and low-dose aspirin in 
women with recurrent miscarriage. Blood 2010; 
115(21):4162-4167.
24 Kaandorp SP, Goddijn M, van der Post JA, 
Hutten BA, Verhoeve HR, Hamulyak K et al. 
Aspirin plus heparin or aspirin alone in women 
with recurrent miscarriage. N Engl J Med 2010; 
362(17):1586-1596.
25 Girardi G, Redecha P, Salmon JE. Heparin 
prevents antiphospholipid antibody-induced 
fetal loss by inhibiting complement activation. 
Nat Med 2004; 10(11):1222-1226.
                            general
          
      part one
c4d and thrombotic
                part two
c4d and adverse  





            appendices
159 viii • general discussion
The introduction of c4d in daily clinical practice in the late nineties 
aroused an ever increasing interest in the role of antibody mediated 
mechanisms in allograft rejection. As a marker of classical comple-
ment activation, c4d made it possible to visualize the direct link 
between anti-donor antibodies and tissue injury at sites of antibody 
binding in a graft. In this thesis c4d has been studied outside the 
field of solid organ transplantation. The most important findings 
described in the different chapters can be summarized as follows:  
(1) c4d deposition is associated with microthrombotic injury in 
kidneys and brains of patients with sle. (2) Placental c4d is associ-
ated with adverse pregnancy outcome in sle and antiphospholipid 
syndrome such as miscarriage, severe preeclampsia, hellp syndrome 
and intrauterine fetal death. (3) In recurrent miscarriage of unknown 
etiology c4d may be helpful to unravel a possible subgroup of pa-
tients in which complement activation and antibody mediated fetal 
rejection plays a pathophysiological role. 
In conclusion, the studies in this thesis have contributed to the 
fact that c4d is now increasingly being recognized as a potential 
biomarker in several fields where antibodies can cause tissue dam-
age, such as systemic autoimmune diseases and pregnancy. c4d holds 
promise to detect patients at risk for the consequences of antibody-
mediated disease. Moreover, the emergence of new therapeutics that 
block complement activation makes c4d a marker that can poten-
tially identify patients who may possibly benefit from these drugs. 
This final chapter provides an overview of the past, present, and 
future perspectives of c4d as a biomarker, focusing on its role in 
solid organ transplantation and discussing its possible new roles in 
autoimmunity and pregnancy. For this purpose, a group of experts 
were interviewed about the role of c4d within their fields of expertise 
and challenged to think about the following issues:
* Will we still be using c4d in 10 years time, and if not, what 
alternatives would you suggest?
* What would you like to investigate if you would receive funding  
to be spent on research in the field of c4d? 
* What is your take home message for readers and listeners? 
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Pros and Cons for C4d as a biomarker 
 
in auto- and alloimmunity
danielle cohen / robert b. colvin / mohamed daha
cinthia beskow dr achenberg / mark ha as / volker nickeleit / jane e. salmon
banu sis / ming-hui zhao / jan a. bruijn / ingeborg m. bajema
adapted from: pros and cons for c4d as a biomarker. kidney international, 2012
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* The interviews form the backbone of this chapter, together with 
a review of the recent literature on c4d. We would like to motivate 
readers to listen to the audio-files that can be found online, which 
include highlights, quotes and authors’ comments on both the state 
of the art and controversies in the field of c4d. A summary of this 
chapters most important points is given in box 1.
Biology of C4d
 
the human complement system The complement system  
is an ancient component of the innate immune system. Complement 
activation is a non-specific, potent force. Once activated, it makes 
no distinction between self and non-self. Therefore its activation is 
as tightly controlled as its natural regulation.1 The three pathways 
by which the complement system can become activated, namely the 
classical, lectin and alternative pathway, converge at the level of c3 
and proceed into the formation of the membrane attack complex 
(mac) on complement activating surfaces, causing direct tissue 
injury by perforation of the cell membrane. Additionally, potent 
anaphylatoxins c3a and c5a are being formed in the process, which 
elicit the recruitment of other inflammatory cells to the site of 
activation. (figure 1a)
the classical pathway and generation of c4d The 
classical pathway of complement is initiated via binding of its 
recognition molecule c1q to immune complex deposits, antibody-
antigen binding or charged molecules. When c1q becomes activated, 
it subsequently activates its natural substrate c4. c4d is a split 
product of c4 activation, without a biological function.2;3 Although 
c4d is mainly interpreted as a trace of classical pathway activation, 
it must be kept in mind that c4 can also be generated via the lectin 
pathway. mbl or Ficolins binding to carbohydrate ligands on the 
surface of a wide variety of pathogens results in activation of the 
lectin pathway and cleavage of c4.4;5 Consequently, c4d may be 
generated without prior antibody binding. (Figure 1a) 
– box 1 –
summary and take home points
c4d as a footprint of antibody-mediated cell 
injury It is interesting that c4d is a biomarker even though  
it is an inactive split product of the complement cascade. c4d  
has been called ‘a footprint’ of antibody-mediated tissue injury.  
This nickname is based on the unusual phenomenon that c4b, the 
larger molecule that c4d is derived from, has an internal thio-ester 
in the molecule, giving it the ability to form a covalent bond with 
any free hydrogen group on target cells. When c4d is cleaved from 
c4b, the covalent bond between c4d and the tissue remains intact. 
Covalently bound c4d has a much longer half-life, and therefore 
remains at the site of complement activation whereas antibodies  
bind to tissue by hydrostatic, van der Waals type of interactions.  
The ‘footprint-effect’ of the internal thio-ester of c4d (figure 1b) 
becomes strikingly apparent when the blood stream can clear all 
soluble/weakly bound molecules quickly, as happens with anti- 
bodies at endothelial surfaces. Covalently bound c4d will not be 
affected, because it is anchored tightly to the tissue and therefore 
serves as a footprint of antibody mediated tissue injury. 
C4d is a widely used marker for antibody 
mediated rejection in kidney, heart, pan-
creas and possibly lung allografts. 
In abo incompatible grafts, c4d is not a 
useful test, and may even indicate graft-
accomodation.
In pregnancy, c4d at the fetal-maternal 
interface indicates antibody mediated 
rejection of ‘the fetal allograft’, as was dem-
onstrated in antiphospholipid antibody-
induced fetal loss. 
C4d shows that the complement system is 
involved: If complement targeted therapies 
will be part of our future treatment options, 
a marker like c4d will be needed to identify 
patients susceptible for those kind of (ex-
pensive) treatments.
Alternatives for c4d are emerging (genom-
ics, molecular diagnostics and endothelial 
transcripts) and if proven useful, effort will 
be made to transform these techniques or 
their progeny to practical tests.
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– box 2 –
state of the art: banff guidelines for the diagnosis of amr
The discovery of C4d as a clinical marker for amr
From hyper-acute rejection episodes it was known that donor spe- 
cific antibodies (dsa), either anti-hla or anti-abo, had the capacity 
to destroy a graft.6-8 However, although there was speculation 
about a role for allo-antibodies in other forms of rejection apart 
from the hyperacute form, it was unclear what fraction of acute 
rejection episodes had a humoral component and how to recognize 
that an amr was present. The publications of Helmut Feucht and 
colleagues in the early nineties marked a turning point in the history 
of solid organ transplantation.9;10 Feucht showed that patients with 
suspected antibody-mediated injury in the renal graft had a linear 
c4d staining pattern in peritubular capillaries and that the presence 
of c4d was associated with impaired graft function. Remarkably, 
these initial publications received relatively little attention in the 
transplant community.9;11;12 At the turn of the century the group  
of Collins et al tested for presence of c4d along with other markers of 
endothelial activation or injury in renal transplant biopsies suspected 
of amr. c4d was found in each of 10 renal biopsies of patients with 
circulating dsa and morphologic signs suspicious of amr, and in 
none of 14 controls with acute cellular rejection without detectable 
dsa.13 This work embodied the connection of dots between c4d, 
the presence of dsa and a selection of histomorphologic features of 
amr, which after 4 decades of an intensive search for a marker was 
nothing short of revolutionary. A few years later the correlation with 
graft survival that Feucht et al had already reported on in 1993, was 
confirmed by other groups.2;14 This led to general acceptance of the 
usefulness of c4d in the identification of acute amr. In 2003 ‘c4d’  
was incorporated in the Banff classification.15 (box 2)
C4d in current clinical practice
For the kidney a consensus was reached that a diagnosis of amr 
requires the simultaneous presence of de novo dsa, distinguishable 
histopathological findings and deposition of c4d in peritubular 
capillaries (figure 2 and figure 3a). Most centers involved in the 
management of transplant-recipients have incorporated routine 
c4d staining in diagnostic pathology evaluation of all renal allograft 
biopsies.15 A solid base for regular c4d staining of biopsied allograft 
tissue is now established for heart transplantation and pancreas 
transplantation.16-18;18 For other transplanted organs such as the 
lung, the usage of c4d staining is still controversial.19;20 In liver 
and short bowel transplantation c4d seems to have no additional 
diagnostic value.21 
In box 3, guidelines are given on how to interpret various  
test outcomes of c4d staining and dsa test results that clinicians  
who work with c4d commonly encounter in daily clinical practice.  
Finally, box 4 elaborates on current treatment options for amr.22-25
The diagnosis of amr in renal allografts 
is currently based on criteria established 
during the Banff conference on Allograft 
Pathology in 2007 which include the three 
following cardinal features:
• Morphologic evidence of acute or chronic    
  tissue injury
• Immunopathologic staining for c4d 
  in peritubular capillaries
• Presence of circulating antibodies to 
  donor hla or other antigens expressed 
  on donor endothelial cells
• It is recommended that every renal, 
  cardiac and pancreas allograft biopsy 
  should be stained for c4d
C4d staining is considered positive only 
when depositions are found in the following 
anatomical locations:
• Kidney: Peritubular capillaries (figure 3a)
• Pancreas: Interacinar capillaries (figure 3b)
• Heart: Endomyocardial capillaries 
C4d is scored semiquantitatively in four 
categories:
• No c4d staining (0% of (peritubular) 
  capillaries)
• Minimal c4d staining (0-10% of 
  (peritubular) capillaries),
• Focal c4d staining (10-50% of (peritubular) 
  capillaries)
• Diffuse c4d staining (>50% of (peritubular) 
  capillaries)
Immunofluorescence is a more sensitive 
method to detect c4d than immunohisto-
chemistry, by approximately one grade of 
the scoring system. Although a diffuse c4d 
staining is defined as positive, the definition 
and clinical significance of  ‘minimal’ and 
‘focal’ c4d staining remain debated issues. 
Most experts consider a focal staining pat-
tern as a red flag, especially when detected 
on paraffin-embedded tissue or in the pres-
ence of dsa and/or suspicious histopatho-
logical features.
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– box 3 –
issues for clinicians working with c4d in daily practice
Debated issues 1: c4d in chronic rejection episodes
Soon after the introduction of c4d in daily clinical practice, the phe-
nomenon of a diffuse c4d staining pattern was frequently observed 
years after transplantation and was associated with chronic changes 
in the graft.26;27 This was in contrast with the idea that antibodies
– box 4 –
therapy-options for amr 
 
were only involved in hyper-acute and acute rejection episodes.  
The presence of c4d in late and chronic rejection episodes prompted 
clinicians and researchers to the hypothesis that an antibody com-
ponent was present in forms of chronic rejection. 
The concrete arguments that underline the role of antibodies in 
chronic rejection are as follows: Firstly, in experimental models of 
non-human primates with transplanted kidneys (with no immuno-
suppressive drugs) progression to chronic graft injury and loss consis-
tently goes through four stages: alloantibody production, deposition 
of c4d in peritubular capillaries and sometimes glome ruli, chronic 
histopathologic changes and finally, graft loss. 28
Secondly, several large (prospective) studies showed that presence 
of circulating anti-hla antibodies are associated with late graft 
failure.29-31 Thirdly, histologic changes associated with late graft 
loss, such as glomerular double contours, peritubular capillary 
basement membrane multilayering, interstitial fibrosis and fibrous 
intimal thickening in arteries, are found in close association with 
Focal staining
In paraffin-embedded tissue combined with 
a positive test for dsa and histopathological 
features: Most laboratories consider this as 
‘positive for amr’. It is advised to treat the 
patient. In frozen tissue combined with a 
positive test for dsa and histopathological 
features: This is sometimes called a ‘prob-
able amr’. Most experts would consider 
treatment, however, prospective studies 
should investigate this group further.
C4D positivity without detectable  
DSA
Possible explanations:
Allo-antibodies are present, but they are not 
detected by standard anti-hla assays (for 
example anti-endothelial antibodies). 
Allo-antibodies are absorbed by the graft, 
as is sometimes shown by reappearance 
of allo-antibodies in the blood after graft 
nephrectomy. 
Allo-antibodies are not present and c4d 
deposition is caused by something else than 
dsa (For instance autoimmune disease 
i.e. lupus nephritis or any form of lectin 
pathway activation)
How to proceed?
In case of diffuse c4d staining in peritu- 
bular capillaries and histological evidence 
for amr: Most experts would advise to treat 
the patient for amr.
In case of focal c4d staining and histological 
evidence for amr : Check for other possible 
underlying diseases. If no other cause can be 
found: Treat the patient for amr.
In case of focal or diffuse c4d staining and 
absence of histologic changes te decision as 
to wether to treat for amr is more uncer-
tain. Treating or close follow-up are bothe 
suitable options. 
C4D positivity in grafts without 
histological abnormalities 
In abo incompatible grafts: In case of no 
histopathology and no graft dysfunction: 
It is suggested to interpret this as ‘graft 
accomodation’. No treatment is necessary, 
but close follow-up is strongly advised, as it 
is unknown what happens with these grafts 
during long term follow-up. 
In positive cross-matched patients (presen-
sitized patient) this should not be seen as 
graft-accomodation and is a rare and more 
worrying situation than the above: In case of 
normal histology and no graft dysfunction: 
Interpret as probable amr and consider 
treating the patient. Prospective studies on 
the long term follow-up of this group of 
patients are awaited. 
Although much progress has been made 
in understanding the etiology of amr and 
diagnosing the condition, it remains to be 
elucidated what treatment option is most 
beneficial. amr is relatively unresponsive 
to therapies targeting t-lymphocytes used 
in acute cellular rejection such as steroids, 
cyclosporine, tacrolimus and sirolimus. 
This issue has not been addressed in a 
randomized controlled fashion so far. 
Therapeutic strategies reported in the 
literature in case-reports, case-series and 
cohort studies are the following:23 
The suppression of the t-cell dependent 
antibody response (steroids, cyclosporine, 
tacrolimus, sirolimus). The removal of 
donor reactive antibody (plasmapheresis)
The blockade of the residual alloantibody 
(IvIg) . The depletion of naive and memory 
b-cells (Rituximab). Inactivation of plasma 
cells (Bortezomib)24;25;26. The blockade of 
complement component c5 by monoclonal 
antibodies (Eculizumab) 
There is large variability between transplant 
centers around the world in their specific 
therapeutic approach but generally a 
combination of IvIg, plasmapheresis 
and recently, Rituximab is used. Trials 
(especially randomized controlled trials) 
investigating the effects of targeted 
complement blockade are awaited. 
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c4d deposition in peritubular capillaries and presence of anti-hla 
antibodies: In about 30-40% of biopsies with late graft dysfunction, 
c4d can be detected in peritubular capillaries. 26;31-35.
Based on current understanding, criteria were proposed to 
diagnose chronic amr in 2007. To establish this diagnosis, three 
elements should be present:
* Histologic evidence of chronic injury
* Immunopathologic evidence of antibody mediated graft injury 
(c4d deposition)
* Evidence of antibodies reactive against the donor
However, there are several controversies surrounding chronic amr. 
Most importantly there is no clear cut definition of what is meant 
by ‘chronic’. For some it simply means burned-out scar formation. 
Others use the word in a broader sense, thinking that there are 
chronic changes with some kind of activity so that chronicity still  
has an ongoing active component (and thus, a potential for 
treatment). Here the advantage of c4d is that it indicates recent 
(weeks) activity of an active immunological process.
It is unknown why donor-specific antibodies cause acute rejection 
in one patient and chronic rejection in another, or even both sequen-
tially in the same patient. Factors such as antibody-titer, antibody-
avidity, and the extent of resistance (or accommodation) of the graft 
endothelium to complement activation could be responsible for this 
phenomenon. More research in this field is certainly needed, as the 
lack of insight into the natural history of chronic amr now entails 
that the optimal therapy for chronic amr remains undetermined.
Debated issues 2: C4d negative amr
Antibodies mainly damage a graft by targeting the endothelium 
of the graft’s microcirculation. This concept is the basis for the 
molecular studies performed by Sis et al since 2007. These studies 
have elegantly uncovered a possible new form of amr, namely, c4d 
negative amr (which has been described in a chronic, but not in 
acute settings). This important finding is currently the most serious 
challenge for the concept of c4d as a biomarker, as the first studies 
using endothelial transcripts combined with dsa show excellent 
sensitivities for amr (although less specificity than c4d), for chronic 
amr.36 As a marker of antibody interaction with the tissue, it is not 
inconceivable that this or a simpler derivative method will partly or 
fully replace c4d in future. In 2007 a retrospective study of biopsies 
from 1320 transplanted patients showed that more than 40% of cases 
with transplant glomerulopathy –a histological lesion considered 
relatively characteristic for chronic amr- were c4d negative despite 
the fact that anti-hla antibodies were detected in 73% of patients.32 
This work was followed by studies looking at mRNA levels of genes 
involved in endothelial activation and injury. Interestingly, biopsies 
with high expression of these endothelial transcripts in combination 
with circulating dsa, showed concurrent histopathological lesions of 
amr (such as capillaritis, glomerulitis, transplant glomerulopathy, 
and fibrosis/atrophy) and had poor outcomes.36;37 Many of these 
active amr cases would have been missed otherwise: Only 40% of 
kidneys with high endothelial gene expression and histopathologic 
signs of chronic amr were c4d positive.38 
So far, two groups have confirmed the concept of c4d negative 
amr. In sensitized recipients Loupy et al showed that c4d or capil-
laritis in 3 month protocol biopsies were risk factors for later trans-
plant glomerulopathy, and capillaritis was predictive even in the 
absence of c4d.38;39 The other evidence came from Haas and Mirocha, 
who investigated patients with donor specific antibodies who had a 
biopsy during the first 3 months after transplantation. Patients with 
a c4d negative biopsy who were not treated for amr had a higher rate 
of progression to transplant glomerulopathy than those who were 
treated for amr post-biopsy.40
Because of these complexities a working group was established at 
the 2011 Banff Conference to refine criteria for diagnosis of chronic 
amr in the kidney, and to investigate whether c4d negative amr 
should be incorporated in the Banff classification. 
If there is indeed a c4d negative form of amr, it must be based on 
a pathophysiological mechanism which is complement independent. 
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There are two types of experimental studies that recently provided 
some insight into this mechanism: Reed et al have set up an in vitro 
model of cultured endothelial cells, to which allo-antibodies can be 
added. The authors were able to show that allo-antibodies themselves 
can alter the state of the endothelium in the absence of complement  
or other inflammatory cells. In response to allo-antibodies, endothelial 
cells started expressing proinflammatory molecules, increased growth 
factor and adhesion molecules like e-selectin, P-selectin, icam-1, 
vcam-1, cx3cL1.41 Subsequently, it was demonstrated that adding  
nk cells or macrophages together with antibodies to cultured endo-
thelial cells could damage the endothelial cells even more severely, 
through Fc receptor interactions.42;43 Apparently, antibodies can in-
duce injury through interaction with leukocytes like nk cells, without 
complement as a mediator. In vivo, this has been recently confirmed 
in mouse heart allografts (Hirohashi et al. A novel pathway of chronic 
allograft rejection mediated by nk cells and alloantibody [Abstract] 
Am.J.Transplant 2011) and within glomerular and peritubular capillar-
ies in human biopsies showing amr.44 New diagnostic and therapeutic 
approaches are warranted to approach these cases in future. 
Debated issues 3: C4d positivity as a sign of graft 
accommodation
Despite the experience that preformed antibodies against hla- 
or blood group antigens due to pregnancy, blood transfusion or 
prior transplants are a major cause of hyperacute rejection of renal 
allografts, the ever expanding deceased-donor waiting list led to 
the development of protocols enabling transplantation across these 
immunologic barriers. Japan and North America were the first to 
successfully transplant abo-incompatible grafts in patients who  
had been pretreated with improved immunosuppressive regimens 
and plasmapheresis to remove preexisting antibodies.45;46 The follow-
up of these cases revealed some unexpected phenomena, which served 
as the basis of a new and exiting concept: Stable graft accommodation. 
As it soon became apparent that recurrence of low levels of anti- 
blood group antibodies occurred frequently in patients transplan- 
ted with an abo-incompatible graft, there was concern about  
the development of amr in these grafts. Not quite unexpectedly,  
diffuse c4d staining of peritubular capillaries in these biopsies  
was commonly found, even in protocol biopsies. However, the  
fact that more than 70-80% of abo-incompatible grafts showed 
diffuse c4d positivity was a surprising finding, especially when 
compared to the marginal 30-40% diffuse positives observed in 
the group of patients with a positive cross match for anti-hla 
antibodies.47-49 
Strikingly, in contrast to conventional transplants where a diffuse 
c4d stain is strongly associated with histological abnormalities 
such as capillaritis and transplant glomerulopathy, the abo-
incompatible kidneys as a rule show diffuse c4d positivity without 
histological tissue injury.50;51 A recent retrospective case-control 
study by Haas et al indicated that persistent c4d positive abo-
incompatible grafts without histological abnormalities are not 
subject to increased graft scarring, transplant glomerulopathy or 
reduced renal function within the first year after transplantation.52 
Moreover, abo-incompatible grafts with persistent diffuse c4d 
positivity had significantly less chronic damage after one year. 
These puzzling observations can possibly be understood in the 
light of accommodation, in which a graft acquires resistance to 
humoral injury and continues to function well despite the constant 
presence of low levels of antibodies against the abo- antigens on the 
endothelium. 
An underlying mechanism that might explain in part the develop- 
ment of graft accommodation as suggested by Park et al 53, could be 
the upregulation of complement regulatory proteins in endothelial 
cells, by which the initial activation of complement due to antibody 
binding is blocked at a point later in the cascade. This could explain 
the persistent presence of c4d without signs of microvascular 
injury54, although why this happens frequently in the setting of 
abo incompatibility but at most rarely in the setting of hla-mis-
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matched patients is poorly understood at the moment.  Still, just 
as antibody-mediated graft injury cannot be completely accounted 
for by complement activation37, complement inhibition alone does 
not appear to prevent chronic antibody-mediated graft injury. 
(Cornell LD et al. Chronic humoral rejection despite c5 inhibition 
after positive-crossmatch kidney transplantation [Abstract]. Am J 
Transplant 2010)
In conclusion, the common finding of c4d positivity in abo 
incompatible grafts without histologic abnormalities currently  
forces pathologists to look more closely into the histology when 
trying to diagnose amr in an abo-incompatible graft, as a c4d  
stain in this group appears to signify something different than 
‘rejection’ and cannot be reliably used as a diagnostic tool. 
New fields 1 – C4d and amr in other transplanted  
solid organs
After the recognition of c4d as a tool to detect amr in the trans- 
planted kidney, this concept was soon translated to virtually all  
other transplanted solid organs. The transplanted organs in which 
the significance of c4d deposition has been most studied are the 
heart, lung, liver, and pancreas. 
c4d in cardiac transplantation Many groups have 
shown that linear c4d deposition along myocardial capillaries is 
a reliable specific marker for antibody-mediated cardiac allograft 
rejection.16;55;56 Moreover, in line with earlier studies in the kidney 
it was also shown that c4d positivity in the heart is an independent 
predictor of cardiac dysfunction and of cardiac mortality.18;57 The 
International Society for Heart and Lung Transplantation (ishlt) 
recommends that a diagnosis of amr in a cardiac allograft can be  
justified when there is clinical evidence of graft dysfunction, histo-
logical evidence of acute capillary injury and immunopathologic 
evidence for c4d capillary positivity on endomyocardial biopsies. 
According to the ishlt, positive histologic features indicative of 
amr are necessary to warrant c4d staining.58 However, a recent 
publication by Fedrigo et al casted doubt upon this approach, 
and suggested that c4d should instead be performed routinely 
on endomyocardial graft biopsies: The authors investigated 985 
endomyocardial biopsies from 107 heart transplant recipients by 
staining them immunohistochemically for c4d. Intragraft c4d 
capillary deposition was present in 34%, but only 7% had amr based 
on the ishlt criteria. Interestingly, c4d positivity, even without  
the presence of dsa, impaired graft function, or histological features 
of amr, was independently associated to a higher mortality risk 
(unadjusted hazard ratio in patients with positive c4d staining, 
without dsa or loss of graft function).18 This study supports the 
concept of routine c4d staining, as no correlation between histology 
alone and clinical status could be elicited. In response to the emerging 
data, the Banff group reached consensus recommending specific 
time points to monitor dsa as well as c4d staining on every cardiac 
allograft biopsy, interpreting c4d staining only in myocardial 
capillaries and scoring as diffuse (>50% of capillaries), focal(<50%)  
or negative, but accepting only diffuse staining as positive.59 
c4d in lung transplantation Hyperacute and acute  
amr episodes are well documented in lung transplantation: In 
such cases, diffuse alveolar damage, neutrophilic infiltrates and 
post-transplant pulmonary capillary injury are typical histological 
findings that are distinct from cellular rejection and less responsive 
to corticosteroid treatment. c4d deposition in such cases was detected 
in several studies, mainly in septal capillaries, and was associated to 
parenchymal injury, clinical status and the presence of dsa or anti-
endothelial antibodies.20;60;61
However, a consistent anatomical deposition pattern of c4d 
in the lung was more problematic to identify than in the kidney 
(peritubular capillaries), the heart (endomyocardial capillaries) or 
even the pancreas (interacinar capillaries). A study by Wallace et al 
could not describe any specific staining pattern in 68 lung allograft 
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biopsy specimens using currently available techniques. Focal non-
specific staining occurred just as often in cases with suspected  
amr compared to more chronic forms of rejection.62 Probably,  
the anatomy of the lung complicates pattern recognition, since the 
frequent occurrence of alveolar hemorrhage and septal damage give 
rise to non-specific staining patterns, which makes it hard to score 
pulmonary allograft biopsies.
Compared to kidney transplants, the role of amr and c4d in 
chronic pulmonary allograft rejection (bronchiolitis obliterans 
syndrome, bos) is heavily debated. Magro et al reported on evident 
c4d deposition in a series of 13 single-lung transplant patients with 
bos, who had circulating anti-endothelial antibodies.63 Westall 
et al investigated septal capillary c4d staining early after lung 
transplantation. Complement staining was not associated with 
acute cellular or chronic rejection, or with morphologic features 
of amr, but in a sub-group analysis the authors identified 9 cases 
who developed early bronchiolitis obliterans syndrome (bos). 
Interestingly, these cases showed significant lung allograft c3d/
c4d deposition along with light-microscopic features suggestive of 
amr, suggesting that c4d staining could potentially play a role in 
the identification of patients at risk of developing a chronic humoral 
form of pulmonary allograft rejection.64 Although these results 
point into the direction of antibody-mediated processes in chronic 
pulmonary graft rejection, these results should be replicated in larger 
cohorts to make any definitive statement.
In conclusion, the presence in one patient of both anti-hla 
antibodies or anti-endothelial antibodies and pathologic findings 
suspicious for amr (including c4d staining) should be seen as strong 
evidence for amr of the pulmonary allograft, but there is not enough 
evidence for c4d as a marker for amr in the lung graft to perform 
routine c4d staining on all pulmonary allograft biopsies.
c4d in pancreas transplantation Few studies are 
available describing the histological and immunohistochemical 
features of rejection episodes of the pancreas, compared to other 
transplanted solid organs. The first large cohort appeared in 2009 
including 27 pancreas biopsies, showing that c4d deposition in 
interacinar capillaries (figure 3c) is associated with de novo dsa 
and impaired graft outcome, suggestive of amr. These results 
were followed by a study that reported on a correlation between 
interacinar c4d staining with several serum and urine pancreas 
rejection markers. A third study discussing the role of amr in 
simultaneous pancreas-kidney transplantation was performed in 
2010, confirming that presence of c4d was associated with impaired 
pancreas survival.17 
In all studies, only c4d staining in interacinar capillaries of 
the pancreas was demonstrated to correlate with circulating dsa. 
Coinciding histological parameters included capillaritis, edema, 
active septal inflammation, acinar inflammation, and acinar cell 
injury/necrosis. These findings led to the inclusion of c4d staining  
in the Banff classification for pancreas transplant pathology.59 
However, to date no prospective studies have been performed 
evaluating the effect of treatment targeted at antibody-mediated 
injury, or reporting on long-term follow up of c4d positive versus 
c4d negative pancreas grafts. These will be future challenges. 
Meanwhile, it is advised to stain all pancreas biopsies for c4d, with 
diffuse positive staining as indicative of amr and focal positivity as 
suspected for amr.
c4d in liver transplantation In the liver there are several 
excellent studies available, but results are variable as well as the 
c4d staining pattern: In different studies, emphasis is being put 
on sinusoidal staining, portal vein staining, central vein staining 
and even stromal staining in the portal tract. There seems to be no 
agreement.21 And even beyond that, studies have reported significant 
c4d staining in cases that are not directly related to rejection, such as 
auto-immune hepatitis, or viral hepatitis. There might be a different 
role for complement in rejection of the liver, since many complement 
components are produced in this organ. The endothelium of the 
liver could thus be more resistant to complement-induced damage. 
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In fact, this may partly explain the relatively low frequency of liver 
rejection in general, as well as the possibility of abo-incompatible 
transplantation. All in all, in liver transplantation c4d is not a useful 
diagnostic marker to detect amr.
New Fields 2 – C4d in native renal disease
The detection of capillary c4d in kidney transplants was the logical 
consequence of previous studies of the classical complement cascade 
in normal and diseased native kidneys65 including also other mam-
malian kidneys.66 After the discovery of c4d as a biomarker in trans-
plantation, many studies have sought evidence for c4d deposition in 
native kidneys, mainly in the setting of autoimmunity. 
In native kidney disease, peritubular capillary c4d staining was 
investigated in many forms of glomerulonephritis 65;67-71 where peri-
tubular capillary c4d staining was virtually never observed. The only 
exception was lupus nephritis, in which granular peritubular capil-
lary staining has been rarely described, which should be kept in mind 
when a diagnosis of amr in a transplanted sle patient is considered. 
Recurrence of the original disease should then be ruled out.
Glomerular c4d deposition on the other hand, is a relatively 
common finding in native diseased kidneys. Zhao et al recently 
investigated which complement pathways were involved in anca-
associated vasculitis. Interestingly, they detected glomerular c4d 
only in a small subgroup of patients with anca negative pauci-
immune gn, whereas in the anca positive patients, it was absent.71 
The authors could not identify glomerular deposition of c1q and 
most c4d positive cases were also mbl positive. This is an example 
of c4d positivity that does not seem to be linked primarily to classic 
pathway activation. mbl positivity may instead be associated with 
exposure of carbohydrate (sugar) moieties in damaged glomeruli 
or gbm, an infectious pathogenesis, or just a consequence of tissue 
damage or remodeling. Although interesting from an etiological 
point of view, it is not likely that c4d will be used as a diagnostic 
marker in anca associated vasculitis in the near future.
In lupus nephritis, glomerular c4d deposition can be detected 
in the majority of cases with a full-house immunofluorescence 
pattern, as a result of immune complex deposition (figure 3b).65;72 
In chapter 3 of this thesis biopsies of patients with lupus nephritis 
with prominent diffuse glomerular c4d staining had detectable 
glomerular microthrombi significantly more often than biopsies 
of patients with focal or mild c4d staining.69 This relation between 
thrombotic microangiopathy and glomerular c4d has been 
confirmed in renal biopsies of patients with antiphospholipid 
syndrome, a similar antibody-mediated autoimmune disease 
leading to endothelial damage and thrombosis in all vascular beds.73 
Apparently, uncontrolled or abundant complement activation can 
cause severe damage to the glomerular endothelium to such an 
extent that a thrombotic microangiopathy can develop. This is in 
line with the occasionally observed thrombotic microangiopathy 
in cases of c4d positive acute amr.74 Furthermore, this mechanism 
also plays a role in atypical Hemolytic Uremic Syndrome (ahus), 
where a genetic defect in complement regulation causes widespread 
microthrombosis.75. In the setting of thrombotic microangiopathies 
independent of the underlying disease, performing a c4d stain might 
help clinicians understand the mechanisms of renal microvascular 
thrombosis. A positive c4d stain could indicate that complement 
is involved, and could even guide future treatment, for instance 
with complement inhibitors. However, this concept needs further 
basic study, and its clinical utility must await trials of complement 
inhibitory therapies. 
New Fields 3 – C4d in pregnancy: Antibody-mediated 
pregnancy loss?
The analogy between pregnancy and transplantation was made as 
early as 1953, when Peter Medawar introduced the concept of ‘the 
fetal allograft’.76 The conceptus represents a foreign body to the 
maternal immune system. This ‘natural’ allograft is usually not 
176 clinical significance of c4d in sle and antiphospholipid syndrome 177 viii • general discussion
rejected. Failure of placentation, which may be triggered by immune 
mechanisms, underlies a spectrum of common pregnancy disorders.77 
Defective placentation is known to occur in a substantial proportion 
of cases of early pregnancy loss, with reduced trophoblast invasion 
into both the decidua and spiral arteries.78 As sporadic miscarriages 
are most often caused by chromosomal anomalies of the fetus, this  
is generally not regarded as an immune-mediated process. However, 
in settings of recurrent miscarriage (>3 consecutive miscarriages)  
this might be different: The more miscarriages a women experien- 
ces, the higher the chance of an underlying maternal condition.79
In certain autoimmune diseases such as sle and antiphospholipid 
syndrome, recurrent early and late miscarriage occur up to 20 
times more often than in the normal population, and placental 
insufficiency leading to preeclampsia and fetal growth restriction are 
also of increased prevalence.80;81 In antiphospholipid syndrome, it has 
been established that pathogenic antibodies bind to trophoblast.82 
The question is: Can these pregnancy losses and other complications 
be interpreted as ‘antibody-mediated’? Chapter 5 of this thesis 
demonstrated that complicated pregnancies of patients with sle and 
antiphospholipid syndrome share several pathophysiological aspects 
with amr (figure 4). 83 Interestingly, placental c4d was detectable in 
the majority of sle and antiphospholipid syndrome cases (>60%) in 
a diffuse staining pattern at the fetal-maternal interface (figure 3d), 
whereas in normal pregnancies c4d was always negative. Excessive 
placental c4d was related to impaired fetal outcome due to fetal 
loss or due to prematurity in the setting of preeclampsia. These  
studies extend previous work showing increased c4d in placentas 
from patients with antiphospholipid syndrome 84, and argue that 
c4d is associated with clinical outcomes. Both antiphospholipid 
antibodies and dsa seem to bind at the interface where cells from  
the one individual (mother or host) meet the other (fetus or graft), 
and c4d functions as a footprint for antibody-mediated tissue  
injury. Chapter 6 further elaborates on this theme by investigating 
c4d in women with recurrent miscarriage of unknown etiology.  
 
Recurrent miscarriage can be interpreted as a multifactorial disorder 
in wich pregnancies are repeatedly lost before 13 weeks of gestation. 
In a subgroup of women extensive deposits of c4d were detected, 
and more than 8o% of these women also had detectable anti-hla 
antibodies. The combination of c4d, presence of anti-hla antibodies 
and placental insufficiency points to a similar disease mechanism as 
in humoral rejection of a solid organ. 
These results point to a role for complement in disease 
pathogenesis and possible role for c4d as a biomarker to verify that 
this pathway is activated in pregnancy complications. Identification 
of patients with c4d and antibody-mediated pregnancy morbidity, 
for instance after a late pregnancy loss or following multiple mis-
carriages, might direct their future therapy.
To take this concept further, a similar mechanism could 
play a role in other pregnancy-related disorders with a possible 
immunological background and a clinical course of miscarriages, 
fetal death or early delivery. Indeed, reports are slowly emerging 
investigating the role of complement and c4d in preeclampsia and 
hellp syndrome85 and spontaneous early delivery.86 In a cohort  
of women with severe preeclampsia with and without underlying 
sle/antiphospholipid syndrome (the promisse-study) Salmon et 
al recently showed that not only excessive activation of complement, 
but also inadequate regulation could contribute to preeclampsia.85 
The authors identified several mutations in complement regulatory 
genes in a subgroup of preeclamptic women, among which a new 
mutation involved in the regulation of c4 activation. These striking 
observations support the concept that c4 activation at the fetal-
maternal interface is an essential mediator of both fetal loss and 
preeclampsia and that insufficient regulation of c4 leads to a more 
severe phenotype. 
Although the diagnostic value of placental c4d has not been tested 
in a prospective manner, these studies would be helpful to investigate 
whether a positive placental c4d staining pattern is a risk factor of a 
future complicated pregnancy.
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New fields 4 – Erythrocyte C4d as a possible biomarker  
for complement mediated disease activity
c4d has been extensively used as a histological biomarker, and 
is interpreted as a footprint of antibody-mediated tissue injury. 
However, c4b, the molecule from which c4d is derived, does 
not discriminate between fixed tissue or circulating cells when 
it is generated in the process of mbl or classical complement 
activation, but instead just forms a covalent bond with the nearest 
free hydrogen-bond available. Thus, c4d may remain behind on 
whichever surface that c4b first attached to, and can therefore also  
be found on circulating blood-cells, such as platelets and erythro-
cytes. A group from Pittsburgh took this as a basis for several studies 
in which they investigated the value of platelet-bound c4d (P-c4d)87 
and erythrocyte-bound c4d (E-c4d) 88 to monitor disease activity 
in Systemic Lupus Erythematosus. They measured levels of e-c4d 
by flow cytometry in 157 patients with sle, 290 patients with other 
diseases and 256 healthy individuals and correlated the findings  
with disease activity scores for sle (sledai, selena, slam).88 
In a multivariable analysis, e-c4d was significantly associated  
with slam and selena-sledai, after adjustment for c3, c4  
and anti-dsdna antibodies. The authors suggest using e-c4d  
for monitoring disease activity in lupus. 
These findings are convincing and the concept could possibly 
be translated to other fields. For instance, in transplant settings it 
would be interesting to investigate if e-c4d levels correlate with c4d 
deposition in the transplanted graft, and with titers of dsa. Another 
option would be to explore whether e-c4d could be an alternative 
marker in cases where complement activity needs to be measured at 
the tissue level, but taking a biopsy is risky or impossible (for instance 
in patients on anti-coagulation or in case of a pancreas biopsy). 
Finally, if c4d on erythrocytes is a good marker for disease activity 
in lupus, other cell-rich fluids could theoretically be used for similar 
measurements. Interestingly, in one study, Miller et al have inves-
tigated cell-bound c4d in bronchoalveolar lavage fluid to investigate 
whether this was related to antibody mediated rejection of the lung.89
Conclusion – Pros and Cons for C4d as a biomarker  
in transplantation, autoimmunity and pregnancy
The introduction of c4d as a biomarker into the standard work-up 
of renal transplant biopsies has provided an enormous amount of 
insight into the role of antibodies in different forms of allograft-
rejection. c4d is now one of the core diagnostic tools to indentify amr, 
and is being used in virtually all transplant centers around the world. 
The vast amount of research into the deposition patterns of c4d in 
different clinical settings such as in kidney, heart, pancreas and lung 
transplantation, has taught us that antibodies contribute largely to 
both acute and chronic rejection episodes. 
In analogy with solid organ transplantation, c4d has recently been 
demonstrated in this thesis in pregnancy, in particular in the set-
ting of ‘antiphospholipid antibody-mediated fetal loss’ and recurrent 
miscarriage. This thesis demonstrated that in auto-immune settings 
c4d might play a role in identifying patients at risk of developing 
thrombotic complications. More research will nevertheless be needed 
to discover the full extent of c4d as a biomarker in these new fields. 
This final chapter has shown that there are certain drawbacks of 
using c4d. The difficulties of interpreting focal staining patterns, 
the relatively low sensitivity of c4d as a marker for amr in late renal 
allograft biopsies, and its lack of utility as a marker for antibody-me-
diated injury in biopsies of abo-incompatible allografts suggests that 
c4d has lost some of its magic during the past decade. However, most 
experts agree that if complement targeted therapies will be part of our 
future treatment options, a marker like c4d will be needed to identify 
patients susceptible for those kind of expensive treatments. Taken 
together, with its unique ability to act as a footprint for antibody-me-
diated injury, c4d will likely remain to play a prominent role in trans-
plantation, and possibly in pregnancy and autoimmunity as well. 
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pros and cons for c4d as a biomarker what would you like to investigate if you would receive 
funding to be spent on research in the field of c4d?
Pro C4D
C4d staining is relatively inexpensive
C4d staining is easy to perform in basic 
laboratories
A diffuse staining pattern is relatively  
easy to interpret
C4d gives very few false positives  
(it is relatively specific)
C4d shows that the complement system is 
involved: If complement targeted therapies 
(Eculizumab) will be part of our future 
treatment options, a marker like c4d will  
be needed to identify patients susceptible 
for those kind of (expensive) treatments.
There are currently no reliable (prospec-
tively tested) alternatives available
Contra C4D 
C4d scoring is subjective and the issue  
of focal staining and c4d/dsa discrepancies 
will not be solved
C4d is not sensitive for chronic (or chronic/
active) amr
C4d is not helpful in abo incompatible 
grafts
Alternatives for c4d are emerging 
(genomics, molecular diagnostics and 
endothelial transcripts) and if proven  
useful, great effort will be made to 
transform these techniques or their  
progeny to practical tests. 
Robert Colvin: ‘’Understand the mechanism 
of accommodation. There must be a 
mechanism that we can intervene with. And 
then I would like to try to find out if it is 
possible to induce the same endothelial state 
in the presence of anti-hla antibodies’’.
Mohamed Daha: ‘’I want to understand the 
effect of modulated and injured tissue to 
complement activation. In addition, I would 
like to know what local production of factors 
that control the complement system do, 
and see if we can influence them to control 
disease.’’ 
Cynthia Drachenberg: ‘’One of the things 
that I find extremely puzzling is the 
contrast between acute amr and chronic 
amr. How do endothelial cells cope with 
this in the chronic setting and why do they 
behave so differently than in the acute form 
of amr?’’ 
Mark Haas: ‘’What would be nice to do is to 
look at the genomics of abo incompatible 
grafts with no histologic signs of rejection, 
and see how this differs from amr meeting 
current Banff criteria, from c4d positivity 
without histologic findings of rejection 
in non abo-incompatible settings, and 
also what genomic changes have occurred 
compared to abo incompatible base-line 
biopsies.’
Volker Nickeleit: ‘’I want to do a large 
prospective clinico-pathological study with 
thousands of patients, protocol biopsies and 
regular monitoring of anti-hla antibodies 
to find out answers to many unanswered 
questions we struggle with in daily clinical 
practice.
Banu Sis: ‘’I want to study the molecular 
phenotypes of early acute amr in 
presensitized patients and c4d positive 
abo incompatible kidneys and compare 
molecular mechanisms of acute amr to 
chronic amr. Subtle molecular changes 
may help us to intervene before irreversible 
tissue injury takes place.’’
Ming-hui Zhao: ‘Recent advances on 
complement research provide us a chance 
to rethink the role and mechanism of 
complement played in many native kidney 
diseases. c4d is not always a reflection of 
classical pathway of complement activation, 
but can be mbl derived too. I would like to 
investigate the different roles for classical 
and mbl pathway-activation further in the 
setting of autoimmune renal disease’. 
Jane Salmon: ’The most elegant approach 
would be to look at c4d in pregnancy from 
all possible directions, which would mean 
to look at the genetics of complement 
regulatory proteins, to investigate c4d 
deposition in placental tissues, to look at 
c4d on erythrocytes, and both complement 
and complement regulatory protein 
whole exome sequencing. And all in the 
context of previous clinical history and well 
phenotyped patients’ 
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fig 1 the complement system and c4d 
 
(a) The classical pathway of complement is initiated via binding of its recognition 
molecule c1q to immune complex deposits, antibody-antigen binding or charged 
molecules. When c1q becomes activated, it subsequently activates its natural substrate 
c4. c4d is a split product of c4 activation, without a biological function. Although c4d 
is mainly interpreted as a trace of classical pathway activation, it must be kept in mind 
that c4 can also be derived from the lectin pathway. Mannose-binding lectin (mbl) or 
ficolins binding to carbohydrate ligands on the surface of a wide variety of pathogens 
results in activation of the lectin pathway and cleavage of c4. Consequently, c4d may be 
generated without prior antibody binding. Classical complement activation converges 
with other pathways at the level of c3 and proceeds into the formation of the membrane 
attack complex on complement-activating surfaces, causing direct tissue injury by 
perforation of the cell membrane. In addition, potent anaphylatoxins c3a and c5a are 
being formed in the process, which elicit the recruitment of other inflammatory cells 
to the site of activation. (b) c4d as a footprint for antibody-mediated tissue injury. c4b, 
the larger molecule that c4d is derived from, has an internal thioester in the molecule, 
giving it the ability to form a covalent bond with target cells. When c4d is cleaved from 
c4b, the covalent bond between c4d and the tissue remains intact. Covalently bound 
c4d has a higher chance to remain at the site of complement activation than the anti-
bodies themselves, which dissociate over time. c4d is anchored tightly to the tissue and 
therefore acts as a footprint of antibody-mediated tissue injury.
fig 2 diagnosing acute antibody-mediated rejection
This flowchart shows that the diagnosis of acute antibody-mediated rejection requires 
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fig 3 c4d staining patterns in different clinical   
 settings
(a) Acute amr* of a kidney graft with typical peritubular capillary staining of c4d on 
paraffin-embedded tissue. (b) Glomerular c4d in a native kidney biopsy of a patient 
with lupus nephritis and thrombotic microangiopathy. (c) c4d in a pancreas graft 
with typical staining of c4d in interacinar capillaries, suggestive for amr. (d) Placental 
c4d in a placenta from a patient with antiphospholipid syndrome and an intrauterine 
fetal death in this pregnancy. c4d is positive at the fetal–maternal interface on the 
maternal side of the syncytiotrophoblast, suggesting severe antibody-mediated injury 
leading to impaired placental development, impaired nutrient exchange, intrauterine 
fetal growth restriction, and finally, fetal death. *amr: antibody-mediated rejection. 
fig 4 analogy between amr and antibody-mediated   
 pregnancy loss
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Het complementsysteem
In het humane immuunsysteem neemt complement een bijzondere 
plaats in. Dit systeem werkt samen met antistoffen en fagocyten bij 
de afweer tegen micro-organismen en is waarschijnlijk evolutionair 
een van de oudste verdedigingssystemen in de biologie. In tegen-
stelling tot lymfocyten, hoeft complement niet te ‘leren’ hoe om  
te gaan met micro-organismen; het werkt direct vanaf de geboorte.
Normaal gesproken is het complementsysteem in een niet-geac-
tiveerde staat aanwezig als een aantal verschillende plasma-eiwitten  
in het bloed. De verschillende complementeiwitten worden geco-
deerd door letters en cijfers, zoals c1, c3 of c4, afhankelijk van  
hun plaats in het systeem. Activatie, en daarmee het ontstaan van 
een kettingreactie aan acties en interacties tussen deze eiwitten, kan 
plaatsvinden na binding van complementeiwitten aan antilichamen 
en immuuncomplexen. Dit wordt de klassieke route genoemd.  
Het complementsysteem kan ook rechtstreeks geactiveerd worden   
door directe interactie tussen complement eiwitten met het cel op - 
per vlak van pathogenen (de zogenaamde ‘Mannose Binding Lectin’  
of mbl route).  Uiteindelijk leidt deze kettingreactie tot de vorming  
van anaphylatoxinen, stoffen die fagocyterende cellen aantrekken,  
en de vorming van het zogenaamde ‘membrane attack complex’,  
een ingenieus complex van eiwitten dat binnen enkele seconden  
tot destructie van de celwand van de ‘target-cell’ kan leiden. 
Als verdedigingsmechanisme is het complementsysteem uiterst 
effectief en onmisbaar. Echter, wanneer het immuunsysteem zich  
tegen het eigen organisme keert en auto-antistoffen gevormd wor-
den, speelt het complementsysteem een fundamentele rol bij het 
ontstaan van ongewenste weefselschade.  Zowel de fysiologie als  
de rol van complement in auto- en alloimmuniteit worden in meer 
detail besproken in de algemene inleiding van dit proefschrift 
(hoofdstuk 2).
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C4d
 
C4d is een molecuul dat als afsplitsproduct overblijft na activatie  
van c4, een eiwit dat een belangrijke rol speelt in de klassieke route 
van het complementsysteem. Hoewel c4d voor zover bekend geen 
bio logische functie heeft, beschikt het over een belangrijke eigen-
schap: Het molecuul c4d vormt een covalente verbinding (een zeer 
stabiele verbinding tussen twee moleculen waarbij electronen ge-
deeld worden) met celoppervlakken of celmembranen. Hierdoor  
blijft c4d langdurig gebonden –veel langer dan antilichamen zelf-  
en kan door immuunhistochemische technieken gemakkelijk in 
beeld gebracht worden. Onder de microscoop kan men doordat c4d 
als een soort spoor op de plaats delict achterblijft, ‘zien’ waar in het 
weefsel antistoffen complement hebben geactiveerd en schade heb-
ben veroorzaakt. Het onderzoeken van de aanwezigheid van c4d in 
weefsel geeft daardoor in de eerste plaats inzicht in ziektemechanis-
men, maar kan ook als diagnosticum gebruikt worden. Als diagnos-
tische test wordt c4d sinds de jaren ’90 gebruikt om antilichaam 
gemedieerde afstoting van getransplanteerde organen aan te tonen. 
In de algemene inleiding (hoofdstuk 2) wordt c4d geïntrodu-
ceerd aan de lezer. In de algemene discussie van het proefschrift 
(hoofdstuk 8) wordt de geschiedenis, de huidige stand van zaken  
en toekomst van c4d als biomarker verder uitgewerkt. 
 
Dit proefschrift
In dit proefschrift wordt de rol van c4d uitgediept in andere klinische 
settings dan orgaantransplantatie - waar het tot nu toe onderzocht en 
gebruikt werd. Waar c4d in getransplanteerde organen een indicator 
is van schade door alloantistoffen (eigen antistoffen gericht tegen 
vreemd weefsel) berust dit proefschrift op de hypothese dat in ziekten 
waar autoantistoffen geproduceerd worden (eigen antistoffen gericht 
tegen eigen weefsel) c4d eveneens van betekenis zou kunnen zijn. 
C4d in SLE en antifosfolipiden syndroom
 
deel 1: c4d en thrombotische complicaties De studies  
in dit proefschrift zijn daarom voornamelijk verricht in patiënten 
met Systemische Lupus Erythematosus (sle) en antifosfolipiden  
syndroom, twee autoimmuunziekten waar autoantistoffen een  
cruciale rol spelen. De antistoffen die deze patiënten aanmaken, 
circuleren in het bloed en komen op allerlei plekken in het lichaam 
terecht. Daar waar ze binden of neerslaan, kan –onder andere via 
activatie van het complement systeem- schade ontstaan. Patiënten 
met deze ziekten hebben derhalve symptomen in alle orgaansyste-
men, waarvan de nieren, de huid, en waarschijnlijk ook de hersenen 
frequent aangedaan raken. De achtergrond, kliniek en epidemiologie 
van sle en antifosfolipiden syndroom komen respectievelijk aan de 
orde in de algemene inleiding (hoofdstuk 2) en in een overzichts-
artikel over antifosfolipiden syndroom (hoofdstuk 3). 
In de daarop volgende hoofdstukken wordt de rol van c4d in de 
nieren (hoofdstuk 4) en hersenen (hoofdstuk 5) van patiënten  
met sle en antifosfolipiden syndroom onderzocht. Het blijkt dat  
in beide organen de aanwezigheid van c4d sterk geassocieerd is  
met trombose in de kleine bloedvaten (microtrombotische schade). 
Wanneer c4d aanwezig is in glomeruli in de nier, is er een sterkere 
kans ook glomerulaire microthrombi aan te treffen. Een c4d-kleu-
ring op een nierbiopt van een patiënt met sle of antifosfolipiden 
syndroom zou in de toekomst mogelijk consequenties kunnen heb-
ben voor de risico-inschatting van patiënten op het ontwikkelen van 
thrombotische microangiopathie, en zelfs op eventuele behandeling 
met antistolling en/of complementremmers. 
In de hersenen van patiënten met sle en antifosfolipiden syn-
droom blijkt c4d sterk aan te kleuren in arteriolen en venulen in 
de cortex. Deze vaatjes hebben vaak een verdikte wand, zonder de 
aan wezigheid van lymfocyten, wat een inflammatoir proces sugge-
reert. Bij patiënten met veel c4d depositie, zijn vaker microthrombi 
te detecteren in vergelijkbare kleine vaatjes, en tevens zijn er vaker 
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aanwijzingen voor micro-infarcten en ischemische schade. Tot nu  
toe was het onbekend hoe auto-antistoffen in het brein van sle  
patiënten zouden kunnen leiden tot deze vorm van thrombo- 
ischemische schade. Hoofdstuk 5 geeft een mogelijke verklaring 
hiervoor, namelijk complement activatie op het cerebrale endo- 
theel met vaatwandveranderingen en microthrombose als gevolg.  
deel 2: c4d en zwangerschap  In het volgende deel van het 
proefschrift ligt de nadruk op zwangerschap en herhaalde miskra-
men. Niet alleen omdat bekend is dat patiënten met sle en antifos-
folipiden syndroom gecompliceerde zwangerschappen doormaken, 
maar ook omdat de zwangerschap in het algemeen sommige immu-
nologische overeenkomsten vertoont met transplantatie, waar c4d 
immers voor het eerst beschreven werd. Wanneer een zwangerschap 
resulteert in een vroege of latere miskraam, zou dit geïnterpreteerd 
kunnen worden als een vorm van ‘afstoting’ van de lichaamsvreemde 
foetus. Deze gedachtengang was het uitgangspunt om de rol van c4d 
te onderzoeken in placenta’s van patiënten met sle en antifosfolipi-
den syndroom (hoofdstuk 6) en in patiënten met herhaalde miskra-
men zonder duidelijke oorzaak (hoofdstuk 7). 
De placenta is een orgaan dat ontstaat tijdens de zwangerschap  
en een cruciale rol speelt bij het in stand houden van de zwanger-
schap, het fasciliteren van groei van de foetus door voedingsstoffen  
naar de circulatie van het kind te transporteren (en afvalstoffen af  
te voeren) en het verschaffen van immunologische tolerantie van de  
foetus. De placentaire vlokken zijn bekleed door syncytiotrophoblast, 
de cellaag die het grensvlak vormt waarop het maternale bloed in  
contact komt met foetaal weefsel. 
In hoofdstuk 6 werd duidelijk dat c4d in sommige placenta’s  
van patiënten met sle en antiphopsholipiden syndroom veelvuldig 
aanwezig was op het foetomaternale grensvlak . In sommige placen-
ta’s bleef geen enkele vlok vrij van c4d. De zwangerschappen waarin 
dit fenomeen werd geobserveerd liepen veelal niet goed af. De aan-
wezigheid van c4d was sterk geassocieerd met intrauterine vrucht-
dood in een groep patiënten met sle en antifosfolipiden syndroom. 
In placenta’s van patienten met een normale zwangerschap, of 
patienten die een intrauterine vruchtdood doormaakten ten gevolge 
van aangeboren afwijkingen waarbij waarschijnlijk geen afstoting 
optrad, kwam c4d vrijwel nooit voor in de placenta. Hoofdstuk 6 
laat zien dat het waarschijnlijk is dat c4d in de placenta een uiting  
is van een sterke antilichaam-gemedieerde immuunrespons. Anti—
fosfolipiden antistoffen zijn een zeer waarschijnlijke kandidaat, om-
dat bekend is dat deze een sterke affiniteit hebben voor trophoblast. 
Andere antistoffen die bij sle patiënten aanwezig zijn zouden echter 
evengoed de veroorzaker kunnen zijn.  Ook is het voorstelbaar dat 
inflammatie op het foetomaternale grensvlak leidt tot een dysfunc-
tionele placenta, met slechte zwangerschapsuitkomsten tot gevolg. 
Toekomstig onderzoek zal uit moeten wijzen of c4d in een placenta 
van een patiënt met sle of antiphospholipiden syndroom (therapeu-
tische) consequenties heeft voor een volgende zwangerschap. 
De bevindingen van hoofdstuk 6 gaven aanleiding om in hoofd-
stuk 7 in een populatie van patiënten met herhaalde miskramen 
zonder duidelijke oorzaak te inventariseren of een vergelijkbaar 
mechanisme hier eveneens een rol zou kunnen spelen. Hier bleken 
sterke aanwijzingen voor te bestaan – in een subgroep van patiënten 
met herhaalde miskramen was er sprake van sterk c4d positief mis-
kraammateriaal. Omdat bij deze patiënten antifosfolipiden antistof-
fen uitgesloten waren, werd in serum gezocht naar de aanwezigheid 
van anti-hla antistoffen. Deze bleken in een aantal vrouwen met c4d 
positief miskraammateriaal aanwezig te zijn. Deze combinatie doet 
erg denken aan ‘antilichaam gemedieerde afstoting’ bij transplanta-
tie, waar eveneens een combinatie van anti-donor antistoffen en c4d 
in het donororgaan pathognomonisch is voor deze vorm van rejec-
tie. Hoofdstuk 7 biedt voornamelijk een nieuw pathofysiologisch 
inzicht in een populatie waar zeer vaak geen oorzaak wordt gevonden 
voor het optreden van herhaalde miskramen. 
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Discussie en conclusie
In de algemene discussie van het proefschrift (Hoofdstuk 8) wordt 
allereerst de rol van c4d in een historisch kader geplaatst door mid-
del van interviews met verschillende experts die een belangrijke 
bijdrage hebben geleverd aan het veld. Ontwikkelingen vanaf de 
eerste studies naar deze marker in de jaren ’90 in getransplanteerde 
nieren, tot de voorzichtige stappen met c4d in nieuwe gebieden 
zoals auto immuunziekten en zwangerschap zoals beschreven in dit 
proefschrift, komen aan de orde. Wellicht zijn nieuwe, sensitievere 
methoden denkbaar om antilichaam gemedieerde rejectie aan te to-
nen. Deze komen in dit hoofdstuk aan de orde, en zijn voor som migen 
reden om aan een toekomst voor c4d als biomarker te twijfelen.  
Aan de andere kant opent de komst van verschillende complement-
remmende medicijnen (eculizumab) nieuwe deuren voor c4d als 
marker: Zouden  hiermee patiënten geïdentificeerd kunnen worden 
die baat zouden kunnen hebben bij deze (zeer kostbare) middelen? 
De bevindingen in dit proefschrift laten zien dat ook buiten de 
transplantatiewereld c4d van nut kan zijn bij het ontrafelen van 
antilichaam-gemedieerde ziektemechanismen, en uiteindelijk 
wellicht ook gebruikt kan worden als voorspellende biomarker voor 
trombotische en obstetrische complicaties. Prospectieve studies zul-
len nodig zijn om de haalbaarheid hiervan in de dagelijkse klinische 
praktijk te toetsen. 
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